Editorial introductions
Current Opinion in Neurology was launched in 1988. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of neurology is divided into 14 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal’s Section Editors for this issue.
Section Editors Peter Goadsby
Peter Goadsby obtained his basic medical degree and training at the University of New South Wales, Australia. His neurology training was done under the supervision of Professor James W. Lance in Sydney. After postdoctoral work in New York with Don Reis at Cornell, with Jacques Seylaz in Paris and post-graduate neurology training at Queen Square in London working with late Professors C David Marsden and W Ian McDonald, he returned to the University of New South Wales, and the Prince of Wales Hospital, Sydney as a consultant neurologist and was promoted to Associate Professor. He was appointed a Wellcome Senior Research Fellow at the Institute of Neurology, University College London in 1995, and this was renewed in 2000. He was Professor of Clinical Neurology and Honorary Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, and the Hospital for Sick Children, Great Ormond St, London. He is now Professor of Neurology in the Department of Neurology, University of California, San Francisco His major research interests are in the basic mechanisms of head pain in both experimental settings and in the clinical context of headache. The work of the Headache Group involves human imaging and electrophysiological studies in primary
headache, as well as experimental studies of trigeminovascular nociception. We aim to understand what parts of the brain drive and modulate headache syndromes, and how those might be modified by treatment. Wendy Ziai
Dr Wendy Ziai is Assistant Professor in the Department of Neurology at the Johns Hopkins University in Baltimore, Maryland. She received her medical degree at Queen’s University in Canada and completed residency training in Neurology at the University of Calgary. She came to the Johns Hopkins Hospital for a fellowship in Neurocritical Care where she was appointed then after in the Departments of Neurology, Anesthesiology and Critical Care Medicine. She also obtained a Masters in Public Health at the Johns Hopkins Bloomberg School of Public Health. Dr Ziai’s clinical and research activities encompass several aspects of acute neurological disease including central nervous system and nosocomial infections in the Neurocritical Care Unit, and treatments for intracerebral and in particular intraventricular hemorrhage. She has published a number of reviews and book chapters on the critical care approach to central nervous system infection and is currently involved in the national ‘‘Positive Deviance’’ MRSA Prevention Partnership, committed to prevention of multi-drug resistant microbial infections in American hospitals. Dr Ziai serves on the Board of Directors of the Neurocritical Care Society since November 2006. She is involved as a member of several committees of an international study of clot lysis for intraventricular hemorrhage using intraventricular rt-PA. The Johns Hopkins Hospital is a major referral center for investigation and management of encephalitis. The Encephalitis Center is dedicated to providing specialty care and diagnosis for patients with acute inflammatory and infectious conditions of the central nervous system and is currently developing experimental neuroprotective strategies for use in clinical trials.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Editorial introductions
Renaud Du Pasquier
After medical studies and residency performed at the University Hospital of Geneva, Renaud A. Du Pasquier, M.D., obtained his Swiss board certification in Internal Medicine and Neurology. In 1999, he moved to Boston where he made a post-doc in neuroimmunology/neurovirology at the Beth Israel Deaconess Medical Center, Harvard Medical School. Under the mentorship of Dr Igor Koralnik and Dr Norman Letvin, head of the Division of Viral Pathogenesis, he studied the cellular immune response against JC virus (JCV), the
agent of progressive multifocal leukoencephalopathy (PML). His research demonstrated the importance of JCV-specific CD8R T lymphocytes in containing the virus and conditioning the prognosis of PML. In 2004, he moved to the Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois, CHUV) where he established his laboratory in a joint-venture between the Divisions of Neurology and Immunology. As an assistant professor, he is currently pursuing his research on PML, in particular in the context of the cases associated with natalizumab in multiple sclerosis patients, but also the possible role of Epstein-Barr as a trigger of multiple sclerosis, or still the new features of HIV-associated cognitive disorders in the highly active anti-retroviral therapies era. The clinical part of his activity is devoted to patients with inflammatory diseases of the nervous system. It is thank to the commitment of these patients that Renaud A. Du Pasquier and his colleagues can gather samples for their research.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
EDITORIAL
A promenade along the stream of demyelination Renaud A. Du Pasquier Service of Neurology, Department of Clinical Neurosciences and Service of Immunology, Department of Medicine, University Hospital of Lausanne, Lausanne, Switzerland Correspondence to Renaud A. Du Pasquier, MD, Assistant Professor, Service of Neurology, Department of Clinical Neurosciences and Service of Immunology, Department of Medicine, University Hospital of Lausanne (CHUV), 1011 Lausanne, Switzerland E-mail:
[email protected] Current Opinion in Neurology 2010, 23:203–204
To try to decipher the pathogenesis of multiple sclerosis (MS) is a little like trying to catch a trout with bare hands in a stream: each time one thinks that one has gotten it, it vanishes, and despite the fact that there are many fishermen (and women) in this stream, the trout is very slippery and does not surrender. Indeed, with the cause of MS still not having been discovered, this field of research is regularly subject to bursts of enthusiasm followed by some disappointment when things turn out to be more complicated than initially thought. The role of cytokines in MS is particularly illustrative of this situation. Such as vividly pointed out by Codarri et al. (pp. 000–000) in this issue of Current Opinion in Neurology, many promising discoveries pertaining to the role of cytokines in experimental autoimmune encephalomyelitis, an animal model of MS, have been ‘lost in translation’ when applied to humans. Is that to say that animal research is useless in the field of MS? Certainly not. As emphasized by these authors, it rather calls for a very careful preclinical evaluation of candidate treatments, such as cytokine-interfering drugs, before introducing them in clinical trials. Another important take-home message of their review is that negative findings should absolutely be published swiftly since they can prevent other researchers from wasting time and money in useless experiments. In addition to allowing establishment of the diagnosis of MS even after a single relapse, that is at the stage of clinically isolated syndrome [1], MRI is a particularly suitable and useful tool to gain an insight into the physiopathology of MS. In this issue, Filippi and Rocca (pp. 000–000) review the recent developments of this technique and demonstrate that ‘novel MR approaches highlight previously unrecognized or neglected aspects of MS pathophysiology’. One can add that the combination of ‘wet lab’ research and MRI analyses is an approach that will be increasingly used to study the pathogenesis of MS [2]. 1350-7540 ß 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
Although it is still in its research stages, stem cell transplantation in MS offers hope for MS patients. Whereas autologous hematopoietic stem cell transplantation addresses ‘only’ the inflammatory component of MS, mesenchymal stem cells not only have immunomodulatory properties but also provide a neuroprotective effect. Interestingly, this effect does not seem to be due to transdifferentiation of mesenchymal stem cells into neurons, but rather to bystander effects, such as rescuing neurons from apoptosis, promoting neurite outgrowth, and producing several trophic factors. These complex issues are comprehensively reviewed by Uccelli and Mancardi (pp. 000–000). In the arsenal of new immunomodulatory therapies, monoclonal antibodies occupy a place of choice. In a few years, these drugs have brought substantial improvement for patients with auto-immune diseases including rheumatoid arthritis, psoriasis, Crohn’s disease, and, of course, MS. Each monoclonal antibody targets a precise step in the broad cascade of the immune response. Thus, based on this knowledge, it was assumed that one would easily predict their putative side effects. Yet, after some years of use, it has become clear that treatment with monoclonal antibodies can lead to unexpected side effects. In this issue, Lysandropoulos and Du Pasquier (pp. 000–000) focus on the demyelinating side effects of some monoclonal antibodies. In addition to trying to sort out facts from hypotheses, the authors emphasize the need for neurologists to become familiar with this new field, located at the interface of neurology, immunology and infectious diseases. Even if MS is the most frequent cause of demyelination, there is a very broad list of other causes, among which are leukodystrophies with late disease onset. It is probably reasonable to state that most neurologists are only poorly familiar with this group of diseases. Yet, some leukodystrophies can pose difficult differential diagnosis with MS, in particular the rare but important to know adultonset autosomal dominant leukodystrophy. It is the merit of Ko¨hler (pp. 000–000) to provide a synthetic and updated review of this group of heterogeneous diseases and to show how most recent therapies such as enzyme replacement or cell-based therapies could change their prognosis. Last but not least, we must not forget that myelin is a major component of the peripheral nervous system. DOI:10.1097/WCO.0b013e328339d15d
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
204 Demyelinating diseases
Tracy and Dyck (pp. 000–000) review the demyelinating polyneuropathies, focusing on the investigations and treatments of chronic inflammatory demyelinating polyradiculoneuropathies. In this field too, new treatments such as monoclonal antibodies are proposed, but their cost–benefit must be cautiously weighted.
along a stream in which evanescent but fascinating fishes swim together.
1
Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol 2005; 58:840–846.
It is our hope that this issue of Current Opinion in Neurology will be of interest to the reader and will guide his/her way
2
Zivadinov R, Zorzon M, Weinstock-Guttman B, et al. Epstein–Barr virus is associated with gray matter atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80:620–625.
References
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Cytokine networks in multiple sclerosis: lost in translation Laura Codarri, Adriano Fontana and Burkhard Becher Department of Pathology, Institute of Experimental Immunology, University Hospital of Zurich, Zurich, Switzerland Correspondence to Professor Burkhard Becher, Department of Pathology, Institute of Experimental Immunology, University Hospital of Zurich, Zurich, Switzerland Tel: +41446353701; e-mail:
[email protected] Current Opinion in Neurology 2010, 23:205–211
Purpose of review This review will discuss aspects of cytokine networks in neuroinflammatory diseases and attempt to provide some explanation for our failures and successes in translating preclinical data to benefit patients with multiple sclerosis (MS). We will discuss innate cytokines such as tumor necrosis factor a and interferon (IFN) b and will then go on to cover recent findings on the role of interleukin-23 and the so-called TH17 cells and how they are implicated in the pathogenesis of neuroinflammation. Recent findings Even though IFN-b has been used for the treatment of MS for many years, it is only recently that the mechanistic underpinnings of the IFN-b-mediated immune modulation was discovered in preclinical models. The timeline is at odds with the idea that preclinical data should shape the design of therapeutic strategies in the clinic. Conversely, the discovery of the so-called TH17 cells and their association with neuroinflammation has broken the dogma that IFN-g-producing TH1 cells have the exclusive capacity to invade and destroy the central nervous system tissue. So why then did a clinical trial targeting the TH17-promoting cytokine interleukin-23 fail? Summary Preclinical studies using the animal models for MS have yielded promising results, but unfortunately the translation into the clinic is often disappointing. The reason for this may be the complex nature of the pathogenesis of autoimmune neuroinflammation, but more often an oversimplified interpretation of preclinical observations appears to hinder our progress. Keywords cytokines, experimental autoimmune encephalomyelitis, innate immunity, multiple sclerosis, T helper cells Curr Opin Neurol 23:205–211 ß 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins 1350-7540
Introduction Multiple sclerosis (MS) is widely held to be mediated by the action of inflammatory lymphocytes, which invade the central nervous system (CNS) to initiate tissue damage and neurological impairment. The cause remains unresolved, but autoimmune-driven processes are believed to initiate/ maintain the disease. It is clear that a major contributor of inflammation is the fact that activated leukocytes invade the ‘tissue’ and deliver soluble mediators such as vasoactive substances and cytokines. Cytokines are polypeptides comprising a large and heterogeneous family of soluble factors produced by different cell types. They are predominantly produced by immune cells, but many other cell types including cells resident in the nervous system stroma are also able to secrete cytokines. During inflammation, cytokines permit cells to communicate between one another and to instruct cell development and function. Antigen-presenting cells (APCs) are key players during both the initiation and progression of an inflammatory 1350-7540 ß 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
autoimmune response as seen in MS. APCs not only provide the T cells with their cognate antigen but also determine the faith of T cells and the ensuing immune response by creating a particular cytokine milieu. T cells can then in turn independently maintain their designated function and/or polarization to a large extent through cytokines in an autocrine manner. Recent advances in the characterization of pathogenic T cells led to the identification of different cytokine signatures associated with T-cell subsets. Researchers have made much progress in understanding these complex communication networks and are in the process of translating this ‘molecular language’ into our language. Specifically interfering with commands such as ‘kill’ or ‘destroy’ and to instead instruct ‘tolerate’ or ‘stop’ is the goal of therapeutic strategies that modulate cytokine-mediated communication. Cytokines are fundamental in the pathogenesis of inflammatory diseases such as MS, and to unravel the roles of individual cytokines in this disease we rely on experimental models. When we use the term preclinical here, we mean primarily the animal model for MS, experimental autoimmune encephalomyelitis DOI:10.1097/WCO.0b013e3283391feb
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
206 Demyelinating diseases
(EAE), and we have picked some examples, which outline the complex networks and the challenges of translation, rather than providing an all-encompassing overview of the state-of-the-art.
Innate immunity and ‘early’ cytokines Although autoimmune diseases are obviously mediated by the actions of adaptive immune cells targeting self-antigen in tissues, the innate immune system plays a key role in the initiation and propagation of tissue inflammation. Here, we will discuss the state-ofthe-art regarding the involvement of typical ‘innate’ cytokines such as tumour necrosis factor alpha (TNFa), interleukin (IL)-6 and type I interferons (IFNs), which can be found abundantly in virtually every inflamed tissue. TNF-a is a prototypical pro-inflammatory mediator, which is produced by a variety of cell types including T cells, astrocytes, macrophages and microglia [1,2]. A TNF-a response is generally elicited very early during infection and inflammation. There is plenty of evidence to suspect a role of TNF-a in the pathogenesis of MS. For instance, autopsy material from MS patients revealed elevated levels of TNF-a within active lesions of the CNS [3]. TNF-a is also present in higher amounts in the serum and the cerebrospinal fluid (CSF) of MS patients compared with healthy donors and also correlates with the severity of the lesions and disease progression [4,5]. These strong implications of TNF-a in the pathophysiology of MS led to the successful TNF-a pathway manipulation in the mouse model of MS [6,7]. A TNF-a receptor 1 (TNFR1)dependent demyelinating role of TNF-a is also suggested in transgenic mice that express the cytokine in glial precursor cells or astrocytes [8]. However, the hope to use TNF-a blockers to treat MS patients was not fulfilled in clinical trials. In fact, patients treated with lenercept (a recombinant soluble TNFR1 fusion protein) suffered significantly more exacerbations compared with pretreatment and placebo controls [9]. Moreover, new-onset MS-like demyelinating lesions developed in the course of treatment with soluble TNFR2 fusion protein (etanercept) or anti-TNF-a antibodies (infliximab) in patients with rheumatoid arthritis [10]. Both biologicals have been claimed to give rise to various forms of demyelinating neuropathies [11]. An explanation for the failure of lenercept in MS may be provided by data from EAE experiments performed after the clinical trials. Even though blockade of TNF-a in EAE has proved to be efficacious, mice lacking the TNFa gene show that its function in EAE development is redundant [12,13]. A beneficial role of TNF-a has also been described [14], and signalling through TNFR2 mediates proliferation of immature oligodendrocytes
that may indicate that TNF-a is involved in repair processes [15]. IL-6, another acute phase reaction cytokine, is secreted by activated T cells and macrophages and has not only pro-inflammatory but also anti-inflammatory properties. IL-6 became recently a potential interesting therapeutic target for autoimmune disease after the discovery that IL6-deficient mice were fully resistant to EAE [16,17]. At the time of this finding, it was believed that those mice were disease-resistant because of a shift in the T-cell responses from TH1 to TH2, and IL-6 was then believed to modulate the TH1/TH2 balance (discussed below). Recently, IL-6 has been shown to play a key role in the generation of TH17 cells [18,19], and its importance in the autoimmune disease has been correlated with the presence of this novel T-helper cell subset. We will discuss the involvement of T cell-derived cytokines in the inflammatory cascade below. Since their first characterization in 1957 as protective molecules against RNA viruses, the functions of type 1 IFNs have enlarged considerably and comprise regulation of the immune response and inflammation, control of tumour growth and angiogenesis. Studies [20,21] in EAE show type 1 IFNs to suppress immune-mediated demyelination. Furthermore, IFNb gene knockout mice are much more susceptible to EAE [22]. In line with these observations, treatment of relapsing–remitting MS with subcutaneous IFN-b injection has been found to reduce the frequency and severity of clinical relapses, and to decrease the progression of disability and the development of new lesions [23–25]. The mechanism by which type 1 IFN ameliorates MS and EAE was largely unknown until recently. Prinz et al. [26] established that type 1 IFNs primarily act on myeloid cells and that engagement of the specific type 1 IFN receptor on CNS resident cells, T and B cells had no bearing on the clinical development of EAE in transgenic mice. It is likely that the same is true for humans. Hence, the preclinical findings regarding the mechanism by which IFN-b inhibits EAE will be guiding the improvement of IFN-b-mediated immune modulation in the future. In summary, even though there is strong evidence that TNF-a and IL-6 are involved in the pathogenesis of MS and EAE, they may not only play a detrimental role and we need to be careful in our interpretations of the available data. The clinical experience with type 1 IFNs over the years confirms its therapeutic, but modest, effects. Given the fact that these innate cytokines are vital for the function of host defence, it will be crucial to balance any protective potential with the increased risk of infection and malignancies when antagonists are therapeutically administered in a chronic fashion.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Cytokine networks in multiple sclerosis Codarri et al. 207
Immune-deviation, the TH1/TH2 paradigm Twenty years ago, Mosmann et al. [27] proposed a model to segregate TH cells based on their cytokine signature into TH1 and TH2 subsets. Subsequently, on the basis of experimental data, a simplistic paradigm of ‘good and evil’ was drawn, in which TH1 cells represented the pathogenic subset while TH2 the protective one. The differentiation of T cells into one or the other subset is dependent upon the cytokine milieu during the antigen presentation. The APC-derived factors, IL-12 and IL-18, are master-regulators in polarization of TH1 cells to secrete IL-2, TNF-a and IFN-g supporting direct cellmediated immunity against intracellular pathogens [27,28]. Conversely, TH2 cells develop after priming in an environment rich in IL-4, IL-10 and transforming growth factor-beta (TGF-b) and produce IL-4, IL-5, IL-10 and IL-13, which promote humoral immunity [27]. On the basis of the fact that TH1 cells were found to be associated with exacerbations in autoimmune disease, whereas TH2 cells were associated with protection, the shift of TH1 cells towards TH2 cells was an attractive therapeutic strategy. This strategy became later known as ‘immune deviation’ [29].
rendered EAE-resistant mice susceptible to EAE [39] and promoted spontaneous relapses in EAE susceptible mice [40]. Finally, abrogation of IFN-g or IFN-g receptor expression converted EAE-resistant mice to a hypersusceptible phenotype [41–43]. All these findings collectively suggest protective effects of IFN-g in EAE. In humans, administration of IFN-g to MS patients caused worsening of disease [44]. One explanation is that IFN-g increases major histocompatibility class (MHC) class II molecule expression and thereby promotes antigen presentation. It also augments MHC class I proteins on the cell surface and thereby favours the generation of cytotoxic T cells. Moreover, IFN-g not only induces relapses but also possibly prevents remyelination [45] by interfering with the mobilization of oligodendrocyte precursors [46]. In the light of these data, treatment of MS patients with IFN-g seems heroic. It is likely that the pleiotrophic functions of IFN-g are not exerted at once, but that IFN-g function may differ drastically depending on the spatial and temporal release during disease development.
From TH1 to TH22: one cytokine one lineage? Immune deviation was a trend, and several approved and not-approved drugs were demonstrated to impact the TH1/2 balance including IFN-b [30]. For instance glatiramer acetate, a mixture of random sequences of four amino acids, fumaric acid, unsaturated dicarboxylic acids and laquinimod, a novel synthetic compound, act on the TH1/TH2 balance in favour of the TH2 polarized phenotype [31–34]. It remains unclear, however, whether the change in T-cell polarization is the cause of the therapeutic effect or merely the result of decreased inflammation due to an unrelated mechanism. Animal models predicted an amelioration of the disease when IL-4, a powerful TH2 cytokine, was administered by inducing a skewing of pathogenic TH1 cells towards protective TH2 cells [35]. Based on preclinical data obtained later, the concept that ‘TH1!TH2’ immune deviation is a potent means to combat MS had to be revised. In fact, in some animal experiments, the TH2 cytokine IL-10 had no effect or even worsened the chronic relapsing EAE [36]. Also, depending on the model system, an overt and overactive TH2 response has been shown to lead to the formation of a humoral response that worsened significantly the disease development [37]. Additional observations against this oversimplification of pathogenic versus protective T helper cells were made in a transgenic animal model in which the expression of the TH1 cytokine IFN-g within the CNS prevented the development of demyelination, axonal damage and thereby reduced the clinical symptoms [38]. An anti-inflammatory role of IFN-g has also been suggested from experiments using neutralizing anti-IFN-g antibodies that
IL-12 is one of the two essential cytokines responsible for the polarization of the TH1 subset, and it is composed of heterodimeric subunits called p40 and p35. Mice deficient in IL-12p40 not only fail to generate TH1 cells but are also completely resistant to EAE. In addition, adoptive transfer recipients treated with neutralizing anti-p40 antibodies at the time of transfer or at disease onset were protected or recovered from the disease [47], while treatment of mice with IL-12 mostly exacerbated EAE [48]. In line with these experimental observations, elevated levels of IL-12 were detectable in CSF and lesions of MS patients. Moreover, there was a correlation between the development of active lesions and the increase in IL-12p40 mRNA levels [49]. Later, it became clear that IL-12 was mistaken for its sister cytokine IL-23. Both IL-23 and IL-12 share a common p40 subunit, which pairs with a different second subunit (p35 for IL-12 and p19 for IL-23) [50]. After the discovery of IL-23, it was found that IL-12p35-deficient mice are not EAE resistant but are even hypersusceptible [51–53]. These findings completely dismissed any detrimental function of IL-12 in autoimmune inflammation while highlighting the fundamental and nonredundant role of IL-23 finally proven by the deletion of the p19 subunit [54]. Subsequently, IL-23 was revealed to be an essential factor for the expansion and survival of a novel effector cell subset coined TH17, after its cytokine signature IL-17A [55], and the lack of functional TH17 cells in IL-23-deficient mice cells was presumed to be the reason of their disease resistance [56,57].
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
208 Demyelinating diseases
TH17 cells also produce other cytokines such as IL-17F, IL-6, TNF-a, IL-22 and IL-21. Murine TH17 cells originate, similar to inducible regulatory T cells (Tregs), from naive CD4 T cells after cognate antigen presentation in a tissue culture environment rich in TGF-b and IL-6 or IL-21 [18]. The presence of IL-6 or IL-21 inhibits the expression of Foxp3 driven by TGF-b [58] and instead induces the upregulation of IL-23R and the expression of the transcription factor RORgt, a key regulator of TH17 differentiation [59]. IL-23 plays a fundamental role in vivo in the generation/maintenance of TH17 cells and in their encephalotropism [60,61]. In fact, T cells deficient in the portion of the receptor that binds IL-12 and IL-23 p40 subunit are unable to secrete IL-17 and do not infiltrate the CNS [61]. Despite the clear link between IL-23, pathogenicity and TH17 polarization, neutralization of IL-17A via antibodies or soluble receptors did not consistently improve EAE symptoms and disease kinetics [62]. Moreover, mice deficient in IL-17A were still EAE susceptible and show only a milder clinical course of disease [63,64]. Also, mice lacking IL-17F and IL-17A were still susceptible to the disease [63]. Comparable results were observed when IL-22, another TH17 cytokine, was deleted and IL-22-deficient mice were still fully susceptible to EAE [65]. IL-21 was reported to be essential for TH17 differentiation, and mice deficient in IL-21 were shown to be resistant to EAE [66]. Others, however, could not confirm this finding and showed that the development of EAE is not at all affected in IL-21R and IL-21-deficient mice [67]. It is relatively safe to conclude that although IL-23 remains vital for EAE development, neither TH17 cells nor their cytokine signatures are essential for the disease development [68]. In other words, even though the TH1/TH2 paradigm of autoimmune disease cannot be universally applied, the newly emerged TH17 cell has not provided us with an integrative unifying theory for the observed phenomena in mice. Ever since TH17 cells were coined, researchers felt that if a T cell makes a certain cytokine, this cytokine would be a hallmark molecule representing the T helper cell lineage [69]. This has led to the ‘discovery’ of TH9 and TH22 cells producing IL-9 and IL-22, respectively. Although IL-22 has no apparent function in EAE pathogenesis [65], the case of IL-9 is slightly more complex. One group showed that IL-9R-deficient mice have lower TH17 responses in the CNS and less mast cells in the lymph nodes [70,71], whereas another group described an increased disease development caused by less suppressive Tregs. A recent report claims encephalitogenic potential of TH9 cells that could transfer EAE with comparable severity but distinct pathological phenotypes [72]. It is difficult to say whether these new T-cell
subsets, which are usually polarized under very specific in-vitro conditions, have any physiological or pathological function at all. In vivo, there appears to be a great potential for ‘plasticity’ [73–75]. It is most likely that the T helper cells produce a set of cytokines based on their cognate antigen, the microenvironment and the duration/strength of the immune response. Probably, multiple effector T cells are actually generated in a different gradient of cytokines, and that these cells give rise to the heterogeneous pathologies seen in inflammatory diseases such as MS. In EAE, everyone appears to agree that IL-23 is a notredundant requirement for the generation of an encephalitogenic immune response. So, why not just target IL-23 in MS patients? On the basis of the importance of IL-12/23 p40 in EAE, ustekinumab, an antihuman p40 antibody, was used in a phase II clinical trial of relapsing– remitting MS [76]. During the clinical trial, even though the antibody was well tolerated, ustekinumab did not show any significant therapeutic benefit in the treated versus the control group. In contrast, patients suffering from psoriasis, an inflammatory skin disorder also strongly linked to IL-23 and TH17 cells, benefited greatly from ustekinumab. There are a few possible explanations for the failure of this study: (1) There is strong evidence that IL-23 produced within the CNS is a critical factor in the pathogenesis of EAE [77]. The large size of the antibody molecule may impede its passage through the blood–brain barrier [78] and thus not deliver it where it would have the desired therapeutic effect [79]. (2) It is likely that ustekinumab would have been more effective as a very early treatment on a group with an early disease stage or clinically isolated syndrome, but ineffective in advanced stages, as previously observed in marmosets [80]. As data from animal experiments suggest that IL-12/IL-23 p40 cytokines have a greater involvement in the generation and expansion of autoreactive T cells, it is possible that the window for treatment intervention with ustekinumab might have already passed once the patients were enrolled. (3) The immunopathogenesis of MS is heterogeneous because of the lack of biomarkers useful to identify disease subtypes. In this case, any possible therapeutic effect could be masked by inter-patients differences. This is a problem not only to this clinical trial but also for every neurologist seeking to make a decision about the best therapeutic strategy for his/ her individual patient. (4) Due to the immunization in the EAE model, preclinical work focuses primarily on CD4þ T cells as the protocol biases the system towards activation in this pathway. In humans, however, there is strong evidence that CD8þ T cells are important effector
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Cytokine networks in multiple sclerosis Codarri et al. 209
cells in MS [81]. Targeting p40 only affects TH1/ TH17 cells but not encephalitogenic CD8 T cells (Tosevsky et al., manuscript in preparation). This would mean that IL-23 may be critical for the development of EAE, but patients in whom T helper cells play a less prominent role are not likely to benefit from targeting IL-23. (5) Finally, although p40 neutralization could on one hand be beneficial by blocking the IL-23 pathway, on the other hand, as it also blocks IL-12, it could annihilate any regulatory/positive effect of IL-12. The take-home message from this clinical trial is clearly that we need to fully understand every aspect of the therapeutic intervention and to use additional preclinical models to predict any efficacious or detrimental effect in patients suffering from MS [82].
References and recommended reading Papers of particular interest, published within the annual period of review, have been highlighted as: of special interest of outstanding interest Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 325–327). 1
Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies integrating mammalian biology. Cell 2001; 104:487–501.
2
Hanisch UK. Microglia as a source and target of cytokines. Glia 2002; 40:140–155.
3
Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989; 170:607–612.
4
Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991; 325:467–472.
5
Maimone D, Gregory S, Arnason BG, Reder AT. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 1991; 32:67–74.
6
Klinkert WE, Kojima K, Lesslauer W, et al. TNF-alpha receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview. J Neuroimmunol 1997; 72:163–168.
7
Baker D, Butler D, Scallon BJ, et al. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 1994; 24:2040– 2048.
8
Taoufik E, Tseveleki V, Euagelidou M, et al. Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis. Neurodegener Dis 2008; 5:32–37.
9
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 1999; 53:457–465.
Conclusion An alternative approach to modulating cytokine therapy is to target adhesion molecules on effector T cells involved in the migration through the blood–brain barrier, such as natalizumab, or to target cell-specific depletion such as rituximab and alemtuzumab. These new biologicals were highly effective in reducing inflammatory brain lesions and clinical relapses [83,84]. Unfortunately, these immunosuppressive agents also impair immunosurveillance or lead to a profound disturbance of the immunoregulatory networks with dramatic side effects [85,86]. But interfering systemically with cytokines does not necessarily present a superior approach as it too may lead to completely unexpected adverse effects. We must stress again that the challenge to translate preclinical data into the clinic not only requires intelligent trial design. It is perhaps more important to take the reported successes in preclinical models with a grain of salt. In this current climate of publication policies, it happens only rarely that the failures (negative data) are being reported. This ‘positive publication bias’ may have caused more damage than good when analysing the translation of preclinical data to clinical trials in stroke patients [87]. Concerted efforts should be made to design larger and more comprehensive preclinical trials (even multicenter) and to place immunologists, neuroscientists and clinical specialists at one table to prevent any ‘loss during translation’.
Acknowledgements This work was supported by the Swiss National Science Foundation (B.B.), the National Center for Competence in Research (NCCRNeuro), the Swiss MS-Society (B.B.), the U.S.-National MS Society (B.B.), an unrestricted grant by Merck-Serono-Geneva (B.B.), and a Fellowship grant by the Forschungskredit of the University of Zurich (L.C.). A.F. is Hertie Senior Research Professor Neuroscience 2009 of the Gemeinnu¨tzige Hertie-Stiftung. The authors declare that they do not have any conflict of interests.
10 Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001; 57:1885–1888. 11 Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009; 66:490–497. 12 Korner H, Riminton DS, Strickland DH, et al. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med 1997; 186:1585–1590. 13 Frei K, Eugster HP, Bopst M, et al. Tumor necrosis factor alpha and lymphotoxin alpha are not required for induction of acute experimental autoimmune encephalomyelitis. J Exp Med 1997; 185:2177–2182. 14 Liu J, Marino MW, Wong G, et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998; 4:78–83. 15 Arnett HA, Mason J, Marino M, et al. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001; 4:1116– 1122. 16 Okuda Y, Sakoda S, Fujimura H, et al. IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glucoprotein 35-55 induced experimental autoimmune encephalomyelitis. J Neuroimmunol 1999; 101:188– 196. 17 Okuda Y, Sakoda S, Saeki Y, et al. Enhancement of Th2 response in IL-6deficient mice immunized with myelin oligodendrocyte glycoprotein. J Neuroimmunol 2000; 105:120–123. 18 McGeachy MJ, Bak-Jensen KS, Chen Y, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007; 8:1390–1397. 19 Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235–238. 20 Tzung SP, Mahl TC, Lance P, et al. Interferon-alpha prevents endotoxininduced mortality in mice. Eur J Immunol 1992; 22:3097–3101. 21 Yu M, Nishiyama A, Trapp BD, Tuohy VK. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol 1996; 64:91–100. 22 Teige I, Treschow A, Teige A, et al. IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J Immunol 2003; 170:4776–4784.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
210 Demyelinating diseases 23 Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1997; 49:358–363.
47 Leonard JP, Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995; 181:381–386.
24 Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol 1999; 46:197–206.
48 Constantinescu CS, Hilliard B, Ventura E, et al. Modulation of susceptibility and resistance to an autoimmune model of multiple sclerosis in prototypically susceptible and resistant strains by neutralization of interleukin-12 and interleukin-4, respectively. Clin Immunol 2001; 98:23–30.
25 Weinstock-Guttman B, Ramanathan M, Zivadinov R. Interferon-beta treatment for relapsing multiple sclerosis. Expert Opin Biol Ther 2008; 8:1435– 1447. 26 Prinz M, Schmidt H, Mildner A, et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008; 28:675–686. This is the first study indicating a distinct protective function of endogenous type 1 IFNs on myeloid cells (macrophages, monocytes and microglia) during autoimmune inflammation of the CNS. 27 Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348–2357. 28 Gutcher I, Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest 2007; 117:1119–1127. 29 Nicholson LB, Kuchroo VK. Manipulation of the Th1/Th2 balance in autoimmune disease. Curr Opin Immunol 1996; 8:837–842. 30 Kozovska ME, Hong J, Zang YC, et al. Interferon beta induces T-helper 2 immune deviation in MS. Neurology 1999; 53:1692–1697. 31 Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001; 56:702–708. 32 Miller A, Shapiro S, Gershtein R, et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998; 92:113–121.
49 Comabella M, Balashov K, Issazadeh S, et al. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 1998; 102:671–678. 50 Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13:715–725. 51 Becher B, Durell BG, Noelle RJ. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest 2002; 110:493– 497. 52 Gran B, Zhang GX, Yu S, et al. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 2002; 169:7104–7110. 53 Zhang GX, Gran B, Yu S, et al. Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system. J Immunol 2003; 170:2153–2160. 54 Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421:744–748. 55 Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201:233–240. 56 Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8:345–350.
33 Ghoreschi K, Rocken M. Immune deviation strategies in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3:193–198.
57 Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol 2007; 19:281–286.
34 Yang JS, Xu LY, Xiao BG, et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004; 156:3–9.
58 Xiao S, Jin H, Korn T, et al. Retinoic acid increases Foxp3þ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol 2008; 181:2277–2284. This study unravels the mechanisms through which retinoic acid affects the TH17 development while promoting the conversion towards Tregs.
35 Racke MK, Bonomo A, Scott DE, et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 1994; 180:1961– 1966. 36 Cannella B, Gao YL, Brosnan C, Raine CS. IL-10 fails to abrogate experimental autoimmune encephalomyelitis. J Neurosci Res 1996; 45:735– 746. 37 Genain CP, Abel K, Belmar N, et al. Late complications of immune deviation therapy in a nonhuman primate. Science 1996; 274:2054–2057. 38 Lin W, Bailey SL, Ho H, et al. The integrated stress response prevents demyelination by protecting oligodendrocytes against immune-mediated damage. J Clin Invest 2007; 117:448–456. 39 Billiau A, Heremans H, Vandekerckhove F, et al. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J Immunol 1988; 140:1506–1510. 40 Heremans H, Dillen C, Groenen M, et al. Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: enhancement by monoclonal antibodies against interferon-gamma. Eur J Immunol 1996; 26:2393– 2398. 41 Krakowski M, Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol 1996; 26:1641–1646.
59 Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17þ T helper cells. Cell 2006; 126:1121–1133. 60 McGeachy MJ, Chen Y, Tato CM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 2009; 10:314–324. The study is the first report giving insights into the in-vivo dependency of encephalitogenic T cells from IL-23. IL-23 licenses T helper cells to invade the target tissue and to exert their effector function. 61 Gyulveszi G, Haak S, Becher B. IL-23-driven encephalo-tropism and Th17 polarization during CNS-inflammation in vivo. Eur J Immunol 2009; 39:1864– 1869. The study is the first report giving insights into the in-vivo dependency of encephalitogenic T cells from IL-23. IL-23 licenses T helper cells to invade the target tissue and to exert their effector function. 62 Hofstetter HH, Ibrahim SM, Koczan D, et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 2005; 237:123–130.
42 Ferber IA, Brocke S, Taylor-Edwards C, et al. Mice with a disrupted IFNgamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996; 156:5–7.
63 Haak S, Croxford AL, Kreymborg K, et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Invest 2009; 119:61– 69. This study is the first providing evidence of the dispensability of IL-17A and IL-17F in EAE development and disease kinetics.
43 Willenborg DO, Fordham S, Bernard CC, et al. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 1996; 157:3223–3227.
64 Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006; 177:566–573.
44 Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1:893– 895. 45 Lin W, Kemper A, Dupree JL, et al. Interferon-gamma inhibits central nervous system remyelination through a process modulated by endoplasmic reticulum stress. Brain 2006; 129:1306–1318. 46 Mana P, Linares D, Fordham S, et al. Deleterious role of IFNgamma in a toxic model of central nervous system demyelination. Am J Pathol 2006; 168:1464–1473.
65 Kreymborg K, Etzensperger R, Dumoutier L, et al. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol 2007; 179:8098–8104. 66 Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007; 448:480–483. 67 Sonderegger I, Kisielow J, Meier R, et al. IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivo. Eur J Immunol 2008; 38:1833–1838. This study contradicts the study by Nurieva et al. [66] and claims that IL-21 and its receptor are redundant for EAE induction.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Cytokine networks in multiple sclerosis Codarri et al. 211 68 Steinman L. A rush to judgment on Th17. J Exp Med 2008; 205:1517–1522. 69 Van Epps HL. JEM’s 2009 tune-up. J Exp Med 2009; 206:968–969. 70 Nowak EC, Weaver CT, Turner H, et al. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med 2009; 206:1653–1660. The study defines IL-9 as an autocrine differentiation factor regulating the pathogenic T cells/Tregs asset. 71 Elyaman W, Bradshaw EM, Uyttenhove C, et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3þ natural regulatory T cells. Proc Natl Acad Sci U S A 2009; 106:12885–12890. The study defines IL-9 as an autocrine differentiation factor regulating the pathogenic T cells/Tregs asset. 72 Jager A, Dardalhon V, Sobel RA, et al. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 2009; 183:7169–7177. This study reveals that different pathogenic T helper cells can give rise through different mechanisms to heterogeneous lesions with similar clinical outcome. 73 Lee YK, Turner H, Maynard CL, et al. Late developmental plasticity in the T helper 17 lineage. Immunity 2009; 30:92–107. 74 Zhou L, Chong MM, Littman DR. Plasticity of CD4þ T cell lineage differentiation. Immunity 2009; 30:646–655. 75 Locksley RM. Nine lives: plasticity among T helper cell subsets. J Exp Med 2009; 206:1643–1646. 76 Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcuta neous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008; 7:796–804. This is the first clinical trial on MS patients with anti-p40 antibodies that surprisingly revealed no beneficial effects. 77 Becher B, Durell BG, Noelle RJ. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest 2003; 112:1186–1191.
78 Longbrake EE, Racke MK. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Rev Neurother 2009; 9:319–321. 79 Martin R. Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis. Lancet Neurol 2008; 7:765–766. 80 t Hart BA, Brok HP, Remarque E, et al. Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-antihuman IL-12p40 antibody. J Immunol 2005; 175:4761–4768. 81 Babbe H, Roers A, Waisman A, et al. Clonal expansions of CD8(þ) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192:393–404. 82 Steinman L. Mixed results with modulation of TH-17 cells in human autoimmune diseases. Nat Immunol 2010; 11:41–44. 83 Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676–688. The data of this study provide evidence of B-cell involvement in the pathophysiology of relapsing–remitting MS. 84 Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006; 180:63–70. 85 Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoence phalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834–4840. This study sheds light on possible side effects of rituximab therapy and raises awareness of the potential for progressive multifocal leukoencephalopathy among rituximab-treated patients. 86 Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46:296–304. 87 Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab 2006; 26:1465–1478.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Novel MRI approaches to assess patients with multiple sclerosis Massimo Filippi and Maria A. Rocca Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, Scientific Institute and University Hospital San Raffaele, Milan, Italy Correspondence to Dr Massimo Filippi, Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, Scientific Institute and University Hospital San Raffaele, Via Olgettina, 60, 20132 Milan, Italy Tel: +39 02 26433033; fax: +39 02 26435972; e-mail:
[email protected] Current Opinion in Neurology 2010, 23:212–217
Purpose of review This review summarizes novel MRI approaches for the investigation of lesion burden and understanding of the pathophysiology of multiple sclerosis (MS). Recent findings Recent technical advances are improving our ability to detect and define the nature of focal lesions and ‘diffuse’ tissue damage in MS as well as the functional consequences of such structural abnormalities. New contrast agents allow to monitor the pluriformity of MS inflammation. Double inversion recovery sequences enable us to detect and monitor the evolution of MS lesions in the cortex. High and ultra-high field scanners are improving imaging of MS-related abnormalities at an unprecedented resolution. Furthermore, this new generation of scanners has the potential to ameliorate structural and functional MR studies of the disease. All of this has contributed, and is likely to continue to contribute, to the definition of the factors associated with the development of irreversible disability in MS. Finally, new analysis methods have allowed to track regional disease-related changes and are resulting in an increased correlation between MRI and clinical deficits. Summary Novel MR approaches highlighted previously unrecognized or neglected aspects of MS pathophysiology, which are likely to improve our understanding of the heterogeneous clinical manifestations of this condition. Keywords analysis methods, double inversion recovery, high field, iron, magnetic resonance imaging, multiple sclerosis, permeability, plasticity, regional assessment, ultrasmall particles of iron oxide Curr Opin Neurol 23:212–217 ß 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins 1350-7540
From its first introduction in the clinical arena [1], magnetic resonance imaging (MRI) appeared as a valuable tool to investigate multiple sclerosis (MS). This was mainly due to its high sensitivity for detecting focal abnormalities in the central nervous system (CNS) of these patients. The effort spent during the past three decades to explore the many potentialities of this instrument has led to the achievement of undisputable milestones, such as the inclusion of MRI findings in the diagnostic criteria for MS (which allows an early diagnosis to be reached) [2], and the identification of MRI markers to monitor the evolution of the disease both in clinical practice and in the context of treatment trials.
MR spectroscopy (1H-MRS)] have been used to study the structural CNS changes associated with this condition and are being progressively moved from a research setting to clinical practice. These techniques have the great advantage of being more specific towards the heterogeneous pathological substrates of the disease than conventional MRI. In addition, they also allow to quantify and monitor the extent of damage not only in lesions but also in normal-appearing tissues. Finally, the development of new analysis approaches to assess functional MRI (fMRI) data is disclosing, at an unprecedented pace, the mechanisms of cortical reorganization following the accrual of tissue damage, which have the potential to limit its clinical consequences.
In addition to conventional MRI [which includes dualecho, fast fluid-attenuated inversion recovery (FLAIR), and T1-weighted imaging with and without gadolinium (Gd) administration], several quantitative MR techniques [including magnetization transfer MRI, diffusion-weighted and diffusion tensor MRI, and proton
Since MRI technology continues to unfold in a seemingly limitless way, new techniques are being currently developed and applied. The most promising of these are presented here and their contributions to the improvement of our understanding of the disease pathophysiology are discussed.
Introduction
1350-7540 ß 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
DOI:10.1097/WCO.0b013e32833787b0
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Novel MRI approaches to assess patients with MS Filippi and Rocca 213
New contrast agents The injection of Gd and the identification of enhancing lesions on T1-weighted scans is the present more powerful MR approach to detect MS inflammatory changes. Such an approach allows the detection of areas with an increased blood–brain barrier permeability. More recently, new MRI contrast agents composed of iron particles, known as ultrasmall particles of iron oxide (USPIO) or super-paramagnetic iron particles of oxide (SPIO), have been used to detect the presence of macrophages in ‘active’ MS lesions [3]. In relapsing remitting MS (RRMS) patients, it has been shown that some lesions may enhance only with Gd, others only with USPIO, and others with both [3]. In addition, the same lesions can change their enhancing pattern over time [3]. These findings indicate that new contrasts might provide pieces of information complementary to that offered by Gd-enhancing MRI scans, with the potential to depict the pluriformity of the MS inflammatory process. The potential of USPIO to detect the cellular component of ‘diffuse’ MS disease has also been explored recently by measuring T1 relaxation time changes in the normal-appearing white matter (NAWM) following its administration [4].
Double inversion recovery sequences and cortical lesions In MS, cortical lesions have been described from the earliest pathological studies [5], but are typically not seen on conventional MRI scans [6]. The development and application of double inversion recovery (DIR – i.e. two inversion times are used to suppress the signal from both white matter and cerebrospinal fluid) sequences have markedly improved the sensitivity of MRI to detect such lesions in vivo (a gain of 538% has been reported vs. the use of T2-weighted spin-echo sequences) [7]. Cortical lesions have been detected in all the major MS clinical phenotypes, including patients with clinically isolated syndromes (CIS) suggestive of MS [8–10]. Remarkably, cortical lesions are more frequently seen in patients with secondary progressive MS than in those with CIS or RRMS [8], whereas in patients with benign MS they are fewer than in those with early RRMS [9]. Lesions have also been visualized in the hippocampus [11]. Recent longitudinal studies have shown that new cortical lesions continue to form in patients with early RRMS [9], and in those with the progressive disease phenotypes over 1 to 2-year periods of follow-up [10,12,13,14]. All of this suggests that cortical lesions might contribute to the accumulation of irreversible disability in MS. This notion is supported by the demonstration of an association between cortical lesion burden and progression of disability over the subsequent 2 [10] and 3 [12] years in patients with different disease phenotypes, as well as
between cortical lesion burden and the severity of cognitive impairment in patients with relapse-onset MS [14,15]. The ability of MRI to visualize cortical lesions is still suboptimal. Indeed, DIR imaging allows to classify, on average, as intracortical only 4.6% of the overall number of gray matter lesions [8] in contrast to a figure of 59% reported by pathological studies [16]. As a consequence, a set of new strategies has been proposed to improve the detection and allow a reliable classification of these lesions, including the use of a single-slab 3D DIR sequence [17], and the combination of DIR with other sequences, such as phase-sensitive inversion recovery [18] and 3D magnetization-prepared rapid acquisition with gradient echo [19]. A better in-vivo understanding of the pathological substrates of cortical lesions is likely to be achieved via the combination of DIR sequences with quantitative MR techniques, such as diffusion tensor MRI [20].
High-field MRI Magnet field strengths higher than 1.5 Tesla (T) improve image resolution, signal-to-noise ratio and chemical shift. In patients with established MS, this has resulted in an increased detection of T2-visible brain [21], but not spinal cord [22], lesions at 3.0 T compared with at 1.5 T. Remarkably, the use of DIR imaging at 3.0 T has led to a higher detection of infratentorial lesions compared with FLAIR and T2-weighted sequences in patients with both CIS and established MS [23]. So far, only one study has assessed the performance of the MRI diagnostic criteria for MS at 1.5 and 3.0 T. In CIS patients, despite an increased lesion detection, 3.0 T imaging led to very little gain in terms of showing the presence of spatial lesion dissemination [24].
Ultra-high field MRI The future of MRI is likely to reside in the use of ultra-high field scanners. A few preliminary studies performed at 7.0 T [25,26–28] showed the ability of MRI to depict the morphological characteristics of MS lesions in the white matter and gray matter at a resolution which resembles that of pathological assessment. In 12 patients with established MS, there were 97 white matter lesions detected on 1.5 T vs. 126 lesions at 7.0 T [28]. Kangarlu et al. [27] compared MR images of brain samples from newly deceased MS patients obtained at 8.0 and 1.5 T, and showed that cortical lesions, invisible on MRI scans at 1.5 T, were clearly seen at 8.0 T. More recently, using a 7.0 T scanner, Mainero et al. [26] identified 199 cortical lesions in 16 MS patients. Three major lesion patterns were identified (type I: leukocortical; type II: intracortical, and types III/IV: subpial
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
214 Demyelinating diseases
extending partly or completely through the cortical layers). These studies [25,26–28] also allowed a better definition of the relationship between demyelinating lesions and the deep venous system to be achieved, and showed in-vivo that MS plaques are centered around the microvasculature. In addition, ultra-high field MRI has the potential to improve quantitative, metabolic and fMRI studies of MS. A recent 1H-MRS study at 7.0 T [29] was able to quantify the concentration of glutathione, a marker of oxidative status, in the NAWM and gray matter from healthy controls and MS patients. In healthy controls, the concentration of glutathione was higher in the gray matter than the white matter, and MS patients had a significant reduction of glutathione concentration in macroscopic lesions and the gray matter, but not in the NAWM, when compared to healthy individuals, which is consistent with a diminished protection against free radicals.
Perfusion MRI Magnetic resonance imaging can be used to assess brain tissue perfusion in vivo using either exogenous tracers (e.g. Gd chelates) or endogenous arterial water [arterial spin labeling (ASL)]. Chronic MS lesions are characterized by a decreased perfusion, whereas Gd-enhancing lesions typically show an increased perfusion. A widespread hypoperfusion in the NAWM as well as in cortical and deep gray matter of patients with relapsing remitting and progressive MS has also been shown [30]. Such changes have been correlated with clinical disability [31] and neuropsychological impairment [32]. Recently, perfusion abnormalities have also been detected in the NAWM, but not in the gray matter, from CIS patients [33], suggesting that tissue perfusion decreases might begin in the NAWM.
relation (MFC) (use of asymmetric spin-echoes to measure the influence of MR signaling by magnetic field inhomogeneity), and susceptibility-weighted imaging (SWI) (3D, high-resolution, flow compensated gradient echo sequences that use magnitude and phase data to enhance information on local tissue susceptibility), are likely to improve our ability to detect iron deposition. Basal ganglia transverse relaxation rate (R2) values were found to be higher in RRMS than in CIS patients [38]. T2’ values, which reflect the relation of local deoxyhemoglobin to oxyhemoglobin and thus the fraction of oxygen extraction, were significantly lower in the deep gray matter nuclei from MS patients compared with healthy individuals, presumably because of a high iron concentration in the former individuals [39]. In contrast, R2 values were significantly increased in patient NAWM than in controls, probably as a consequence of a reduced tissue metabolism [39]. Using a 3.0 T scanner, MFC in the deep gray matter was found to be significantly increased in RRMS patients and to correlate with T2 visible lesions and neuropsychological abnormalities [40]. Two studies, at 4.0 T [41] and 4.7 T [42], demonstrated that the use of phase and magnitude SWI can contribute to identify additional (from 18 to 47%) lesions, that are not visible on T2weighted images. SWI has also been applied to assess cerebral venous oxygen level changes in RRMS patients and showed a significantly reduced visibility of the venous vasculature in the periventricular white matter [43]. Finally, using phase imaging at 7.0 T, Hammond et al. [25] found an increased local field shift, caused by magnetic susceptibility-shifted compounds such as iron, in the deep gray matter nuclei of MS patients compared to healthy individuals, which was correlated with disease duration.
Plasticity Magnetic resonance techniques to image iron deposition Iron deposition is likely to be associated to neurodegeneration and contribute to MS pathogenesis by promoting oxidative damage. Abnormal iron deposition is thought to be the substrate of T2 hypointense areas and reduced T2 relaxation time seen in the basal ganglia, thalamus, dentate nucleus, and cortical regions seen in the majority of MS clinical phenotypes [34], including patients with benign MS (BMS) [35] and those with CIS suggestive of MS [36]. Gray matter T2 hypointensity was found to be correlated with the severity of clinical disability and cognitive impairment in patients with MS [34], as well as with clinical progression [37]. At 3.0 T or more, T2 and other imaging approaches, such as T2, T2’ or T2-rho relaxometry, magnetic field cor-
Technical advances in methods of analysis have allowed, on the one hand, to study the function of relatively small CNS structures, and, on the other, to obtain estimates of the activations and synchrony between brain areas. An increased activation of the cervical spinal cord has been demonstrated in all the major MS clinical phenotypes and has been related to the severity of clinical disability and the extent of tissue damage to this structure [44,45]. Abnormal effective connectivity within the motor [46] and the cognitive [47] networks has been shown in patients with RRMS [46] and BMS [47]. On the contrary, no such changes have been detected in patients with pediatric MS [48]. More recently, the use of measures of abnormal effective connectivity has been shown to be feasible in the context of multicenter studies [49]. These data suggest that assessing fMRI changes in MS patients might shed light
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Novel MRI approaches to assess patients with MS Filippi and Rocca 215
on the mechanisms responsible for the accumulation of irreversible clinical deficits.
Combined analysis of different magnetic resonance techniques The combination of different MR modalities, sensitive toward different aspects of MS disease, is likely to improve our understanding of the mechanisms responsible for the accumulation of fixed neurological deficits in this disease. Damage to the optic radiations measured using diffusion tensor MRI was related with retinal nerve fiber layer thickness and visual impairment in patients with relapsing remitting and progressive MS [50]. In RRMS patients, corticospinal tract (CST) damage, measured using diffusion tensor MRI tractography, was associated with an altered effective connectivity of the motor network [46]. In BMS patients a correlation between diffusivity changes of the corpus callosum and an abnormal interhemispheric effective connectivity during the performance of attention-related tasks was shown [47]. Diffusion tensor MRI abnormalities of transcallosal white matter pathways connecting the primary motor cortices have been correlated with changes of low-frequency blood oxygen level dependent fluctuations [51]. By combining cortical thickness measurements with T2 lesion load burden, an increase of white matter lesion volume was found to be correlated with impairment of both global and local topological organization of brain structural networks [52]. This provides evidence that a disconnection of brain areas may play a role in the pathophysiology of MS.
New analysis methods Additional important achievements have been obtained from the development and application of new methods to analyze MR data. Lesions
Novel approaches to the analysis of macroscopic visible lesions include the assessment of their regional distribution using lesion probability maps [53], the use of timeseries modeling of MR imaging intensity to study dynamic pixel-wise signal changes related to lesion evolution [54], and the use of subtraction approaches to display lesion changes over time [55]. Chen et al. [56] used a voxel-based analysis of magnetization transfer MRI scans to track demyelination and remyelination in individual MS lesions. Topographical distribution of normal-appearing white matter damage
Using a voxel-based approach, a recent study [53] showed that patients with RRMS and BMS differ in term of topographical distribution of white matter damage, whereas no between-group differences were found when
the overall extent of white matter diffusivity changes was assessed using a histogram-based approach. Tract-based spatial statistics (TBSS) is a technique that allows voxelwise analysis of multipatients’ diffusion tensor MRI data. Using such a technique, compared to healthy controls, MS patients had reduced fractional anisotropy values in several white matter fiber bundles, which were related to deficits of specific cognitive domains [14,57]. Regional damage can also be assessed by means of diffusion tensor MRI tractography methods, which allow to segment clinically eloquent white matter pathways. A diffusion tensor MRI tractography study showed that CIS patients with motor impairment have increased mean diffusivity in the CST compared to patients without pyramidal symptoms [58]. In patients with RRMS, corpus callosum diffusivity values were found to be associated with the level of cognitive performance [59]. Using a magnetization transfer weighted approach, a study showed that signal abnormalities in the dorsal and lateral columns of the spinal cord are correlated with vibration sensation and strength, respectively [60]. Topographical distribution of gray matter damage
The use of voxel-wise approaches has allowed to define the distribution of gray matter abnormalities in MS, thus improving the correlation with disease clinical manifestations. Voxel-based morphometry (VBM) studies have shown consistently that the patterns of regional gray matter loss differ among patients with the major disease clinical phenotypes [53]. In CIS patients, gray matter atrophy involves the thalamus, hypothalamus, putamen and caudate nucleus [61], whereas in RRMS patients cortical atrophy, which affects preferentially the fronto-temporal lobes, is typically detected [62]. In these latter patients, cortical volume reduction over 1 year was correlated to white matter lesion progression [62]. Compared to controls, BMS patients have a reduced gray matter volume in the subcortical and frontoparietal regions [63]. In comparison with BMS patients, those with secondary progressive MS (SPMS) have a significant gray matter loss in the cerebellum [63]. Patients with pediatric MS experience gray matter atrophy in the thalamus only, with sparing of the cortex and other deep gray matter nuclei [64], suggesting that the overall amount of tissue damage in pediatric MS is modest in comparison with the adult forms of the disease. Voxel-wise analysis of magnetization transfer and diffusion tensor MRI data can also be used to assess intrinsic gray matter damage. Khaleeli et al. [65] showed, in primary progressive MS patients, a significant correlation between decrease of magnetization transfer ratio (MTR) values of cortical motor areas and the Expanded Disability Status Scale (EDSS) scores, as well as between MTR values in cortical cognitive areas and the Paced Auditory Serial Addition Task scores. Similarly, using a voxel-based
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
216 Demyelinating diseases
analysis of diffusion tensor MRI maps, Ceccarelli et al. [66] showed diffusivity abnormalities of brain areas associated with motor and cognitive functions in primary progressive MS (PPMS).
Conclusion The development and application of novel MR techniques of acquisition and postprocessing have resulted in an improved understanding of MS pathophysiology. This technical advancement has allowed to disclose additional factors, previously unrecognized or neglected, which are likely to contribute to the accumulation of irreversible clinical deficits in this condition. Nevertheless, at least some of the novel MR approaches discussed here are in their infancy and several issues are still to be resolved (such as those related to their optimization and standardization across centers) to move them from a research setting to daily-life clinical practice.
References and recommended reading Papers of particular interest, published within the annual period of review, have been highlighted as: of special interest of outstanding interest Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 328–329). 1
Young IR, Hall AS, Pallis CA, et al. Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet 1981; 2:1063–1066.
2
McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50:121–127.
Vellinga MM, Oude Engberink RD, Seewann A, et al. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain 2008; 131:800–807. In this study, ultra-small superparamagnetic particles of iron oxide (USPIO) were used to track longitudinally the patterns of enhancement in 19 patients with relapsing remitting MS. It was shown that USPIO is more frequent than gadolinium (Gd) enhancement, can persist for longer periods of time and, in some cases, can be detected 1 month earlier.
3
4
Vellinga MM, Vrenken H, Hulst HE, et al. Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: an exploratory study. J Magn Reson Imaging 2009; 29:774–779.
5
Dawson KT. The histology of multiple sclerosis. Trans R Soc Edinburgh 1916; 50:517–740.
6
Filippi M, Rocca MA. Conventional MRI in multiple sclerosis. J Neuroimaging 2007; 17 (Suppl 1):3S–9S.
7
Geurts JJ, Pouwels PJ, Uitdehaag BM, et al. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 2005; 236:254–260.
8
Calabrese M, De Stefano N, Atzori M, et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol 2007; 64:1416–1422.
9
Calabrese M, Filippi M, Rovaris M, et al. Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. Mult Scler 2009; 15:36–41.
10 Calabrese M, Rocca MA, Atzori M, et al. Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology 2009; 72:1330–1336. 11 Roosendaal SD, Moraal B, Vrenken H, et al. In vivo MR imaging of hippocampal lesions in multiple sclerosis. J Magn Reson Imaging 2008; 27:726–731. 12 Calabrese M, Rocca M, Atzori M, et al. A three-year MRI study of cortical lesions in relapse-onset multiple sclerosis. Ann Neurol (in press). Using a double inversion recovery sequence, this 3-year longitudinal study of 107 relapse-onset MS patients demonstrated that cortical lesions accumulate over time and are associated with disability progression.
13 Calabrese M, Filippi M, Rovaris M, et al. Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study. Neuroimage 2008; 42:1324–1328. 14 Roosendaal SD, Moraal B, Pouwels PJ, et al. Accumulation of cortical lesions in MS: relation with cognitive impairment. Mult Scler 2009; 15:708–714. 15 Calabrese M, Agosta F, Rinaldi F, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 2009; 66:1144–1150. 16 Kidd D, Barkhof F, McConnell R, et al. Cortical lesions in multiple sclerosis. Brain 1999; 122 (Pt 1):17–26. 17 Pouwels PJ, Kuijer JP, Mugler JP 3rd, et al. Human gray matter: feasibility of single-slab 3D double inversion-recovery high-spatial-resolution MR imaging. Radiology 2006; 241:873–879. 18 Nelson F, Poonawalla AH, Hou P, et al. Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging. AJNR Am J Neuroradiol 2007; 28:1645–1649. 19 Nelson F, Poonawalla A, Hou P, et al. 3D MPRAGE improves classification of cortical lesions in multiple sclerosis. Mult Scler 2008; 14:1214–1219. 20 Poonawalla AH, Hasan KM, Gupta RK, et al. Diffusion-tensor MR imaging of cortical lesions in multiple sclerosis: initial findings. Radiology 2008; 246:880–886. By combining double inversion recovery imaging with diffusion tensor MRI, this study detected increased fractional anisotropy and mean diffusivity values in cortical lesions of nine MS patients in comparison with the corresponding regions from healthy individuals. 21 Wattjes MP, Barkhof F. High field MRI in the diagnosis of multiple sclerosis: high field-high yield? Neuroradiology 2009; 51:279–292. 22 Stankiewicz JM, Neema M, Alsop DC, et al. Spinal cord lesions and clinical status in multiple sclerosis: a 1.5 T and 3 T MRI study. J Neurol Sci 2009; 279:99–105. 23 Wattjes MP, Lutterbey GG, Gieseke J, et al. Double inversion recovery brain imaging at 3T: diagnostic value in the detection of multiple sclerosis lesions. AJNR Am J Neuroradiol 2007; 28:54–59. 24 Wattjes MP, Harzheim M, Lutterbey GG, et al. Does high field MRI allow an earlier diagnosis of multiple sclerosis? J Neurol 2008; 255:1159–1163. This study compared the performance of the International Panel and the Swanton criteria at 1.5 and 3.0 T in 40 patients at presentation with a clinically isolated syndrome suggestive of MS. It showed that 3.0 T imaging allows to meet the criteria for disease dissemination in space in only one additional patient compared to 1.5 T imaging. 25 Hammond KE, Metcalf M, Carvajal L, et al. Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008; 64:707–713. Using a 7.0 T magnet, these authors showed an increased local field in phase images of the basal ganglia of MS patients relative to healthy controls. In addition, phase images increased lesion detection by more than 30% compared to conventional magnitude images and allowed to visualize the relationship between lesions and vasculature. 26 Mainero C, Benner T, Radding A, et al. In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology 2009; 73:941–948. 27 Kangarlu A, Bourekas EC, Ray-Chaudhury A, Rammohan KW. Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla. AJNR Am J Neuroradiol 2007; 28:262–266. 28 Kollia K, Maderwald S, Putzki N, et al. First clinical study on ultra-high-field MR imaging in patients with multiple sclerosis: comparison of 1.5T and 7T. AJNR Am J Neuroradiol 2009; 30:699–702. 29 Srinivasan R, Ratiney H, Hammond-Rosenbluth KE, et al. MR spectroscopic imaging of glutathione in the white and gray matter at 7 T with an application to multiple sclerosis. Magn Reson Imaging 2009 [Epub ahead of print]. Using a 7.0 T scanner, these authors measured brain glutathione concentration and showed a significant reduction of its concentration in the gray matter, but not in the white matter, of MS patients compared to healthy individuals. 30 Inglese M, Park SJ, Johnson G, et al. Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3 T. Arch Neurol 2007; 64:196–202. 31 Adhya S, Johnson G, Herbert J, et al. Pattern of hemodynamic impairment in multiple sclerosis: dynamic susceptibility contrast perfusion MR imaging at 3.0 T. Neuroimage 2006; 33:1029–1035. 32 Inglese M, Adhya S, Johnson G, et al. Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. J Cereb Blood Flow Metab 2008; 28:164–171. Using dynamic susceptibility contrast-enhanced T2-weighted MRI, a significant hypoperfusion was found in the normal-appearing white matter and gray matter from 32 MS patients, which was related to deficits of specific cognitive domains.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Novel MRI approaches to assess patients with MS Filippi and Rocca 217 33 Varga AW, Johnson G, Babb JS, et al. White matter hemodynamic abnormalities precede sub-cortical gray matter changes in multiple sclerosis. J Neurol Sci 2009; 282:28–33.
50 Reich DS, Smith SA, Gordon-Lipkin EM, et al. Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability. Arch Neurol 2009; 66:998–1006.
34 Neema M, Stankiewicz J, Arora A, et al. T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis. J Neuroimaging 2007; 17 (Suppl 1):16S–21S.
51 Lowe MJ, Beall EB, Sakaie KE, et al. Resting state sensorimotor functional connectivity in multiple sclerosis inversely correlates with transcallosal motor pathway transverse diffusivity. Hum Brain Mapp 2008; 29:818– 827.
35 Ceccarelli A, Filippi M, Neema M, et al. T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis. Mult Scler 2009; 15:678–686. 36 Ceccarelli A, Rocca MA, Neema M, et al. Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis. Mult Scler 2010; 16:39–44. 37 Neema M, Arora A, Healy BC, et al. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging 2009; 19:3–8. 38 Khalil M, Enzinger C, Langkammer C, et al. Quantitative assessment of brain iron by R(2) relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Mult Scler 2009; 15:1048–1054. 39 Holst B, Siemonsen S, Finsterbusch J, et al. T2’ imaging indicates decreased tissue metabolism in frontal white matter of MS patients. Mult Scler 2009; 15:701–707. 40 Ge Y, Jensen JH, Lu H, et al. Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. AJNR Am J Neuroradiol 2007; 28:1639–1644. 41 Haacke EM, Makki M, Ge Y, et al. Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging 2009; 29:537–544. 42 Eissa A, Lebel RM, Korzan JR, et al. Detecting lesions in multiple sclerosis at 4.7 tesla using phase susceptibility-weighting and T2-weighting. J Magn Reson Imaging 2009; 30:737–742. This study compared high resolution three-dimensional susceptibility-weighted imaging (SWI) with 2D T2-weighted fast spin echo (T2WFSE) at 4.7 Tesla (T) and showed that high resolution T2WFSE provides an excellent depiction of MS hyperintense lesions. When combined with phase SWI, 124 lesions were identified; of these 18% were visible only on phase SWI.
52 He Y, Dagher A, Chen Z, et al. Impaired small-world efficiency in structural cortical networks in multiple sclerosis associated with white matter lesion load. Brain 2009; 132:3366–3379. 53 Ceccarelli A, Rocca MA, Pagani E, et al. A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. Neuroimage 2008; 42:315–322. 54 Meier DS, Weiner HL, Guttmann CR. MR imaging intensity modeling of damage and repair in multiple sclerosis: relationship of short-term lesion recovery to progression and disability. AJNR Am J Neuroradiol 2007; 28:1956–1963. 55 Duan Y, Hildenbrand PG, Sampat MP, et al. Segmentation of subtraction images for the measurement of lesion change in multiple sclerosis. AJNR Am J Neuroradiol 2008; 29:340–346. 56 Chen JT, Collins DL, Atkins HL, et al. Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 2008; 63:254–262. In MS patients participating in a three-year longitudinal study, the authors measured changes of magnetization transfer ratio (MTR) of individual lesion voxels, as well as the mean normalized MTR over all lesion voxels during and after contrast enhancement. The mean normalized MTR of Gd-enhancing lesions was significantly decreased at the time of lesion enhancement, partially recovered over the subsequent four months, and then appeared to stabilize. Individual lesions showed considerable heterogeneity in the evolution of their mean normalized MTR: some showed a partial MTR recovery, others a steadily low MTR, and others a further MTR decline over time. 57 Dineen RA, Vilisaar J, Hlinka J, et al. Disconnection as a mechanism for cognitive dysfunction in multiple sclerosis. Brain 2009; 132:239– 249.
43 Ge Y, Zohrabian VM, Osa EO, et al. Diminished visibility of cerebral venous vasculature in multiple sclerosis by susceptibility-weighted imaging at 3.0 Tesla. J Magn Reson Imaging 2009; 29:1190–1194.
58 Pagani E, Rocca MA, Gallo A, et al. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. AJNR Am J Neuroradiol 2005; 26:341–346.
44 Agosta F, Valsasina P, Absinta M, et al. Evidence for enhanced tactile associated functional MRI activity in the cervical cord of patients with primary progressive multiple sclerosis. Radiology (in press). Using functional MRI, these authors demonstrated a higher mean spinal cord activity in 23 primary progressive MS patients compared to 18 healthy controls. Severely disabled patients had a more bilateral pattern of activation than those with mild disability. Spinal cord fMRI abnormalities were found to be correlated with diffusivity changes of the same structure.
59 Lin X, Tench CR, Morgan PS, Constantinescu CS. Use of combined conventional and quantitative MRI to quantify pathology related to cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008; 79:437–441.
45 Valsasina P, Agosta F, Absinta M, et al. Cervical cord functional MRI changes in relapse-onset MS patients. J Neurol Neurosurg Psychiatry 2009 [Epub ahead of print]. 46 Rocca MA, Pagani E, Absinta M, et al. Altered functional and structural connectivities in patients with MS: a 3-T study. Neurology 2007; 69:2136–2145. 47 Rocca MA, Valsasina P, Ceccarelli A, et al. Structural and functional MRI correlates of Stroop control in benign MS.Hum Brain Mapp 2009; 30:276–290. 48 Rocca MA, Absinta M, Ghezzi A, et al. Is a preserved functional reserve a mechanism limiting clinical impairment in pediatric MS patients? Hum Brain Mapp 2009; 30:2844–2851. 49 Rocca MA, Absinta M, Valsasina P, et al. Abnormal connectivity of the sensorimotor network in patients with MS: a multicenter fMRI study. Hum Brain Mapp 2009; 30:2412–2425. In this multicenter study, the authors used dynamic causal modeling to assess effective connectivity of the sensorimotor network in 61 MS patients and 74 healthy individuals. They found abnormal coefficients of effective connectivity in patients. This suggests that large multicenter fMRI studies of effective connectivity changes in diseased people are feasible.
60 Zackowski KM, Smith SA, Reich DS, et al. Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord. Brain 2009; 132:1200–1209. 61 Henry RG, Shieh M, Okuda DT, et al. Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 2008; 79:1236–1244. 62 Bendfeldt K, Kuster P, Traud S, et al. Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis: a longitudinal voxel-based morphometry study. Neuroimage 2009; 45:60– 67. 63 Mesaros S, Rovaris M, Pagani E, et al. A magnetic resonance imaging voxelbased morphometry study of regional gray matter atrophy in patients with benign multiple sclerosis. Arch Neurol 2008; 65:1223–1230. 64 Mesaros S, Rocca MA, Absinta M, et al. Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology 2008; 70:1107–1112. 65 Khaleeli Z, Cercignani M, Audoin B, et al. Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability. Neuroimage 2007; 37:253–261. 66 Ceccarelli A, Rocca MA, Valsasina P, et al. A multiparametric evaluation of regional brain damage in patients with primary progressive multiple sclerosis. Hum Brain Mapp 2009; 30:3009–3019.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Stem cell transplantation in multiple sclerosis Antonio Uccellia,b,c and Gianluigi Mancardia,b a Department of Neurosciences, Ophthalmology and Genetics, bCenter of Excellence for Biomedical Research, University of Genoa, Genoa and cAdvanced Biotechnology Center (ABC), Genoa, Italy
Correspondence to Antonio Uccelli, MD, Department of Neurosciences, Ophthalmology and Genetics, University of Genoa, Via De Toni 5, 16132 Genoa, Italy Tel: +39 0103537028; e-mail:
[email protected] [email protected] Current Opinion in Neurology 2010, 23:218–225
Purpose of review The recent advances in our understanding of stem cell biology, the availability of innovative techniques that allow large-scale acquisition of stem cells, and the increasing pressure from the multiple sclerosis (MS) patient community seeking tissue repair strategies have launched stem cell treatments as one of the most exciting and difficult challenges in the MS field. Here, we provide an overview of the current status of stem cell research in MS focusing on secured actuality, reasonable hopes and unrealistic myths. Recent findings Results obtained from small clinical studies with transplantation of autologous hematopoietic stem cells have demonstrated that this procedure is feasible and possibly effective in severe forms of MS but tackles exclusively inflammation without affecting tissue regeneration. Results from preclinical studies with other adult stem cells such as mesenchymal stem cells and neural precursor cells have shown that they may be a powerful tool to regulate pathogenic immune response and foster tissue repair through bystander mechanisms with limited cell replacement. However, the clinical translation of these results still requires careful evaluation. Conclusion Current experimental evidence suggests that the sound clinical exploitation of stem cells for MS may lead to novel strategies aimed at blocking uncontrolled inflammation, protecting neurons and promoting remyelination but not at restoring the chronically deranged neural network responsible for irreversible disability typical of the late phase of MS. Keywords autoimmunity, experimental autoimmune encephalomyelitis, multiple sclerosis, stem cells, transplantation Curr Opin Neurol 23:218–225 ß 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins 1350-7540
Introduction In the last few years, the extraordinary progress in our understanding of adult stem cell biology has led to major advances in the field of cell therapy, allowing us to translate our basic knowledge about different kinds of stem cells into therapeutic strategies aimed at treating neurological diseases such as multiple sclerosis (MS). Although autologous hematopoietic stem cell transplantation (AHSCT) has now been proven to be a powerful, although risky, therapy for some forms of MS, other stem cell types have gained attention as potential future therapeutic options for MS. However, experimental data have posed us with an unforeseen scenario. As most scientists moved into the stem cell arena due to an unmet need for therapies for tissue repair, current evidence suggests that stem cells that have been proven to ameliorate symptoms and protect neural cells in experimental autoimmune encephalomyelitis (EAE), a model of MS, also have a limited, if any, capacity for transdifferentiating into neural cells, but may foster tissue 1350-7540 ß 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
protection and repair through unexpected mechanisms of action.
Autologous hematopoietic stem cells for the treatment of autoimmunity AHSCT has been proposed for severe autoimmune disorders unresponsive to conventional treatments [1] based on results from experimental models [2]. AHSCT procedure consists of mobilization from the bone marrow of peripheral blood stem cells (PBSCs) usually with cyclophosphamide in combination with granulocyte-colony stimulating factor. PBSCs expressing the surface antigen CD34 are collected by leukapheresis and cryopreserved. The graft can be manipulated with a positive selection of CD34þ cells or a negative depletion of T cells, in order to eliminate autoreactive clones. The patient is then treated with the conditioning regimen, usually with high-dose cytotoxic agents such as BEAM (BCNU, carmustine, etoposide, cytosine–arabinoside and melphalan), total body irradiation (TBI) or other various combinations of DOI:10.1097/WCO.0b013e328338b7ed
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
SCT in multiple sclerosis Uccelli and Mancardi 219
cytotoxic agents. The conditioning regimens are usually classified as high-intensity (TBI or any busulphan-containing protocol), medium-intensity (BEAM, carmustine and cyclophosphamide) or low-intensity regimens (cyclophosphamide alone or fludarabine-based schemes). The cryopreserved graft is then re-infused into the patient and antithymocyte globulin (ATG) is administered in order to eradicate self-reactive T cells. After a period of aplasia of 2–3 weeks, engraftment occurs. The rationale of the procedure relies on intense immunosuppression aimed at destroying autoreactive cells and the subsequent immune reconstitution that is associated with profound qualitative changes of the immune repertoire.
Autologous hematopoietic stem cell transplantation in multiple sclerosis: clinical outcome More than 400 MS cases have been reported so far in the European Bone Marrow Transplantation database. However, although no phase III clinical trial has been completed yet, a series [3] of small phase I/II studies have been reported. Despite the concerns regarding different protocols and disease forms treated, 60–70% of patients after 3 years and 50–60% after 6–8 years do not progress from transplantation [4]. In a recent study [5], 50 MS patients were treated with BEAM and ATG followed by AHSCT at different disease phases with Expanded Disability Status Scale (EDSS) ranging from 1.5 (‘early AHSCT’) to 8.0 (‘salvage AHSCT’). The procedure was well tolerated and effective and 62% of patients improved at least 0.5 points on EDSS, particularly when AHSCT was performed in young individuals. Progression-free survival at 6 years was 72%. The Canadian MS BMT Study Group [6] treated 17 aggressive MS patients with a high-intensity conditioning regimen (busulphan and cyclophosphamide) with ex-vivo and in-vivo T-cell depletion. These patients had a favorable outcome, with 75% progression-free survival at 3 years, without any relapse or new MRI lesions nearly 5 years after treatment [6]. The retrospective analysis of transplanted patients data performed in 2002 [7] and 2006 [4], did not show any difference in disability progression between high and intermediate-intensity regimens, whereas a correlation was observed for transplant-related mortality (TRM; 6 and 5.3%, respectively) and regimens including busulphan. Although TRM has been reported to decrease to 1.3% in a recent analysis [3], most likely as a result of better patient selection and improved experience of the transplanting centers, low-intensity treatments, with minimal myelotoxic effects, have been proposed [8]. In a recent study, 21 young, relapsing– remitting MS (RRMS) patients with mild disability and short disease duration were treated using a low-intensity conditioning regimen (cyclophosphamide 200 mg/kg followed by alemtuzumab or ATG). After 3 years, 81%
of patients improved by at least 1 point on EDSS and 62% were disease free. Modest toxicity was reported and 23% of patients relapsed after 6–16 months. Recently, in an open-label study [9], the effect of low-intensity (cyclophosphamide and rabbit ATG) and medium-intensity (BEAM and horse ATG) regimens was addressed. Regardless of a similar clinical outcome, individuals treated with cyclophosphamide and rabbit ATG displayed significantly less toxicity as compared with those treated with BEAM and ATG. AHSCT has also been reported to have a significantly positive impact on rapidly evolving, ‘malignant’ MS refractory to conventional treatments [10]. In a small cohort of young patients with RRMS presenting with high number of relapses per year and high EDSS, AHSCT was able to halt disease progression and reverse disability [11]. Overall, these studies confirm that AHSCT is more effective in very active, young RRMS individuals with a short disease history.
Autologous hematopoietic stem cell transplantation-related changes of the immune repertoire The restoration of immune tolerance following AHSCT is characterized by a profound renewal of the T-cell repertoire mainly due to the expansion of naive CD4þ T cells of recent thymic origin [12]. This study [12] suggests for the first time that AHSCT results in the induction of a new immune system less prone to selfreactivity. Although self-reactive T cells may persist after transplantation [13,14], they do not seem to arise from mobilized HSC-enriched graft [15]. Thus, some peripheral or central nervous system (CNS) infiltrating T and B-cell clones may survive the conditioning regimen, as demonstrated by the persistence of oligoclonal bands in the cerebrospinal fluid of most patients and high levels of soluble CD27, a marker of lymphocyte activation, after AHSCT [16].
Future perspective for autologous hematopoietic stem cell transplantation in multiple sclerosis At the present time, a few studies on AHSCT in severe forms of MS are ongoing, including ASTIMS (Autologous Stem cell Transplantation International Multiple Sclerosis), a European Union-based phase II study comparing the effect of AHSCT versus mitoxantrone, which has been recently stopped for the insufficient accrual of patients, the Halt-MS study, a US trial, investigating the effect of BEAM, ATG and CD34þ cell selection in RRMS or progressive–relapsing MS patients and the ‘Stem Cell Therapy for Patients with MS Failing Interferon’ randomized clinical trial in the United States
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
220 Demyelinating diseases
enrolling inflammatory patients with the aim of comparing transplantation of unmanipulated autologous PBSCs using a conditioning regimen of cyclophosphamide and ATG versus US Food and Drug Administration-approved MS therapies. The scientific community interested in AHSCT for MS met recently in Florence on 19–20 November 2009, discussing the possible design of a two-arm study focusing on young rapidly deteriorating patients refractory to standard therapies and with clinical and MRI signs of disease activity. Patients will be randomized to an intermediate intensity regimen or the best available treatment, with the possibility to crossover into the other study arm in case of continuing disease activity. Although the clinical effectiveness of AHSCT compared with conventional therapies is still debated, a recent analysis [17] of cost effectiveness of AHSCT versus mitoxantrone in secondary progressive MS suggests that the probability of AHSCT being cost effective, when TRM is low, depends on the achievement of a long enough disease stabilization (10 years).
Mesenchymal stem cells definition Multipotential stromal precursor cells were first isolated from the bone marrow, as the common ancestors of mesenchymal tissues such as cartilage, fat, bone and other connective tissues [18], and commonly termed as mesenchymal stem cells (MSCs). Many other tissues have been reported to be the source of MSCs, more recently the vasculature being a source of perivascular cells with the phenotype of MSCs [19,20]. The study [19] demonstrates that bone marrow stem cells capable of giving rise to the complete hematopoietic microenvironment reside exclusively in a small fraction of perivascular cells. However, such a conventional view of marrow stromal cell plasticity was challenged by several studies reporting their capability to also differentiate into cells from unrelated germ lineages including neural cells [21,22]. This heterogeneity is reflected by a complex transcriptome encoding a wide array of proteins involved in a large number of diverse biological processes that are likely to result in some unexpected therapeutic features [23].
Mesenchymal stem cells display immunomodulatory properties Several reports have demonstrated in the last few years that MSCs are endowed with a robust regulatory effect on many cells of innate and adaptive immunity [24]. MSCs were first demonstrated to inhibit in-vitro proliferation of T cells [25,26] and this was later demonstrated to be the result of an inhibition of T-cell division [27]. More recently, it has become clear that the immunoregulatory features of MSCs are elicited by inflammatory cytokines, mainly interferon-gamma and tumor necrosis factor-
alpha, resulting in the production of species-specific immunosuppressive factors, namely indoleamine 2,3 dioxygenase in humans and nitric oxide in mice [28]. The in-vivo translation of these results were achieved when the intravenous (i.v.) injection of MSCs into EAE mice led to the striking inhibition of proliferation of ex-vivo isolated lymph node T cells [29]. B lymphocytes are also the target of MSCs immunosuppressive activity. In fact, MSCs can inhibit in-vitro proliferation of B cells, differentiation to plasma cells and production of antibodies [30–32]. Similarly to what was observed for T cells, i.v. MSCs administration in EAEaffected mice resulted in the inhibition of the production of immunoglobulins specific for the encephalitogenic myelin antigen proteolipid protein [33]. Interestingly, the suppression of immunoglobulin production was recently demonstrated to depend on the effect of a variant of the MSC-derived chemokine (C–C motif) ligand 2 (CCL2), which is proteolytically degraded by matrix metalloproteinases secreted by MSCs themselves [34]. A third cell type significantly affected by the interaction with MSCs is the dendritic cell. MSCs can spoil dendritic cell in-vitro maturation resulting in an impaired secretion of interleukin (IL)-12 [35] and increased production of IL-10 [36]. MSC-induced immature dendritic cells do not upregulate major histocompatibility complex and costimulatory molecules and poorly present antigens to naive T cells [37]. These findings suggest that the net effect of MSCs on adaptive immunity is the consequence of a direct inhibition on T and B lymphocytes but also of an impaired ability of MSC-affected immature dendritic cells to properly instruct T cells, which, in turn, could also affect the capacity of T cells to provide help to B cells [24].
Are mesenchymal stem cells neuroprotective? The original observation that MSCs can transdifferentiate into neurons [21,22] in vitro and, upon in-vivo administration, acquire some markers of neural cells [38] is currently a matter of controversy, as the marker analysis alone may well be due to an aberrant expression [39,40]. Since then, in-vitro MSC neuronal differentiation has been achieved by treatment with trophic factors [41] and also by genetic manipulation [42]. Although the exploitation of ‘in-vitro neuralized’ MSCs appears a promising strategy for the treatment of neurodegenerative diseases, it is not known whether in-vitro transdifferentiation would result in the loss of other therapeutic properties such as immunoregulatory features, thus hampering their use in MS. On the contrary, current evidence from EAE suggest that in-vivo administration of in-vitro expanded undifferentiated MSCs does not result in a substantial
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
SCT in multiple sclerosis Uccelli and Mancardi 221
CNS engraftment and acquisition of a neural phenotype [33,34,43,44,45]. Regardless of the limited evidence of transdifferentiation by histological analysis, there is no clear experimental confirmation that MSC-derived neuronal cells are able, when transplanted in vivo, to correctly integrate among neural networks as functional neurons. However, MSCs could act on neural cells through other modalities that may lead to tissue repair. For example, MSCs have been demonstrated in vitro to rescue neurons from apoptosis [46,47] and promote neurite outgrowth [48]. It has also been demonstrated that MSCs are able to produce a wide variety of trophic factors, cytokines, chemokines and antioxidant molecules, resulting in increased neuronal survival [34,49,50,51]. Moreover, some secreted proteins could trigger host brain plasticity, thereby inducing endogenous precursor proliferation that, in turn, may lead to neurogenesis [52] and oligodendrogenesis [44,53,54].
Administration of mesenchymal stem cells improves experimental autoimmune encephalomyelitis Clinical interest in EAE was sparked by the hope that MSCs could, on the one hand halt the autoimmune attack on the CNS and, on the other hand, repair injured tissue. Preclinical studies demonstrated that this hypothesis was correct but also that MSCs were clinically effective when cells were given early, before the onset of the chronic phase of disease, sustained by irreversible damage of the nervous system. Unexpectedly, pioneer experimental work demonstrated that a striking clinical effect was achieved in EAE by i.v. administration of either syngeneic (mouse) [29] or xenogeneic (human) [55] MSCs. In fact, i.v. administration resulted in the induction of peripheral immune tolerance leading to the inhibition of pathogenic T and B-cell reactivity [29,33]. Many other groups have now confirmed that MSCs can ameliorate EAE in different animal models when injected intravenously [43,44,45], intraventricularly [56] and even intraperitoneally [34]. Although no clear evidence of neural transdifferentiation was obtained in most of these studies [33,34,43,44], MSCs administration was sufficient to decrease axonal loss and improve neuronal survival [33,56,57], as well as to induce oligodendrocytes proliferation and remyelination [44]. These findings support the concept that MSCs are likely to foster CNS repair, acting as tolerogenic cells, elicited by inflammatory cues, on autoimmune cells and as bioactive providers of trophic and antiapoptotic factors leading to neuroprotection [51,58].
Clinical experience with mesenchymal stem cells in multiple sclerosis MSCs have been utilized in a few studies with limited numbers of patients and also as single-case, uncontrolled
treatment by many patients obtaining yet unproven stem cell therapies, a phenomenon known as ‘stem cell tourism’ [59]. Despite the fact that allogeneic MSCs have been shown to be well tolerated and effective in treating graft versus host disease (GVHD) [60], autologous MSCs from MS individuals share almost identical functional properties with those from healthy individuals [61] and, therefore, have been preferred thus far for clinical exploitation in MS. In pioneer studies, the administration of autologous MSCs, either i.v. or intrathecal, was well tolerated and, despite the lack of a proper clinical design to address efficacy, exhibited some beneficial effect on clinical and MRI parameters [62,63,64]. In order to avoid the proliferation of numerous small studies utilizing MSCs for the treatment of MS, a consensus [65] on their utilization was recently published by a panel of experts, setting the stage for an international phase II clinical trial. The consensus recognized that, at this stage, current evidence supports the i.v. administration of autologous MSCs as inhibitors of the autoimmune response in patients continuing to show inflammatory activity despite attempts to treat with immunomodulatory agents, and proof of principle of MSC biological activity on validated parameters such as MRI metrics should be achieved before testing their ability to promote tissue repair.
Neural stem cells definition Neural precursor/stem cells (NPCs) can be detected in the developing and adult CNS as a heterogeneous population of proliferating, self-renewing and multipotent cells, with the ability to differentiate toward different neuroectodermal cell lineages [66,67]. In the study [67], the authors describe that the therapeutic features of NPCs were based mainly on bystander mechanisms. In the adult CNS, at least two distinct areas, the subventricular zone of the lateral ventricles and the subgranular zone of the hippocampal dentate gyrus, have been demonstrated to contain multipotent progenitors of neural cells and, therefore, have been named CNS germinal neurogenic niches [68]. Within the neurogenic niches, NPCs are a restricted and diverse population of progenitors whose behavior is regulated by a specialized microenvironment leading to the generation of different types of neurons [69]. It has been demonstrated that endogenous NPCs residing in the germinal niches are mobilized to demyelinated periventricular lesions by inflammatory cues occurring during EAE and proliferate, giving rise to neural cells [70]. Similarly, it has been shown that activation of early glial precursors from germinal niches occurs in MS, wherein they could give rise to oligodendrocyte precursors [71]. However, the intrinsic CNS ability of undergoing self-repair is impaired during MS due to microenvironmental cues [72] that could be directly dependent on molecules associated with
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
222 Demyelinating diseases
inflammation [67], due to a dysregulation of embryogenetic pathways [73], or both.
Therapeutic plasticity of neural precursor/ stem cells Although NPCs are the natural progenitors of neural cells, and NPCs-based therapies have been fairly regarded as a source for newly formed CNS cells [74], recent experimental data have shown that they display unexpected therapeutic plasticity, which mostly relies on diverse bystander effects [67]. A seminal study [75] demonstrated that i.v. or intraventricular administration of NPCs in mice with EAE led to their engraftment into demyelinating lesions and to some level of differentiation into nervous cells, including oligodendrocyte progenitors actively remyelinating axons. Despite this early report, most studies have shown very low neural differentiation of transplanted NPCs. Conversely, it was reported that systemically injected NPCs ameliorate EAE through anti-inflammatory and neuroprotective mechanisms [76,77]. These bystander mechanisms occur through the engraftment of i.v. transplanted NPCs in the perivascular area of inflamed CNS vessels where they form atypical ectopic niches and release neurotrophins, immunomodulatory molecules and factors inhibiting the formation of glial scar [67]. Recent evidence shows that i.v.
injected NPCs also display regulatory functions of the immune response within peripheral lymphoid organs through the inhibition of myelin-specific peripheral T cells [78] and an impairment of dendritic cell functions through a bone morphogenetic protein 4-dependent mechanism [79]. The study [78] shows that NPCs display also the ability to regulate autoreactive immune cells in the peripheral blood. Moreover, a recent study [80] has shown that intraventricularly transplanted NPCs could lead also to the induction of endogenous neurogenesis, as demonstrated by a mitogenic effect on host oligodendrocyte precursors. Although the clinical translation of these preclinical studies is under scrutiny, it has been demonstrated that human NPCs can be safely administered intravenously in nonhuman primates with EAE and result in the successful amelioration of symptoms and disease mainly through immunoregulatory mechanisms [81].
Other (stem) cells for the treatment of multiple sclerosis Other types of myelin-forming cells have been transplanted into rodents affected by experimental CNS demyelination [72]. For example, transplantation of oligodendrocyte progenitor cells into demyelinated lesions inside the spinal cord leads to extensive remyelination
Figure 1 The mechanisms involved in the therapeutic plasticity of adult stem cells for multiple sclerosis are depicted
HSC, hematopoietic stem cell; MSC, mesenchymal stem cell; NPC, neural precursor cell.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
SCT in multiple sclerosis Uccelli and Mancardi 223
[82]. Similar results have been obtained following the transplantation of Schwann cells [83], olfactory ensheathing cells [84] and also embryonic stem cells (ESCs) [85]. Interestingly, it has recently been shown that in-vitro differentiation of ESCs to multipotent neural progenitors ameliorates EAE but results in the loss of their capacity of remyelinate upon in-vivo transplantation [86]. Several concerns arise from these approaches. In particular, lineage-restricted myelinogenic cells show limited growth and expansion characteristics in vitro and, following in-vivo transplantation, induce scarce remyelination, often due to environmental cues limiting precursor differentiation and proliferation and their limited ability to spread far from the transplantation site [72]. Further, the use of ESCs is restricted by ethical and technical concerns about source of cells and the intrinsic risk of tumor formation. On the basis of these considerations, such strategies require further studies before their clinical exploitation for the treatment of MS.
Conclusion To date, the only ‘stem cells’ that can be considered a therapeutic option for MS are AHSCs, whose administration, however, must be mainly considered as a rescue therapy following intense immune suppression with cytotoxic drugs and may, at best, lead to an immune system less prone to autoimmunity (Fig. 1). Thus, in this case, ‘stemness’ per se does not represent a therapeutic opportunity for CNS repair. Other adult stem cells are likely to provide a realistic opportunity for remyelination and axon reorganization due to their therapeutic plasticity. It is noteworthy that results from the administration of adult stem cells in preclinical models of MS moved from almost opposite starting points to end up with some common therapeutic features, although occurring through complex and different mechanisms of action. In fact, NPCs were first described as cells giving rise to newly formed neural cells capable of remyelinating [75], then were shown to provide pleiotropic neuroprotective factors in situ [77] and, more recently, to also display a regulatory effect on the autoimmune response [78] and induce endogenous neurogenesis [80]. In contrast, MSCs were first demonstrated to induce peripheral tolerance to myelin antigens [29] and then to be capable of protecting neural cells through paracrine mechanisms [50] and even inducing local oligodendrocyte precursor proliferation [44]. Thus, a common signature defines the therapeutic plasticity of adult stem cells based on shared bystander activities, namely immunomodulation, neuroprotection and induction of endogenous neurogenesis (Fig. 1).
Acknowledgements A.U. received financial support for research, honoraria for consultation or speaking at meetings from Genetech, Roche, Allergan, Merck-
Serono and Sanofi-Aventis. G.M. received financial support for research, honoraria for consultation or speaking at meetings from Bayer-Schering, Biogen-Idec, Sanofi-Aventis and Merck-Serono. Some of the results discussed here were obtained from research supported by grants from the Fondazione Italiana Sclerosi Multipla (A.U. and G.L.M.), the Italian Ministry of Health (Ricerca Finalizzata) (A.U. and G.L.M.), the Italian Ministry of the University and Scientific Research (A.U. and G.L.M.), the ‘Progetto LIMONTE’ (A.U.) and the Fondazione CARIGE (A.U. and G.L.M.). There are no conflicts of interest.
References and recommended reading Papers of particular interest, published within the annual period of review, have been highlighted as: of special interest of outstanding interest Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 330–331). 1
Marmont AM. Immune ablation followed by allogeneic or autologous bone marrow transplantation: a new treatment for severe autoimmune diseases? Stem Cells 1994; 12:125–135.
2
Van Bekkum DW. Experimental basis of hematopoietic stem cell transplantation for treatment of autoimmune diseases. J Leukoc Biol 2002; 72:609– 620.
3 Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplanta tion in multiple sclerosis. Lancet Neurol 2008; 7:626–636. A comprehensive and up-to-date review about AHSCT in MS. 4
Saccardi R, Kozak T, Bocelli-Tyndall C, et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 2006; 12:814–823.
5
Shevchenko YL, Novik AA, Kuznetsov AN, et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol 2008; 36:922–928.
6
Atkins H, Freedman M. Immune ablation followed by autologous hematopoietic stem cell transplantation for the treatment of poor prognosis multiple sclerosis. Methods Mol Biol 2009; 549:231–246.
7
Fassas A, Passweg JR, Anagnostopoulos A, et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 2002; 249:1088–1097.
Burt RK, Loh Y, Cohen B, et al. Autologous nonmyeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009; 8:244–253. This study provides evidence that a less-myelotoxic low-intensity conditioning regimen for AHSCT is effective in severe MS patients but is associated with some level of relapse of disease.
8
9
Hamerschlak N, Rodrigues M, Moraes DA, et al. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. Bone Marrow Transplant 2010; 45:239–248.
10 Mancardi GL, Murialdo A, Rossi P, et al. Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. Mult Scler 2005; 11:367–371. 11 Fagius J, Lundgren J, Oberg G. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult Scler 2009; 15:229–237. 12 Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005; 201:805–816. 13 Sun W, Popat U, Hutton G, et al. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain 2004; 127:996–1008. 14 Storek J, Zhao Z, Liu Y, et al. Early recovery of CD4 T cell receptor diversity after ‘lymphoablative’ conditioning and autologous CD34 cell transplantation. Biol Blood Marrow Transplant 2008; 14:1373–1379. 15 Dubinsky AN, Burt RK, Martin R, Muraro PA. T-cell clones persisting in the circulation after autologous hematopoietic SCT are undetectable in the peripheral CD34þ selected graft. Bone Marrow Transplant 2009; 45:325– 331. This study demonstrates that T-cell clones that can survive in the circulation of MS individuals who underwent AHSCT do not originate from the mobilized CD34þ enriched graft.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
224 Demyelinating diseases 16 Mondria T, Lamers CH, te Boekhorst PA, et al. Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2008; 79:1013–1015. This study shows results suggesting that AHSCT cannot wipe out the chronic activation of lymphocytes inside the CNS. 17 Tappenden P, Saccardi R, Confavreux C, et al. Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis. Bone Marrow Transplant 2009. doi:10.1038/bmt.305 [Epub ahead of print]. 18 Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143–147. 19 Sacchetti B, Funari A, Michienzi S, et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007; 131:324–336. 20 Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008; 3:301–313. In this study, authors demonstrate that perivascular cells isolated from different tissues are ‘bona fide’ MSCs. 21 Woodbury D, Schwarz EJ, Prockop DJ, Black IB. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res 2000; 61:364–370. 22 Sanchez-Ramos JR. Neural cells derived from adult bone marrow and umbilical cord blood. J Neurosci Res 2002; 69:880–893. 23 Pedemonte E, Benvenuto F, Casazza S, et al. The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. BMC Genomics 2007; 8:65. 24 Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8:726–736. This study exuastively describes the immunoregulatory activity of MSCs on cells of innate and adaptive immunity providing the rationale for their exploitation for the treatment of immune-mediated diseases. 25 Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99:3838–3843. 26 Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101:3722–3729. 27 Glennie S, Soeiro I, Dyson PJ, et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105:2821– 2827. 28 Ren G, Zhang L, Zhao X, et al. Mesenchymal stem-cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2:141–150. 29 Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T cell anergy. Blood 2005; 106:1755–1761. 30 Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107:367–372. 31 Tabera S, Perez-Simon JA, Diez-Campelo M, et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica 2008; 93:1301–1309. 32 Asari S, Itakura S, Ferreri K, et al. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol 2009; 37:604–615. 33 Gerdoni E, Gallo B, Casazza S, et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol 2007; 61:219–227. 34 Rafei M, Campeau P, Aguilar-Mahecha A, et al. Mesenchymal stromal cells ameliorate EAE by inhibiting CD4 Th17 T-cells in a CCL2-dependent manner. J Immunol 2009; 182:5994–6002. In this article, authors demonstrate a novel mechanism, dependent on metalloproteinases released by MSCs, to transform CCL2 into an anti-inflammatory molecule capable of ameliorating EAE. 35 Jiang XX, Zhang Y, Liu B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105:4120–4126. 36 Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005; 105:2214–2219. 37 Nauta AJ, Kruisselbrink AB, Lurvink E, et al. Mesenchymal stem cells inhibit generation and function of both CD34þ-derived and monocyte-derived dendritic cells. J Immunol 2006; 177:2080–2087.
38 Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci U S A 1999; 96:10711–10716. 39 Bertani N, Malatesta P, Volpi G, et al. Neurogenic potential of human mesenchymal stem cells revisited: analysis by immunostaining, time-lapse video and microarray. J Cell Sci 2005; 118:3925–3936. 40 Montzka K, Lassonczyk N, Tschoke B, et al. Neural differentiation potential of human bone marrow-derived mesenchymal stromal cells: misleading marker gene expression. BMC Neurosci 2009; 10:16. 41 Cho KJ, Trzaska KA, Greco SJ, et al. Neurons derived from human mesenchymal stem cells show synaptic transmission and can be induced to produce the neurotransmitter substance P by interleukin-1 alpha. Stem Cells 2005; 23:383–391. 42 Dezawa M, Kanno H, Hoshino M, et al. Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest 2004; 113:1701–1710. 43 Gordon D, Pavlovska G, Glover CP, et al. Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neurosci Lett 2008; 448:71–73. 44 Bai L, Lennon DP, Eaton V, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009; 57:1192– 1203. This study confirms that MSCs can switch the peripheral proinflammatory immune response in mice with EAE and, more importantly, can foster, within the CNS, endogenous remyelination. 45 Constantin G, Marconi S, Rossi B, et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 2009; 27:2624–2635. 46 Scuteri A, Cassetti A, Tredici G. Adult mesenchymal stem cells rescue dorsal root ganglia neurons from dying. Brain Res 2006; 1116:75–81. 47 Kemp K, Hares K, Mallam E, et al. Mesenchymal stem cell-secreted super oxide dismutase promotes cerebellar neuronal survival. J Neurochem 2009. doi: 10.1111/j.1471-4159 [Epub ahead of print]. This study shows that human MSCs display a superoxide dismutase-dependent antioxidant activity resulting in the protection of cerebellar neurons in vitro. 48 Crigler L, Robey RC, Asawachaicharn A, et al. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol 2006; 198:54–64. 49 Wilkins A, Kemp K, Ginty M, et al. Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res 2009; 3:63–70. 50 Lanza C, Morando S, Voci A, et al. Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. J Neurochem 2009; 110:1674–1684. This study provides evidence that MSCs injected intravenously can affect the CNS microenvironment by regulating antioxidant and stress-associated molecules. 51 Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009; 20:419–427. 52 Munoz JR, Stoutenger BR, Robinson AP, et al. Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. Proc Natl Acad Sci U S A 2005; 102:18171– 18176. 53 Akiyama Y, Radtke C, Kocsis J. Remyelination of the rat spinal cord by transplantation of identified bone marrow stromal cells. J Neurosci 2002; 22:6623–6630. 54 Rivera FJ, Couillard-Despres S, Pedre X, et al. Mesenchymal stem cells instruct oligodendrogenic fate decision on adult neural stem cells. Stem Cells 2006; 24:2209–2219. 55 Zhang J, Li Y, Chen J, et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol 2005; 195:16–26. 56 Kassis I, Grigoriadis N, Gowda-Kurkalli B, et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 2008; 65:753–761. 57 Zhang J, Li Y, Lu M, et al. Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice. J Neurosci Res 2006; 84:587–595. 58 Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol 2007; 28:219–226.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
SCT in multiple sclerosis Uccelli and Mancardi 225 59 Ryan KA, Sanders AN, Wang DD, Levine AD. Tracking the rise of stem cell tourism. Regen Med 2010; 5:27–33. 60 Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371:1579–1586. This study reports on the result of a phase II clinical trial for an immune-mediated disease such as GVHD, which demonstrates the efficacy of bone-marrow-derived MSCs in halting disease progression in steroid-resistant patients.
73 Fancy SP, Baranzini SE, Zhao C, et al. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev 2009; 23:1571–1585. 74 Goldman S. Stem and progenitor cell-based therapy of the human central nervous system. Nat Biotechnol 2005; 23:862–871. 75 Pluchino S, Quattrini A, Brambilla E, et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 2003; 422:688–694.
61 Mazzanti B, Aldinucci A, Biagioli T, et al. Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment. J Neuroimmunol 2008; 199:142–150.
76 Einstein O, Karussis D, Grigoriadis N, et al. Intraventricular transplantation of neural precursor cell spheres attenuates acute experimental allergic encephalomyelitis. Mol Cell Neurosci 2003; 24:1074–1082.
62 Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J, et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol 2007; 4:50–57.
77 Pluchino S, Zanotti L, Rossi B, et al. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 2005; 436:266–271.
63 Karussis D, Kassis I, Kurkalli BG, Slavin S. Immunomodulation and neuro protection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J Neurol Sci 2008; 265:131–135. This study provides some preliminary clinical experience with systemically administered MSCs in a few neurological patients.
78 Einstein O, Fainstein N, Vaknin I, et al. Neural precursors attenuate autoimmune encephalomyelitis by peripheral immunosuppression. Ann Neurol 2007; 61:209–218.
64 Liang J, Zhang H, Hua B, et al. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult Scler 2009; 15:644–646.
80 Einstein O, Friedman-Levi Y, Grigoriadis N, Ben-Hur T. Transplanted neural precursors enhance host brain-derived myelin regeneration. J Neurosci 2009; 29:15694–15702. In this manuscript, authors demonstrate that NPCs can induce endogenous neurogenesis.
65 Freedman MS, Bar-Or A, Atkins H, et al. The Therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study group. Mult Scler 2010 [Epub ahead of print]. A consensus paper from an international panel of experts defines the rationale for utilizing MSCs in MS and designs the clinical setting for future clinical trials. 66 Temple S. The development of neural stem cells. Nature 2001; 414:112–117. 67 Martino G, Pluchino S. The therapeutic potential of neural stem cells. Nat Rev Neurosci 2006; 7:395–406. 68 Alvarez-Buylla A, Lim DA. For the long run: maintaining germinal niches in the adult brain. Neuron 2004; 41:683–686. 69 Merkle FT, Mirzadeh Z, Alvarez-Buylla A. Mosaic organization of neural stem cells in the adult brain. Science 2007; 317:381–384. 70 Picard-Riera N, Decker L, Delarasse C, et al. Experimental autoimmune encephalomyelitis mobilizes neural progenitors from the subventricular zone to undergo oligodendrogenesis in adult mice. Proc Natl Acad Sci U S A 2002; 99:13211–13216. 71 Nait-Oumesmar B, Picard-Riera N, Kerninon C, et al. Activation of the subventricular zone in multiple sclerosis: evidence for early glial progenitors. Proc Natl Acad Sci U S A 2007; 104:4694–4699. 72 Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008; 9:839–855. This is an exaustive review focusing on our current basic knowledge about demyelination and remyelination mechanisms and on future therapeutic strategies aimed at promoting remyelination.
79 Pluchino S, Zanotti L, Brambilla E, et al. Immune regulatory neural stem/ precursor cells protect from central nervous system autoimmunity by restraining dendritic cell function. PLoS One 2009; 4:e5959.
81 Pluchino S, Gritti A, Blezer E, et al. Human neural stem cells ameliorate autoimmune encephalomyelitis in nonhuman primates. Ann Neurol 2009; 66:343–354. This paper sets the stage for a future clinical trial in humans by demonstrating that allogeneic NPCs intrathecally injected can successfully treat EAE in nonhuman primates. 82 Groves AK, Barnett SC, Franklin RJ, et al. Repair of demyelinated lesions by transplantation of purified O-2A progenitor cells. Nature 1993; 362:453– 455. 83 Franklin RJ, Gilson JM, Franceschini IA, Barnett SC. Schwann cell-like myelination following transplantation of an olfactory bulb-ensheathing cell line into areas of demyelination in the adult CNS. Glia 1996; 17:217– 224. 84 Imaizumi T, Lankford KL, Waxman SG, et al. Transplanted olfactory ensheathing cells remyelinate and enhance axonal conduction in the demyelinated dorsal columns of the rat spinal cord. J Neurosci 1998; 18:6176–6185. 85 Brustle O, Jones KN, Learish RD, et al. Embryonic stem cell-derived glial precursors: a source of myelinating transplants. Science 1999; 285:754– 756. 86 Aharonowiz M, Einstein O, Fainstein N, et al. Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis. PLoS One 2008; 3:e3145.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
EDITORIAL REVIEW
Demyelination as a complication of new immunomodulatory treatments Andreas P. Lysandropoulosa and Renaud A. Du Pasquiera,b a Service of Neurology, Department of Clinical Neurosciences and bService of Immunology and Allergy, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Correspondence to Renaud A. Du Pasquier, MD, Service of Neurology and Service of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), BH-10, Rue du Bugnon 46, 1011 Lausanne, Switzerland Tel: +41 21 314 1228; fax: +41 21 314 1256; e-mail:
[email protected] Current Opinion in Neurology 2010, 23:226–233
Purpose of review This review discusses demyelinating events of the nervous system that have been associated with new immunomodulatory treatments, in particular monoclonal antibodies (mAbs). Recent findings Natalizumab, a mAb targeting the a-4 integrins, which is efficient in relapsing–remitting multiple sclerosis, has been associated with progressive multifocal leukoencephalopathy (PML). We will review the putative mechanisms linking natalizumab with JC virus, the agent of PML. Efalizumab, a mAb targeting a member of the integrin family, CD11a, was approved for the treatment of psoriasis, but had to be withdrawn in 2009 because of the occurrence of three cases of PML. Rituximab, an antiCD20 mAb, is used in different neoplastic and autoimmune diseases and may soon enter the pharmacopeia of multiple sclerosis. It has been suggested that rituximab is a risk factor for PML; however, evidence of such a link is unclear. Antitumor necrosis factor-alpha agents are used in several autoimmune diseases. Several cases of demyelinating events of the nervous system have been reported, prompting a heightened surveillance of treated patients. Recent data are reassuring, suggesting that the incidence of such events is relatively low. Summary Neurologists must become familiar with neurological complications of new immunomodulatory treatments, a field situated at the interface of neurology, immunology and infection. Keywords antitumor necrosis factor-alpha agents, demyelination, efalizumab, mAbs, multiple sclerosis, natalizumab, progressive multifocal leukoencephalopathy, rituximab Curr Opin Neurol 23:226–233 ß 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins 1350-7540
Introduction New immunomodulatory molecules are being developed at a fast pace and are of great benefit for patients suffering from a large spectrum of disease, in particular autoimmune diseases. Among these new drugs, monoclonal antibodies (mAbs) are on the front line. Developed by Kohler and Milstein [1], the first mAbs, grown from hybridomas that produced antibodies from other species, proved to be highly immunogenic. As molecular biology progressed, chimeric and then humanized mAbs that greatly reduced the amount of foreign antibody sequences were developed [2]. mAbs are elaborated to target a precise immunological mechanism, which confers their specificity. Nevertheless, the onset of demyelinating disease, for example, progressive multifocal leukoencephalopathy (PML), in some mAbs-treated patients suggests that the mechanism of action of these drugs is not fully understood. It is important 1350-7540 ß 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
that neurologists become familiar with not only the new immunomodulatory treatments that are used as treatment for neurological disease, for example, multiple sclerosis (MS), but also those that have other indications but may have neurological demyelinating side effects.
Progressive multifocal leukoencephalopathy PML is a rare but severe viral infection of the brain, which causes demyelination by lytic infection of the oligodendrocytes [3]. PML was initially described in patients with hematological malignancies, mostly lymphoproliferative diseases, but since the 1980s, more than 80% of all cases occur in AIDS patients [4]. Despite the use of highly active antiretroviral therapies (HAARTs), the incidence of PML has not decreased as much as other central nervous system (CNS) opportunistic infections [5]. DOI:10.1097/WCO.0b013e3283398c96
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Demyelination and immunomodulatory treatments Lysandropoulos and Pasquier 227
PML, which is caused by the polyoma JC virus (JCV), usually occurs in the context of severe immunosuppression, but rarely has been described in patients with minimal or occult immunosuppression [6]. The seroprevalence of immunoglobulin (Ig)G specific to JCV, in healthy blood donors, is 50% at the age of 20–29 years and rises to 68% at the age of 50–59 years [7]. IgM having never been detected in PML patients, this disease is considered to be due to reactivation of JCV rather than primo infection. JCV DNA is detected in the urine of 20–30% of healthy individuals, suggesting that the kidney is a site of latency [7]. However, JCV harvested from the urine does not infect human glial cells, and the DNA sequences of the regulatory region (the region that determines JCV replication) are different from the ones that are recovered from JCV found in the brain in cases of PML [8]. These findings suggest that the virus staying in the kidneys is not neurotropic. By contrast, JCV DNA harvested from the bone marrow, another presumed site of latency, displays sequences that are close to those in PML lesions [9,10]. In the latter compartment, JCV infects preferentially hematopoietic precursors CD34þ and B cells and uses these cells to migrate to the brain. This migration usually occurs in cases of severely decreased cellular immune competence, as even a low number of JCV VP1 (VP1 being the major capsid protein) or the virus-specific cytotoxic CD8þ T cells seems to be sufficient to maintain the virus in its latency sites [11]. Although the CNS is not considered as a primary latent site, a recent report has put this notion into question. Indeed, JCV DNA, but not full virions, was detected in oligodendrocytes and astrocytes of non-PML patients [12]. Interestingly, the neurotropism of JCV is wider than previously thought; following initial description in 2003 [13], further reports have confirmed that JCV is able to productively infect neurons of the internal granule cell layer of the cerebellum [14–17], a condition coined JCV granule cell neuronopathy [14]. Owing to the natalizumab-related PML cases, the neurological community is now more aware of this disease, the reason why we will only shortly review its clinical aspects and invite the interested reader to refer to recent reviews [4]. The diagnosis of PML remains difficult, especially in MS patients, as both diseases are leukoencephalopathies. Cognitive impairments or behavioral changes are often the heralding symptoms of PML [10,18]. Ensuing neurological deficits are typically corticospinal syndrome with motor weakness, visual disturbances due to hemianopsia and, somewhat less frequently, sensitive disorders, cerebellar ataxia, seizures and so on. Contrasting with MS, optic neuritis or spinal cord involvement is exceedingly rare. T2-weighted or fluid-attenuated inversion recovery are the best sequences to identify PML lesions on brain
MRI. Contrasting with MS, PML lesions are usually diffuse, mainly subcortical, rarely involving the periventricular area [19]. However, at the beginning, PML lesions can be unique and discrete [20]. Lesions edges are ill defined, tend to spare the cortical ribbon, destroy the U-fibers and grow asymmetrically. The posterior fossa is frequently involved [19]. Except in the context of immune reconstitution inflammatory syndrome (IRIS), PML lesions do not enhance after contrast administration and there is no mass effect. Nowadays, the diagnosis of PML rests on the detection of JCV DNA in the cerebrospinal fluid (CSF). Quantitative PCR (qPCR) techniques in experimental laboratories allow the detection of 10 copies/ml of viral DNA [21,22]. This assay is very specific (98%), and its sensitivity is reported to exceed 90% [23]. However, in practice, the sensitivity is often lower, which may be due to suboptimal processing of the sample (delay in bringing it to the laboratory, CSF kept at room temperature instead of cold, and so on). In cases of strong suspicion of PML despite repeated negative JCV DNA PCR in the CSF, brain biopsy is warranted if permitted by localization of the lesion. In HIV-negative immunosuppressed patients with PML, the only proven therapy is to relieve the immunosuppression, which is unfortunately often impossible. This fact explains why the prognosis of PML in this category of patients is grim, 10% of them surviving more than 1 year. In AIDS/PML patients, however, the prognosis is better, as HAART has raised the 1-year survival rate from 10% to more than 50% [24]. JCV uses the 5HT2A serotoninergic receptor to enter glial cells [25]. Some case reports [26– 28] have proposed that drugs, such as mirtazapine, that use the same receptor may compete with JCV for this receptor and hence decrease glial cells infection; however, a reappraisal of the effect of this drug has shown no antiviral activity at therapeutic doses [29]. Mefloquine, an antimalarial drug, has recently demonstrated an in-vitro inhibiting effect on JCV, even at relatively low doses [29]. A randomized multicentrer trial has been launched to assess the effect of mefloquine on JCV DNA levels (http://clinicaltrials.gov/ct2/show/NCT00746941).
Natalizumab Natalizumab, marketed under the name of Tysabri (Biogen Idec/Elan), is a humanized mAb, which binds to the a chain of a4b1 and a4b7 integrins that are expressed at the cell surface of hematopoietic cells [30]. Binding of natalizumab to a4b1 integrins prevents firm adhesion and diapedesis of activated lymphocytes through the blood– brain barrier (BBB) [31]. In one phase III study, the AFFIRM study (Natalizumab Safety and Efficacy in Relapsing–Remitting Multiple
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
228 Demyelinating diseases
Sclerosis) [32], this drug has been shown to decrease the annual relapse rate at 1 year by 68% and the risk of sustained disability progression over 2 years by 42% as compared with placebo. In another phase III trial, the SENTINEL study (The Safety and Efficacy of Natalizumab in Combination with Interferon Beta-1a in Patients with Relapsing–Remitting Multiple Sclerosis), the combination therapy of interferon-beta 1a (IFNb1a) and natalizumab was associated with a lower annualized rate of relapse over a 2-year period than was IFNb1a alone (0.34 vs. 0.75, P < 0.001) and with fewer new or enlarging lesions on T2-weighted MRI (0.9 vs. 5.4, P < 0.001) [33]. As the blockade of a4b7 integrins prevents activated lymphocytes from crossing the epithelium of the intestinal barrier, natalizumab has been approved for the treatment of mild-to-moderate Crohn’s disease with evidence of inflammation in the United States [34]. Unfortunately, the efficacy of this drug was overshadowed by the occurrence of PML in two MS patients in the SENTINEL studies [33,35,36] and one patient in the Crohn study [37]. Thus, in 2005, Biogen Idec (Cambridge, Massachusetts, USA) and Elan (Gainesville, Georgia, USA) voluntarily suspended its marketing. After a large assessment of clinical, MRI and laboratory data of patients who had received natalizumab [19], the health authorities of the USA and Europe allowed this drug to go back on the market, provided that there would be a close postmarketing surveillance. Although there are some nuances between countries, this drug can now be given only in monotherapy and either as a first intention in aggressive relapsing–remitting multiple sclerosis (RRMS) or as a second intention in patients who failed on conventional immunomodulatory drugs, that is, IFNb or glatiramer acetate [38]. As of 9 February 2010, there had been 35 cases of PML in MS patients treated with natalizumab in monotherapy, with an overall incidence of PML of 0.52 (0.36–0.73) per 1000 natalizumab-treated patients. The incidence seems to be the highest after 2 years of infusion, being 1.29 per 1000 natalizumabtreated patients (0.84–1.91) and somewhat decreasing at later time points. At the time of writing this manuscript, two cases out of the 35 had been published and the interval between natalizumab onset and PML was 12 [18] and 14 months [20]. As natalizumab has not been consistently associated with opportunistic infections other than PML, this drug cannot be considered as a classical immunosuppressant [33]. Thus, there must be a specific mechanism that causes PML in rare patients. Deciphering this mechanism would be of great help to identify those patients at risk. By binding to integrins of CD34þ hematopoietic precursor cells, natalizumab prevents them from attaching to vascular cell adhesion molecule in the sinusoid of
the bone marrow and thus forces them to migrate out of the bone marrow [39]. Yet, an increase in CD34þ cells in peripheral blood is evident shortly after natalizumab injection [40,41]. Knowing that the bone marrow is a latency site of JCV, it has been hypothesized that cells purged from the bone marrow may carry JCV with them [42]. Consistent with this hypothesis, JCV DNA was detected by qPCR in the plasma of three of 15 (20%) and the peripheral blood mononuclear cells (PBMCs) of nine of 15 (60%) natalizumab-treated patients after 18 months of treatment. However, in studies from different groups totalling more than 2000 patients with MS, some of them being treated for up to 2 years, detection of JCV was exceedingly rare in the plasma and never present in the PBMCs [19,43,44,45,46,47]. Of note, there was no case of PML in any of these studies. Interestingly, the JCV-specific T-cell response seems to increase on natalizumab [45,48], which in itself may be a good thing, considering that such cells have been associated with containment of JCV [49]. Since T cells specific not only for JCV but also for other viral and myelin antigens seem to be increased at the same time points in natalizumab-treated patients, one can hypothesize that there is trapping of antigen-specific activated T cells in the peripheral blood [45]. Thus, a mechanism to explain the occurrence of PML in some natalizumab-treated patients is the so-called ‘double-edged sword’ theory: by blocking the BBB and thus by preventing autoimmune T cells from reaching the brain, natalizumab is very efficient, but, by doing so, this drug may also impair the immune surveillance against foreign antigens such as JCV [50,51]. Indeed, this drug decreases dramatically the number of dendritic and CD4þ T cells in the cerebral perivascular space [52] as well as B cells and T cells in the CSF for more than 6 months [53]. Yet, JCV-specific CD8þ cytotoxic T lymphocytes can be detected in the CSF of patients recovering from PML, suggesting that the protective effect of these JCV-specific CD8þ cytotoxic T cells is mediated at the CNS level [54]. Nevertheless, how would JCV reach the brain if precisely the BBB is blocked [55]? One has to postulate that either a very small number of JCV-infected cells are sufficient to bring JCV into the CNS or that JCV can freely cross the BBB, which has not been demonstrated so far. A third possibility is that JCV is already present in the brain of some individuals before natalizumab treatment. Supporting the latter hypothesis, authors have detected JCV DNA fragments in normal brain tissue [12]. Thus, it is conceivable that diminished immune surveillance plays a role in the natalizumabassociated cases of PML. However, if a decreased immune surveillance is an important feature of natalizumab, why don’t we see more often other opportunistic infections of the brain than PML? Indeed, so far, there has been ‘only’ one case each of fatal herpetic encephalitis, varicella zoster
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Demyelination and immunomodulatory treatments Lysandropoulos and Pasquier 229
virus (VZV) acute retinal necrosis, VZV encephalomyelitis [56] and ocular toxoplasmosis [57]. A patient with primary CNS lymphoma (PCNSL) was also recently reported [58]; however, the latter tumor was Epstein–Barr virus negative, which implies that this PCNSL was not due to immunosuppression and thus puts the causative role of natalizumab into question [59]. Clearly, more studies are warranted to elucidate why natalizumab is rarely but consistently associated with PML.
Management of natalizumab-associated progressive multifocal leukoencephalopathy As soon as PML is suspected, natalizumab should be stopped and plasma exchanges (PLEXs), with or without immunoabsorption, instituted. Five PLEXs have been shown to decrease natalizumab below 1 mg/ml in the plasma, a concentration that was associated with less than 50% of a-4 integrin saturation [60]. However, a consequence of this treatment is the so-called IRIS [61]. By rapidly restoring the capacity of T cells to cross the BBB, there can be a massive infiltration of PML lesions by activated T cells [62], likely including JCV-specific cytotoxic T lymphocytes [63]. Even if, ultimately, the most important factor for a favorable outcome of PML is immune reconstitution, in the case of IRIS, there can be a transient worsening of the symptoms due to the massive inflammation. On brain MRI, this is reflected by contrast enhancement and mass effect. In such cases, corticosteroids, sometimes at high doses, are warranted [20,62]. But, altogether, natalizumab-treated patients who develop PML seem to have a better outcome than other HIV-negative patients who develop PML (Biogen Idec/Elan Medical Information Services). Some authors found a rebound effect after natalizumab treatment, but, in these studies [64,65], this drug was given only for 2–3 months. Contrasting with these findings, Stuve et al. [66] found that 23 patients from AFFIRM and SENTINEL studies who had received natalizumab for about 30 months did not experience any clinical, immunological or MRI rebound 14 months after natalizumab cessation. As noted in an accompanying editorial, these findings are encouraging as they suggest that in patients who have been treated for a prolonged period, it is unlikely that there will be a sudden rebound [67]. However, it is important to notice that patients who were enrolled in AFFIRM and SENTINEL studies had a less active form of MS than patients who are currently on natalizumab.
Efalizumab and progressive multifocal leukoencephalopathy Efalizumab is a recombinant humanized mAb directed against CD11a, a component of leukocytes function-
associated antigen-1 chain (LFA1). LFA1 plays a critical role in allowing these leukocytes to egress from the peripheral circulation into sites of inflammation. Thus, inhibition of LFA1 reduces the recruitment of effector cells, thereby quelling the inflammatory responses [68]. Efalizumab was approved by the US Food and Drug Administration for the treatment of moderate-to-severe plaque psoriasis in 2003. Three out of 48 000 psoriasis patients treated with efalizumab had PML. All three had received efalizumab as monotherapy for longer than 3 years [69]. A fourth patient developed progressive neurologic symptoms and died of an unknown cause, raising the possibility that he also had PML (US Department of Health and Human Services, 2009). On 8 April 2009, Genentech (South San Francisco, California, USA) announced a phased voluntary withdrawal of efalizumab from the market based on its association with PML. Interestingly, as natalizumab, efalizumab is directed against members of the integrin family, which raises the question whether there may be a relationship between anti-integrins agents and JCV/ PML.
Rituximab Rituximab is a chimeric mouse–human anti-CD20 mAb that depletes mature circulating B lymphocytes in the blood, and apparently also in the CNS [70]. It is approved for CD20-positive B-cell non-Hodgkin’s lymphoma, untreated chronic lymphocytic leukemia (in the EU) and as a second-line treatment for rheumatoid arthritis (RA) [71]. Its mode of action may be based on the decrease not only of the humoral immune response but also of the cellular one due to dimished help provided by B cells to T cells [72]. Rituximab has also shown a strong efficacy in some severe cases of RRMS [73]. In a 48-week phase II trial [74], RRMS patients on rituximab (n ¼ 69) had significantly less active lesions on brain MRI and fewer relapses as compared with placebo group. Fewer new gadoliniumenhancing or T2 lesions and an apparent reduction in relapses were also observed compared with the year before therapy in a 72-week, open-label phase I trial in which patients received two courses of rituximab therapy 6 months apart for a total dose of 4000 mg [75]. In addition, the use of rituximab has been advocated in neuromyelitis optica [76,77]. Rituximab has been incriminated as being responsible of PML. However, this relation of causality is unclear. In a recent work, Carson et al. [10] reported 57 cases of PML in patients treated with rituximab either for lymphoma/leukemia (52) or for autoimmune diseases (5), the latter group including two patients with
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
230 Demyelinating diseases
systemic lupus erythematosous (SLE). However, rituximab was always associated with other immunosuppressive treatments. Rituximab is not recommended for SLE, nevertheless, at least 8000 SLE patients have been treated with this drug and two of them developed PML [71]. Conversely, there have been so far 30 cases of PML reported in SLE patients who had never received rituximab. Thus, on the basis of these data, it seems that SLE rather than rituximab may be a trigger of PML [78]. Of note, no case of PML has been reported so far in MS patients treated with rituximab [74]. Nevertheless, these reassuring data are mitigated by the findings of Goldberg et al. [79], who followed 338 adult lymphoma patients with autologous peripheral blood stem cell transplantation. Two hundred and seventysix of them received a conditioning regimen consisting of carmustine, etoposide, cytarabine and cyclophosphamide and had no infectious complications, whereas among the 62 patients who received the same conditioning regimen and rituximab, two patients developed PML, another had a cytomegalovirus (CMV) pneumonitis and a fourth one a CMV retinitis [79]. Preliminary data suggest that there may be a reactivation of JCV in a few rituximab-treated patients with concomitant immunosuppressive drugs who have a very efficient suppression of B and T lymphocytes [80], but additional studies are warranted to confirm this hypothesis. For the time being, in Europe and in the USA, the manufacturer in collaboration with the respective health agencies proposes a patient alert card mentioning the risk of PML for patients on rituximab [71].
unexpected increase of MS relapses in the treatment group as compared with placebo [86]. Since then, additional anti-TNFa drugs have been developed, including the fusion protein etanercept and the mAbs adalimumab and infliximab. These are recognized treatments for RA, psoriatic arthritis, ankylosing spondylitis and Crohn’s disease. In 2006, the Study Group on Autoimmune Diseases (GEAS) of the Spanish Society of Internal Medicine created the BIOGEAS project, a multicenter study devoted to collecting data on the use of biological agents in adult patients with systemic autoimmune diseases [87]. Up to July 2009, 175 cases of demyelinating CNS processes after starting anti-TNFa therapies have been reported, including optic neuritis in 123, MS or MS-like (sensory disturbances, motor weakness, ataxia and so on) in 55 and others (e.g. cognitive dysfunction) in five. Eight patients presented with optic neuritis and MS-like episodes. The majority of cases occurred between 1 month and 1 year after initiation of the biological agent. Forty-four patients on anti-TNFa also presented with demyelination of the peripheral nervous system, including Guillain–Barre´ syndrome in 20, multifocal motor neuropathy with conduction block in 11, chronic inflammatory demyelinating polyradiculoneuropathy in six, axonal polyneuropathy in five and Lewis–Summer syndrome in two patients [88].
Antitumour necrosing factor-alpha and multiple sclerosis
The mechanism by which anti-TNFa medications would trigger demyelination remains unexplained. It has been hypothesized that exposure to anti-TNFa might, between other effects, increase survival of autoreactive peripheral T cells penetrating the CNS, produce proinflammatory cytokines such as IFNg and cause demyelination [89–91]. It has even been suggested that these episodes of demyelination could correspond to aborted PML [92].
There are conflicting data in the literature as to whether anti-TNFa treatment could worsen demyelination or even cause demyelination. TNFa is thought to play a significant role in the pathophysiological mechanism of several inflammatory diseases such as RA, Crohn’s disease, ankylosing spondylitis, inflammatory bowel diseases and MS [81]. High levels of TNFa have been found in plaques and in CSF of MS patients [82]. In chronic progressive MS, CSF levels of TNFa correlate with disability and the rate of neurological deterioration [83]. In experimental autoimmune encephalomyelitis, an animal model of MS, administration of anti-TNFa therapy improves the outcome of the disease [84]. On the basis of these findings, anti-TNFa treatment was advocated for MS patients. However, van Oosten et al. [85] first reported an increased immunological and MRI activity in two MS patients treated with the antiTNFa antibody cA2. Then, lenercept, a TNFa inhibitor, was administered to RR-MS patients, but led to an
However, tempering these alarming data, members of the BIOGEAS project conducted a meta-analysis [88] of randomized control trials and postmarketing studies and found that these demyelinating events were rare, ranging between 0.05 and 0.20% of anti-TNFa-treated patients. Finally, and interestingly, the failure of lenercept can be viewed differently with the current knowledge about anti-TNFa treatments; in addition to its worsening effect in MS patients, lenercept failed to be effective in patients with RA [93], which stands in sharp contrast with the high efficacy of infliximab, a more recent anti-TNFa mAb, when given to RA patients [94]. Thus, it is currently hypothesized that it was not the biological action of lenercept – that is, its anti-TNFa properties – which was responsible for paradoxical worsening of MS or RA, but rather a toxicity linked to the molecule itself or the presence of antilenercept antibodies [95].
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Demyelination and immunomodulatory treatments Lysandropoulos and Pasquier 231
Nevertheless, because of the concern that anti-TNFa treatment may trigger or worsen demyelination in some patients, a baseline brain MRI is recommended prior to the initiation of anti-TNFa treatment [95]. It has been suggested that MS patients should not be treated with TNFa inhibitors [88]. As for the demyelinating events of the peripheral nervous system on anti-TNFa treatment, it is not established that their incidence is different from the one in the general population [96].
Conclusion mAbs are very promising agents for autoimmune diseases and for MS. Nevertheless, mAbs can be accompanied by rare, but definite (at least for natalizumab and efalizumab), serious adverse demyelinating effects such as PML. Thus, postmarketing surveillance is necessary to gather information on long-term efficacy of these mAbs and on identification and management of their side effects. At the same time, neurologists must follow the indication of these mAbs and be aware of their potential demyelinating side effects. If patients are correctly informed about the potential risks of these treatments and are followed closely by informed neurologists, demyelinating side effects can be diagnosed early and thus clinical prognosis improved.
Acknowledgements This work was made possible by a grant from the Swiss National Foundation (#PP00B3-124893), a grant from the Swiss Society for Multiple Sclerosis and the Biaggi Foundation to Remote Area Development Program.
8
Major EO, Amemiya K, Tornatore CS, et al. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 1992; 5:49– 73.
9
Tan CS, Dezube BJ, Bhargava P, et al. Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis 2009; 199:881– 888.
10 Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoence phalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834–4840. An exhaustive review on patients who developed PML while on rituximab. 11 Du Pasquier RA, Schmitz JE, Jean-Jacques J, et al. Detection of JC virusspecific cytotoxic T lymphocytes in healthy individuals. J Virol 2004; 78:10206–10210. 12 Perez-Liz G, Del Valle L, Gentilella A, et al. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol 2008; 64:379–387. This study suggests that the brain might be a latent site of JCV in some healthy individuals. 13 Du Pasquier RA, Corey S, Margolin DH, et al. Productive infection of cerebellar granule cell neurons by JC virus in an HIVþ individual. Neurology 2003; 61:775–782. 14 Koralnik IJ, Wuthrich C, Dang X, et al. JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 2005; 57:576–580. 15 Wuthrich C, Cheng YM, Joseph JT, et al. Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 2009; 68:15–25. 16 Granot R, Lawrence R, Barnett M, et al. What lies beneath the tent? JC-virus cerebellar granule cell neuronopathy complicating sarcoidosis. J Clin Neurosci 2009; 16:1091–1092. 17 Tan IL, Brew BJ. Possible JCV granular cell neuronopathy in a patient with HIV infection. Neurology 2009; 73:1598–1599. 18 Wenning W, Haghikia A, Laubenberger J, et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 2009; 361:1075–1080. 19 Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354:924–933. 20 Linda H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009; 361:1081– 1087.
There were no conflicts of interest.
21 Ryschkewitsch C, Jensen P, Hou J, et al. Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J Virol Methods 2004; 121:217–221.
References and recommended reading
22 Iacobaeus E, Ryschkewitsch C, Gravell M, et al. Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. Mult Scler 2009; 15:28–35.
Papers of particular interest, published within the annual period of review, have been highlighted as: of special interest of outstanding interest Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 329–330). 1
Ko¨hler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495–497.
2
Rose JW, Foley JF, Carlson NG. Monoclonal antibody treatments for multiple sclerosis. Curr Treat Options Neurol 2009; 11:211–220.
3
Astrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leukoencephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin’s disease. Brain 1958; 81:93–111.
4
Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 2006; 60:162–173.
5
Ammassari A, Cingolani A, Pezzotti P, et al. AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Neurology 2000; 55:1194– 1200.
6
Gheuens S, Pierone G, Peeters P, Koralnik IJ. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry 2010; 81:247–254.
7
Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009; 199:837–846.
23 Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010; 61:35–47. 24 Antinori A, Cingolani A, Lorenzini P, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003; 9 (Suppl 1):47–53. 25 Elphick GF, Querbes W, Jordan JA, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004; 306:1380–1383. 26 Vulliemoz S, Lurati-Ruiz F, Borruat FX, et al. Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis. J Neurol Neurosurg Psychiatry 2006; 77:1079–1082. 27 Lanzafame M, Ferrari S, Lattuada E, et al. Mirtazapine in an HIV-1 infected patient with progressive multifocal leukoencephalopathy. Infez Med 2009; 17:35–37. 28 Verma S, Cikurel K, Koralnik IJ, et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis 2007; 196:709–711. 29 Brickelmaier M, Lugovskoy A, Kartikeyan R, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 2009; 53:1840–1849. 30 Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005; 4:510–518.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
232 Demyelinating diseases 31 Coisne C, Mao W, Engelhardt B. Cutting edge: natalizumab blocks adhesion but not initial contact of human T cells to the blood–brain barrier in vivo in an animal model of multiple sclerosis. J Immunol 2009; 182:5909–5913. 32 Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899–910. 33 Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta1a for relapsing multiple sclerosis. N Engl J Med 2006; 354:911–923. 34 Edula RG, Picco MF. An evidence-based review of natalizumab therapy in the management of Crohn’s disease. Ther Clin Risk Manag 2009; 5:935–942. 35 Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353:369–374. 36 Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353:375–381. 37 Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005; 353:362–368. 38 Wiendl H, Toyka KV, Rieckmann P, et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008; 255:1449–1463. 39 Major EO. Reemergence of PML in natalizumab-treated patients: new cases, same concerns. N Engl J Med 2009; 361:1041–1043. 40 Bonig H, Wundes A, Chang KH, et al. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008; 111:3439–3441. 41 Zohren F, Toutzaris D, Klarner V, et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34þ hematopoietic progenitor cells in humans. Blood 2008; 111:3893–3895. 42 Ransohoff RM. Natalizumab and PML. Nat Neurosci 2005; 8:1275. 43 Varnier O, McDermott J, Giacomazzi C. Non invasive surveillance of JCV reactivation in blood and urine from natalizumab treated MS patients, blood donors and immunocompromised patients identifies two PML cases in HIV and congenital immunodeficiency patients. Mult Scler 2009; 15:S276–S277. 44 Warnke C, Adams O, Kieseier BC. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009; 361:2489; author reply 2489–2490. 45 Jilek S, Jaquiery E, Hirsch HH, et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 2010; 9:264–272. This study reported no reactivation of JCV in the blood of patients on natalizumab after 18 months of treatment. However, there was an enhanced cellular immune response against different antigens, including JCV. 46 Rudick R, Polman C, O’Connor P. Evaluation of natalizumab treatment on the presence of JC virus in blood or urine from multiple sclerosis patients. Mult Scler 2009; 15:S274–S275. 47 Gorelik L, Goelz S, Sandrock AW. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009; 361:2487–2488; author reply 2489–2490. 48 Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009; 361:1067–1074. Here, the authors found a reactivation of JCV in the PBMCs and the plasma of patients on natalizumab after 18 months of treatment, although none developed PML. 49 Du Pasquier RA, Kuroda MJ, Zheng Y, et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 2004; 127:1970–1978.
55 Hartung HP. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 2009; 8:28–31. 56 Berger JR, Houff S. Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann Neurol 2009; 65:367–377. A nice review. 57 Zecca C, Nessi F, Bernasconi E, Gobbi C. Ocular toxoplasmosis during natalizumab treatment. Neurology 2009; 73:1418–1419. 58 Schweikert A, Kremer M, Ringel F, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 2009; 66:403– 406. 59 DeAngelis LM. Natalizumab: a double-edged sword? Ann Neurol 2009; 66:262–263. 60 Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009; 72:402–409. This study establishes the usefulness of PLEXs in accelerating the removal of natalizumab from the blood of treated patients. 61 Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009; 72:1458– 1464. 62 Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 2003; 9 (Suppl 1):25–31. 63 Wuthrich C, Kesari S, Kim WK, et al. Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: co-localization of CD8(þ) T cells with JCV-infected glial cells. J Neurovirol 2006; 12:116– 128. 64 Tubridy N, Behan PO, Capildeo R, et al. The effect of antialpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999; 53:466–472. 65 Vellinga MM, Castelijns JA, Barkhof F, et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 2008; 70:1150–1151. 66 Stuve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 2009; 72:396–401. 67 Schiess N, Calabresi PA. Natalizumab: bound to rebound? Neurology 2009; 72:392–393. 68 Molloy ES, Calabrese LH. Therapy: Targeted but not trouble-free: efalizumab and PML. Nat Rev Rheumatol 2009; 5:418–419. 69 Korman BD, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol 2009; 145:937–942. 70 Martin Mdel P, Cravens PD, Winger R, et al. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol 2009; 66:1016– 1020. 71 Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10:816–824. An important review on this topic. 72 Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006; 180:63–70. 73 Stuve O, Leussink VI, Frohlich R, et al. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Arch Neurol 2009; 66:259–261. 74 Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676–688.
50 Berger J, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab: unforeseen consequences. N Engl J Med 2005; 353:414–416.
75 Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008; 63:395–400.
51 Becher B. Central nervous system immune surveillance: on natalizumab, dendritic cells, and dangerous immune privilege. Arch Neurol 2008; 65: 1566–1567.
76 Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol 2008; 10:55–66.
52 del Pilar Martin M, Cravens PD, Winger R, et al. Decrease in the numbers of dendritic cells and CD4þ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 2008; 65:1596–1603. 53 Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006; 59:743–747. 54 Du Pasquier RA, Autissier P, Zheng Y, et al. Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies. AIDS 2005; 19:2069–2076.
77 Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64:1270–1272. 78 Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 2008; 67 (Suppl 3):iii64–iii65. 79 Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after highdose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99:1486–1488.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Demyelination and immunomodulatory treatments Lysandropoulos and Pasquier 233 80 Kamar N, Mengelle C, Rostaing L. Incidence of JC-virus replication after rituximab therapy in solid-organ transplant patients. Am J Transplant 2009; 9:244–245. 81 Andreakos E. Targeting cytokines in autoimmunity: new approaches, new promise. Expert Opin Biol Ther 2003; 3:435–447. 82 Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991; 87:949–954. 83 Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991; 325:467–472. 84 Selmaj KW, Raine CS. Experimental autoimmune encephalomyelitis: immunotherapy with antitumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology 1995; 45:S44–S49. 85 van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal antitumor necrosis factor antibody cA2. Neurology 1996; 47:1531– 1534. 86 The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53: 457–465. 87 Ramos-Casals M, Brito-Zeron P, Munoz S, Soto MJ. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 2008; 87:345–364.
88 Ramos-Casals M, Roberto Perez A, Diaz-Lagares C, et al. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010; 9:188–193. This study recapitulates the findings from the BIOGEAS observational project on patients who are treated with anti-TNFa therapies. 89 Mitoma H, Horiuchi T, Hatta N, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNFalpha. Gastroenterology 2005; 128:376–392. 90 Zheng L, Fisher G, Miller RE, et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995; 377:348–351. 91 Cope A, Ettinger R, McDevitt H. The role of TNF alpha and related cytokines in the development and function of the autoreactive T-cell repertoire. Res Immunol 1997; 148:307–312. 92 Roos JC, Ostor AJ. Neurological complications of infliximab. J Rheumatol 2007; 34:236–237; author reply 237–238. 93 Rau R, Sander O, van Riel P, et al. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis. J Rheumatol 2003; 30:680–690. 94 Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother 2004; 5:581–594. 95 Winkelmann A, Patejdl R, Wagner S, et al. Cerebral MRI lesions and antitumor necrosis factor-alpha therapy. J Neurol 2008; 255 (Suppl 6):109–114. 96 Braun J, Sieper J. Biological therapies in the spondyloarthritides: the current state. Rheumatology (Oxford) 2004; 43:1072–1084.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Leukodystrophies with late disease onset: an update Wolfgang Ko¨hler Fachkrankenhaus Hubertusburg, Klinik fu¨r Neurologie und Neurologische Intensivmedizin, Wermsdorf, Germany Correspondence to Wolfgang Ko¨hler, Fachkrankenhaus Hubertusburg, Klinik fu¨r Neurologie und Neurologische Intensivmedizin, D-04779 Wermsdorf, Germany Tel: +49 34364 62356; fax: +49 34364 62632; e-mail:
[email protected] Current Opinion in Neurology 2010, 23:234–241
Purpose of review Knowledge of the metabolic and genetic basis of known and previously unknown leukodystrophies is constantly increasing, opening new treatment options such as enzyme replacement or cell-based therapies. This brief review highlights some recent work, particularly emphasizing results from studies in adulthood leukodystrophies. Recent findings Evidence from recent studies suggests increasing importance of metabolic dysfunctions, for example, in peroxisomal lipid metabolism or energy homeostasis, influencing axonal integrity and oligodendrocyte function and leading to white matter demyelination. In addition, diagnostic and therapeutic progress in metachromatic leukodystrophy, X-linked adrenoleukodystrophy, Krabbe diseases and other rare leukodystrophies with late onset are summarized. Summary Better understanding of leukodystrophies in neurological routine practice is of crucial importance for differentiating between other white matter diseases such as toxic, inflammatory or vascular leukoencephalopathies. Many leukodystrophies are particularly important to recognize because specific treatments already exist or are currently under investigation. The article also provides an overview of currently known leukodystrophies in adulthood. Keywords enzyme replacement, gene therapy, hematopoietic stem cell transplantation, inborn error of metabolism, leukodystrophy Curr Opin Neurol 23:234–241 ß 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins 1350-7540
Introduction Leukodystrophies are genetically determined, chronic progressive white matter disorders with a variable pathogenetic background and a great diversity of clinical and paraclinical findings. Abnormalities in cerebral white matter are frequently detected by MRI in routine diagnostic procedures associated with a great variety of possible causes including multiple acquired causes and late-onset leukoencephalopathies caused by inborn errors of metabolism (IEM). Recent developments are related to increasing expertise in genotypic and phenotypic differentiation of leukodystrophies in children and adults. Sophisticated diagnostic strategies and, more importantly, advanced knowledge of biochemical and genetic background open new therapeutic opportunities with respect to metabolic treatments and gene therapy approaches.
General developments in diagnosis, treatment and understanding of leukodystrophies The interplay of myelin formation and degradation, inflammation, axonal loss and IEM is not understood 1350-7540 ß 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
widely. Recent results from experimental animal studies provided unexpected insight into the role of oligodendrocytes in supporting long-term axonal function and survival, neuroinflammation and central nervous system (CNS) demyelination [1,2]. Lack of expression of glia-specific proteins, including 20 ,30 -cyclic nucleotide 3’-phosphodiesterase (CNP), proteolipid protein (PLP) and myelin-associated glycoprotein (MAG), as well as defective peroxisomal functions causes progressive axon degeneration and inflammatory demyelination, both of which contribute to a variety of CNS diseases such as inflammatory leukodystrophies and multiple sclerosis (MS) [3,4]. These studies provide a deeper understanding of gene functions involved in hypomyelinating or demyelinating leukodystrophies and the role of glial cells in myelin formation and white matter homeostasis. In the light of substantial improvement in therapeutic efforts, such as enzyme replacement therapy or stem cell treatment, early diagnosis of the underlying IEM appears to be crucial, in both well known and previously undiagnosed leukodystrophies. As diagnoses are frequently missed in adult patients, special efforts are being undertaken to improve clinical awareness [5,6,7] and diagnostic algorithms in adulthood leukodystrophies [8]. DOI:10.1097/WCO.0b013e328338313a
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Leukodystrophies with late disease onset Ko¨hler
MRI and neurophysiological pattern recognition [8,9,10], characterization of clinical phenotypes and enhancing genetic techniques has been shown to be effective tools for optimizing diagnostic safety.
Recent developments in known leukodystrophies Increasing availability of effective treatments in specific diseases urges the need for newborn screening. As an example, detection and treatment of adrenal insufficiency in early infancy may be life-saving in X-linked adrenoleukodystrophy (X-ALD) [11], as well as early treatment with bone marrow transplantation in XALD; thus, optimized new and well tolerated newborn screening methods have been achieved [12].
Metachromatic leukodystrophy Metachromatic leukodystrophy (MLD) is an autosomal recessive neurodegenerative lysosomal disease characterized by accumulation of sulfatides, extensive white matter damage and loss of both cognitive and motor functions [13]. Its incidence is estimated to be 1 : 40 000. In vivo, the catabolism of sulfatide requires both the enzyme arylsulfatase A (ASA) and a specific sphingolipid activator protein, saposin-B, encoded by the PSAP gene. ASA activity is deficient in the classical forms of MLD with mutations in the ARSA gene, but exceedingly rare cases of MLD are due to saposin-B deficiency [14–17]. The disease manifests itself with a broad spectrum of clinical variants. During adulthood, two main clinical presentations with different genetic but identical biochemical background are described, presenting as spino-cerebellar ataxia or psychosis [18]. The correlation between MLD mutations, residual enzymatic activity associated with the mutated alleles [19] and patients’ phenotype is well established [20] and of particular relevance for patients’ prognostic evaluation, presymptomatic management and patient selection for emerging treatments. Results from hematopoietic stem cell transplantation (HSCT) have been inconclusive in MLD; however, subsets of patients may benefit from HSCT [21,22, 23]. Further improvement may be expected from new transplantation strategies using a gene therapy approach with genetically modified autologous hematopoietic stem cells or encapsulated baby hamster kidney (BHK) cells [24] that can express supraphysiological levels of ASA, thus serving as a quantitatively more effective source of functional enzyme than normal donor cells when transplanted in patients with MLD [21]. Another new approach is the treatment with pluripotent neural stem cells (NSCs). After transplanting NSCs in ARSA-deficient mice brain, the cells acquired not oligodendrocyte but
235
astrocyte cell type, with improved ASA activity and a significant amelioration of neurological deficits [25]. In addition, signs of enzyme cross-correction between transplanted and host cells were found. The success of any cell therapy approach depends on its ability to deliver sufficient amounts of gene across the blood–brain barrier to achieve distribution of the deficient enzyme throughout the brain. Intracerebral injection of a viral vector encoding human ARSA corrects the biochemical, neuropathological and behavioral abnormalities in mice and large animals [26]; however, the procedure may be too invasive in humans and not sufficient to improve enzyme levels throughout the whole brain. Alternatively, an intrathecal injection of adeno-associated viral vector serotype 1 (AAV1) was tested [27], followed by a widespread distribution of ASA activity and a significant reduction of sulfatide content in ARSA knockout mice, suggesting a useful alternative approach. Enzyme replacement therapy (ERT) has been developed recently for MLD [28,29], and a phase III trial is ongoing in late infantile MLD variants (www.Clincal Trials.gov). Recurrent intravenous treatment with the lacking enzyme significantly reduces sulfatide storage in MLD mice in a dose-dependent manner; however, the blood–brain barrier limits the access of the recombinant product to the nervous tissues. Furthermore, ERT with ASA depends on N-linked oligosaccharidemediated delivery of intravenously injected recombinant enzyme to the lysosomes of patient cells that may widely vary depending on the composition of the oligosaccharide and other secondary conditions [30].
Globoid cell leukodystrophy (Krabbe disease) Krabbe disease is an autosomal recessive neurometabolic disorder caused by the deficiency of galactocerebrosidase (GALC) activity, with an estimated incidence rate of 1 : 100 000. The enzyme defect results in the accumulation of psychosine, which leads to oligodendrocyte apoptosis, induction of gliosis and expression of proinflammatory cytokines and inducible nitric oxide synthase in astrocytes of the CNS [31]. In addition, recent studies revealed a psychosine-induced energy depletion in oligodendrocytes and astrocytes resulting in increased lipid biosynthesis [32], a phenomenon that may also participate in the disruption of the structure of lipid rafts in oligodendrocyte membranes and neurons [33]. Inflammatory cells and increased levels of cytokines and chemokines are present in the CNS and may play a significant role in the pathogenesis of the disease. The gene coding for GALC is localized on chromosome 14q31. A number of clinical phenotypes from early
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
236 Demyelinating diseases
infantile to adolescent adult can be distinguished with phenotype–genotype correlation lacking, resulting in a progressive demyelinating disease of the CNS and peripheral nervous system. Clinical symptoms in early-onset variants show rapid and severe mental and motor deterioration, seizures and visual failure leading to vegetative state and death within month to 3 years. Later-onset forms progress more slowly with spastic paraparesis, hemiparesis, visual problems and cerebellar ataxia. Adult onset with polyneuropathy and psychosis is rare but possible.
pathy. As the various phenotypes frequently co-occur within the same family, involvement of disease modifier genes has been proposed; however, environmental factors like head trauma may also contribute [41]. In the search for disease modifier genes or other cofactors, recent studies highlight a putative role of polymorphisms within the methionine metabolism [42], which is of high importance, both, as a major methyl group donor for brain myelination and for oxidative stress control via a glutathione peroxidase system.
Signal abnormalities in MR are characteristic, showing deep white matter, cerebellar and long tract involvement [34,35] and cerebral atrophy. In addition, the combination of both enlargement and enhancement of multiple cranial nerves in conjunction with unusual cystic lesions adjacent to the frontal horns of the lateral ventricles has been reported [36].
Accumulation of VLCFAs is a general finding in all XALD phenotypes, but their pathogenetic importance remains to be elucidated. However, an increasing number of studies point out the deleterious effects of elevated VLCFA, such as direct toxic effects of VLCFA on glial cells and neurons from rat hippocampus in culture [43], increased pro-inflammatory secretion of effector molecules in X-ALD lymphoblasts [44], enhanced production of nitric oxide, reactive oxygen species and pro-inflammatory cytokines in VLCFA-accumulated macrophages [45], increased cytokine expression in X-ALD astrocytes [46], widespread microglial activation and apoptosis induced by lysophosphatidylcholine (C24 : 0) injection in mice brain [47] and a VLCFAdependent defective antioxidant response [48,49]. Normalization of elevated VLCFA plasma levels, therefore, continues to be a therapeutic target in X-ALD patients despite missing results from controlled clinical trials [50].
HSCT is the only available treatment for infants with early infantile Krabbe disease. Most transplanted patients show a better outcome compared with the expected clinical course from natural history cohorts but eventually develop motor and language deterioration in many cases despite treatment [37]. New treatment options are urgently warranted concomitant with upcoming results from newborn screening programs [38]. Recent animal studies in twitcher mice highlight the importance of the gene therapy approach with intracerebrally administered genetically modified neural progenitor cells leading to an increased enzyme activity in oligodendrocytes, correction of astrocytic gliosis and providing evidence for remyelination [39]. As inflammatory mechanisms are known to be involved in brain disorder in globoid cell leukodystrophy (GLD), additional anti-inflammatory treatment strategies are investigated in GLD mice, suggesting a possible role of such treatments in combination with HSCT [40].
X-linked adrenoleukodystrophy X-ALD is a neurodegenerative disorder characterized by progressive demyelination within the CNS, adrenal insufficiency and a pathognomonic accumulation of saturated very long chain fatty acids (VLCFAs) in plasma and tissues. The disease is likely the most frequent leukodystrophy with incidence rates of 1 27 000–1 : 40 000. X-ALD is caused by mutations in the ABCD1 gene that leads to loss of function of a peroxisomal membrane protein whose putative role is the transport of VLCFAs into the peroxisome for degradation by beta-oxidation. The clinical presentation ranges from a severe childhood cerebral form (CCALD), which is rapidly progressive and associated with an inflammatory response in the brain white matter, to a slowly progressive adult adrenomyeloneuropathy (AMN) variant, which presents with distal axonopathy in spinal cord tracts and peripheral neuro-
In addition, increasing evidence shows that oxidative damage is an important pathogenetic component causing neurodegeneration in X-ALD similar to in a growing number of other neurodegenerative disorders. In this context, peroxisomes are no longer regarded as autonomous but more likely as interactive organelles involved in numerous metabolic pathways including beta-oxidation of fatty acids and the metabolism of reactive oxygen species [51,52]. Dysfunction of peroxisomes may, therefore, contribute in part to white matter disease [53,54]. Recent diagnostic progress had been made with MR spectroscopy at 7 T scanners showing global elevated myo-inositol-to-creatine ratios correlating with the severity clinical phenotypes [55] and in the detection of long tract involvement in AMN phenotype using quantitative magnetization transfer techniques [56]. Although previous studies with Lorenzo’s oil provided evidence for some preventive effects in asymptomatic boys and noncerebral X-ALD variants, normalization of VLCFA plasmas levels is not fully preventive from the onset of inflammatory cerebral demyelination and the progression of neurodegeneration. In-vitro experiments demonstrate that ABCD2, a close homologue to the
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Gene
Low C27-steroid 26-hydoxylase, high cholesterol Low folate, methionine, high homocysteine, methylmalonic aciduria Organic aciduria (depending on the metabolic defect)
Autosomal recessive
Autosomal recessive
Homocysteine remethylation defects Methylenetetrahydrofolate (MTHFR) deficiency Cobalmin C deficiency Organic acidurias Glutaric aciduria type I 1-2-OH-Glutaric aciduria 3-HMG-CoA lyase deficiency 3-Methyl-glutaconic aciduria type I
b-Hexosaminidase
HEXA, 15q23–q24
CYP27A1, 2q33–qter
b-Mannosidase b-Galactosidase
MANBA, 4q22–25 GLB1, 3p21.33
Gangliosidosis (GM1-type 3, GM2)
Cerebrotendinose xanthomatose (CTX)
a-Mannosidase
MAN2B1, 19 p13.2–q12
Mannosidosis (a,b)
Iron depletion, lysosomal lipid storage Urin-free sialic acid Low fatty aldehyde dehydrogenase
a-Galactosidase A
GLA, Xq22
MCOLN1, 19p13.3–p13.2 SLC17A5, 6q14–q15 ALDH3A2, 17p11.12
Galactocerebrosidase
GALC, 14q31
Mucolipidosis, type IV Sialuria (Salla disease) Sjo¨gren–Larsson syndrome
Arylsulfatase A, urin sulfatides elevated Saposin B, urine sulfatides elevated
ARSA, 22q13.31-qter PSAP, 10q22.1
VLCFA
Biochemical defect
Metachromatic leukodystrophy (MLD) With arylsulfatase A deficiency With activator defect Globoid cell leukodystrophy (GLD, Morbus Krabbe) Fabry’s disease
Leukodystrophies with known inborn errors of metabolism X-chromosomal adrenoleukodystrophy (X-ALD) ABCD1, Xq28 Adrenomyeloneuropathy (AMN) Adult cerebral X-ALD (ACALD)
Disease
[83]
[83]
[82]
[79] [80] [81]
[78]
[76] [77]
[75]
[74]
Reference
(continued overleaf )
AMN: spastic paraparesis, sensory and autonomic dysfunctions ACALD: behavioral changes, dementia, seizures, optic atrophy, hearing loss, spasticity Psychosis, slowly progressive spasticity, ataxia, dystonia, dementia and polyneuropathy Spastic paraparesis, visual disturbances and polyneuropathy Burning pain, angiokeratomas, corneal opacifications, strokes, cardial and renal dysfunction Immune deficiency, facial and skeletal abnormalities, hearing impairment, seizures and intellectual disability Spinocerebellar ataxia Dystonia, akinetic-rigid parkinsonism, short statue, skeletal dysplasia Ataxia, dysarthria, deafness, weakness and dementia Visual disturbances, mental retardation Ataxia, progressive dementia, visceromegaly Mental retardation, spastic paraparesis, macula dystrophy and ichthyosis Spastic paraparesis, ataxia, dementia, tendon, diarrhea, cataract and xanthomata Psychosis (also as transient episodes of confusion and coma), depression, cognitive deficits, spastic paraparesis, strokes and polyneuropathy Variable signs (macrocephalia, cognitive deficits, epilepsia, supranuclear gaze palsy, optic atrophy, spasticity)
Main symptoms
Table 1 Gene, locus, biochemical defect and leading symptoms of currently known leukodystrophies with exclusive or possible adulthood presentation
Leukodystrophies with late disease onset Ko¨hler 237
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
[86] [87] [88]
[89,90]
Very slow progressive spasticity and dementia, dystonia, ataxia and seizures Dementia, bladder dysfunction, upper and lower motor neuron disease and parkinsonism Transient stroke like episodes and dementia
Bulbar signs, palatal myoclonus, cerebellar ataxia, urinary disturbance and spastic paraparesis
MLC1, 22q13.33 GBE, 3p14 NOTCH3, 19p13.2–p13.1
GFAP, 17q21, NDUFV1, 11q13
deficient ABCD1, exhibits a high degree of functional redundancy on the catabolism of VLCFA. Although ABCD2 function is not associated with specific phenotypes [57], activation of ABCD2 is able to prevent X-ALD-related neurodegeneration in mice [58]. Further studies with compounds overexpressing ABCD2 function, such as thyromimetics [59,60], are needed to confirm previous results in vivo. A second therapeutic target is currently focusing on regenerative aspects. Viral vectors engineered to produce insulin-like growth factor-1 or neurotrophin-3 were administered into the cerebrospinal fluid (CSF) of an X-ALD mouse model resulting in significant effects on neurodegeneration [61].
References for further reading are given for leukodystrophies that are not described in detail in the article.
[85] Slowly progressive spastic paraparesis, ataxia and dementia DARS2, 1q25.1
[84] metabolism EIF2B1-5 LMNB1, 5q23.3–q31.1 Autosomal dominant or sporadic
Leukodystrophies without a known inborn error of Vanishing white matter disease (VWMD) Autosomal dominant leukodystrophy (ADLD) Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS) Familial pigmentary orthochromatic leukodystrophy (POLD) Leukencephalopathy with brainstem and spinal cord involvement and elevated lactate (LBSL) Megalencephalic leukodystrophy with cysts (MLC-1) Adult polyglucosan body disease (APBD) Cerebral autosomal dominant arteriopathy with subcortical infarcts and leuko-encephalopathy (CADASIL) Alexander’s disease
Progressive spasticity, ataxia and dementia Slowly progressive spasticity and ataxia Memory disturbances, mood disorders, epilepsia, spasticity. More rapid progression in POLD
Gene Disease
Table 1 (continued )
Biochemical defect
Main symptoms
Reference
238 Demyelinating diseases
Up to now, allogeneic HSCT is the only promising treatment in cerebral inflammatory X-ALD variants, provided that it can be performed at an early stage of the disease. The long-term benefits of HSCT in X-ALD are mediated by the replacement of brain microglial cells derived from donor bone marrow myelo-monocytic cells. In contrast to a generally high mortality rate in untreated patients with cerebral inflammatory disease, HSCT is able to halt X-ALD progression in more than half of the treated patients [62]; however, human leukocyte antigen (HLA)-matched donors are not always available and procedure-related toxicity is high. A recent study reported results from a hematopoietic stem cell gene therapy approach using an ex-vivo lentivirus-mediated transfer of the ABCD1 gene into CD34þ cells from two boys with cerebral X-ALD [63]. ABCD1 protein was stably expressed in 9–14% of granulocytes, monocytes, T and B cells and bone marrow progenitors in both patients throughout the 24–30 months of follow-up, respectively. The clinical results were comparable to that achieved by allogeneic HSCT, showing halted cerebral demyelination beginning 14–16 months after the transplantation.
Advances in other leukodystrophies and overview Recent work highlights the clinical and genetic heterogeneity in eIF2B-related disorders including vanishing white matter disease and ovarioleukodystrophy [64, 65–67] with onset of symptoms at all ages, indicating that the disease most likely is widely underestimated. Neurological features are dominated by cerebellar ataxia and spasticity with relatively preserved mental abilities. Brain MRI shows abnormal increased T2 signal of the cerebral white matter and cystic degeneration, best seen in FLAIR sequences. A reduced asialotransferrin-totransferrin ratio in the CSF appears to be highly sensitive and specific to identify patients with likely eIF2B-related disorder for mutation analysis [68].
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Leukodystrophies with late disease onset Ko¨hler
239
Adult-onset autosomal dominant leukodystrophy (ADLD) is a rare but important differential diagnosis mimicking MS. A relapsing course is possible with spastic paraparesis, cranial nerve dysfunction and autonomic dysfunctions. Ataxia and cognitive disturbances are seen less frequently. Familial occurrence of progressive neurological illness suggestive of chronic MS is also highly suspicious of ADLD. The autonomic symptoms, which involve bowel and bladder regulation and orthostatic hypotension, may be the earliest changes. Patchy white matter lesions with frontal preponderance, involvement of cerebellar peduncles and spinal cord atrophy [69] are characteristic MRI features. The gene defect has been localized on chromosome 5q23, frequently as a lamin B1 gene (LMNB1) duplication [70,71].
and Krabbe disease. Finally, hematopoietic stem cell gene therapy in X-ALD appears to be a very promising treatment strategy that clearly warrants further clinical trials in X-ALD and other life-threatening leukodystrophies.
Adult-onset leukodystrophy with neuroaxonal spheroids usually commenced with behavioral changes, progressive dementing illness and epilepsy and with impaired neurological functions later in the clinical course. Axonal degeneration, myelin loss, lipid laden or pigmented macrophages, gliosis and axonal spheroids are the pathological hallmarks [72]. MRI revealed bilateral, symmetric T2 hyperintense and T1 hypointense white matter abnormalities predominantly involving the frontal lobe in most patients. Two distinct entities with an autosomal dominant pattern of inheritance as well as sporadic cases had been described: hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS) and familial pigmentary orthochromatic leukodystrophy (POLD), both showing a considerable overlap in their morphologic findings, suggesting that these diseases may all be part of the same disease spectrum [73].
1
Growing numbers of genetically defined or yet undefined leukodystrophies with possible or exclusive late disease onset are reported (Table 1), underlining an urgent need for further research in adulthood leukodystrophies. Most but not all leukodystrophies are combined with inborn errors of metabolism, which sometimes provides the essential diagnostic clue [74–76,77,78,79,80,81–90].
Conclusion
Acknowledgements This work was supported in part by the German Federal Ministry of Education and Research grant 01GM0641 (German Leukodystrophy Network, LEUKONET, www.leukonet.de).
References and recommended reading Papers of particular interest, published within the annual period of review, have been highlighted as: of special interest of outstanding interest Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 331–332). Kassmann CM, Lappe-Siefke C, Baes M, et al. Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat Genet 2007; 39:969–976.
2 Kassmann CM, Nave KA. Oligodendroglial impact on axonal function and survival: a hypothesis. Curr Opin Neurol 2008; 21:235–241. Innovative work providing important new data on a potential link between peroxisomal dysfunction, inflammation and demyelinating diseases with wide implications for future treatment strategies, not only in leukodystrophic diseases but also in multiple sclerosis and other white matter inflammatory diseases. 3
Nave KA, Trapp BD. Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci 2008; 31:535–561.
4 Birchmeier C, Nave KA. Neuregulin-1, a key axonal signal that drives Schwann cell growth and differentiation. Glia 2008; 56:1491–1497. Detection of neuronal factors promoting myelin physiology is of highest importance for the development of preventive and regenerative strategies in demyelinating diseases. 5 Sedel F, Tourbah A, Fontaine B, et al. Leukoencephalopathies associated with inborn errors of metabolism in adults. J Inherit Metab Dis 2008; 31:295–307. Comprehensive overview on recent leukodystrophies in adulthood. 6
Costello DJ, Eichler AF, Eichler FS. Leukodystrophies: classification, diagnosis, and treatment. Neurologist 2009; 15:319–328.
Kohlschu¨tter A, Bley A, Brockmann K, et al. Leukodystrophies and other genetic metabolic leukoencephalopathies in children and adults. Brain Dev 2009; 32:82–89. Comprehensive overview on recently known leukodystrophies.
7
8
Ko¨hler W. Diagnostic algorithm for the differentiation of leukodystrophies in early MS. J Neurol 2008; 255 (Suppl 6):123–126.
9 Schiffmann R, van der Knaap MS. Invited article: an MRI-based approach to the diagnosis of white matter disorders. Neurology 2009; 72:750–759. Long-lasting clinical experiences and results from pattern recognition analysis in an extensively large number of known and unknown leukodystrophies in children and adults are condensed in a MRI-based algorithm of great value for treating clinicians. 10 Eichler F, Grodd W, Grant E, et al. Metachromatic leukodystrophy: a scoring system for brain MR imaging observations. AJNR Am J Neuroradiol 2009; 30:1893–1897. 11 Raymond GV, Jones RO, Moser AB. Newborn screening for adrenoleukodystrophy: implications for therapy. Mol Diagn Ther 2007; 11:381–384.
Leukodystrophies are an important and often challenging clinical differential diagnosis in white matter diseases, especially in adulthood. Significant diagnostic and therapeutic improvements have been made in recent years providing deeper insights into the understanding of inborn errors of metabolism and their link to white matter diseases, resulting in new treatment concepts such as enzyme replacement therapy in Fabry’s disease, MLD and potentially others.
12 Hubbard WC, Moser AB, Liu AC, et al. Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatography-tandem mass spectrometric (LC–MS/MS) method. Mol Genet Metab 2009; 97:212–220. Validation of a newborn screening LC–MS/MS method with high sensitivity for practical use in X-ALD.
Cell therapies such as bone marrow transplantation have been successfully established in cerebral X-ALD, MLD
15 Deconinck N, Messaaoui A, Ziereisen F, et al. Metachromatic leukodystrophy without arylsulfatase A deficiency: a new case of saposin-B deficiency. Eur J Paediatr Neurol 2008; 12:46–50.
13 Gieselmann V. Metachromatic leukodystrophy: genetics, pathogenesis and therapeutic options. Acta Paediatr Suppl 2008; 97:15–21. Comprehensive overview of MLD. 14 Grossi S, Regis S, Rosano C, et al. Molecular analysis of ARSA and PSAP genes in twenty-one Italian patients with metachromatic leukodystrophy: identification and functional characterization of 11 novel ARSA alleles. Hum Mutat 2008; 29:E220–E230.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
240 Demyelinating diseases 16 Kuchar L, Ledvinova´ J, Hrebı´cek M, et al. Prosaposin deficiency and saposin B deficiency (activator-deficient metachromatic leukodystrophy): report on two patients detected by analysis of urinary sphingolipids and carrying novel PSAP gene mutations. Am J Med GenetA 2009; 149A:613–621. 17 Matzner U, Breiden B, Schwarzmann G, et al. Saposin B-dependent reconstitution of arylsulfatase A activity in vitro and in cell culture models of metachromatic leukodystrophy. J Biol Chem 2009; 284:9372–9381. 18 Colsch B, Afonso C, Turpin JC, et al. Sulfogalactosylceramides in motor and psycho-cognitive adult metachromatic leukodystrophy: relations between clinical, biochemical analysis and molecular aspects. Biochim Biophys Acta 2008; 1780:434–440. 19 Tan MA, Fuller M, Zabidi-Hussin ZA, et al. Biochemical profiling to predict disease severity in metachromatic leukodystrophy. Mol Genet Metab 2010; 99:142–148. 20 Cesani M, Capotondo A, Plati T, et al. Characterization of new arylsulfatase A gene mutations reinforces genotype–phenotype correlation in metachromatic leukodystrophy. Hum Mutat 2009; 30:E936–E945. Important work with clinical relevance for patient counselling. 21 Biffi A, Lucchini G, Rovelli A, et al. Metachromatic leukodystrophy: an overview of current and prospective treatments. Bone Marrow Transplant 2008; 42 (Suppl 2):S2–S6. 22 Meuleman N, Vanhaelen G, Tondreau T, et al. Reduced intensity conditioning haematopoietic stem cell transplantation with mesenchymal stromal cells infusion for the treatment of metachromatic leukodystrophy: a case report. Haematologica 2008; 93:e11–e13. 23 Pierson TM, Bonnemann CG, Finkel RS, et al. Umbilical cord blood trans plantation for juvenile metachromatic leukodystrophy. Ann Neurol 2008; 64:583–587. First report on umbilical cord blood transplantation with documented neurological outcome in metachromatic leukodystrophy. 24 Lagranha VL, Baldo G, de Carvalho TG, et al. In vitro correction of ARSA deficiency in human skin fibroblasts from metachromatic leukodystrophy patients after treatment with microencapsulated recombinant cells. Metab Brain Dis 2008; 23:469–484. Controlled trial on a new therapeutic strategy for the treatment of MLD using encapsulated rBHK clones, reaching normal enzyme levels in human MLD fibroblasts. 25 Givogri MI, Bottai D, Zhu HL, et al. Multipotential neural precursors trans planted into the metachromatic leukodystrophy brain fail to generate oligodendrocytes but contribute to limit brain dysfunction. Dev Neurosci 2008; 30:340–357. The study provides a first insight into the effect of metabolic disturbances in IEM on transplanted NSCs. 26 Colle MA, Piguet F, Bertrand L, et al. Efficient intracerebral delivery of AAV5 vector encoding human ARSA in nonhuman primate. Hum Mol Genet 2010; 19:147–158. Proof of concept in large animals that intracerebral gene therapy is possible in MLD. 27 Iwamoto N, Watanabe A, Yamamoto M, et al. Global diffuse distribution in the brain and efficient gene delivery to the dorsal root ganglia by intrathecal injection of adeno-associated viral vector serotype 1. J Gene Med 2009; 11:498–505. 28 Matzner U, Herbst E, Hedayati KK, et al. Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum Mol Genet 2005; 14:1139–1152. 29 Matzner U, Lu¨llmann-Rauch R, Stroobants S, et al. Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy. Mol Ther 2009; 17:600–606. Important work from experimental animals providing proof of concept for the innovative concept of enzyme-replacement therapy in MLD and giving rise to further clinical trials in humans for a previously untreatable disease. 30 Schro¨der S, Matthes F, Hyden P, et al. Site specific analysis of N-linked oligosaccharides of recombinant lysosomal arylsulfatase A produced in different cell lines. Glycobiology 2010; 20:248–259. 31 Sakai N. Pathogenesis of leukodystrophy for Krabbe disease: molecular mechanism and clinical treatment. Brain Dev 2009; 31:485–487. Comprehensive overview of Krabbe disease. 32 Giri S, Khan M, Nath N, et al. The role of AMPK in psychosine mediated effects on oligodendrocytes and astrocytes: implication for Krabbe disease. J Neurochem 2008; 105:1820–1833. 33 White AB, Givogri MI, Lopez-Rosas A, et al. Psychosine accumulates in membrane microdomains in the brain of Krabbe patients, disrupting the raft architecture. J Neurosci 2009; 29:6068–6077. This study describes a previously unknown biophysical aspect for the mechanism of pathogenesis in Krabbe disease. 34 Romano A, De Simone R, Fasoli F, et al. Selective white matter involvement in a patient with late onset Krabbe disease: MR, MR spectroscopy, and diffusion tensor study. J Neuroimaging 2009; 19:191–193.
35 Provenzale JM, Peddi S, Kurtzberg J, et al. Correlation of neurodevelopmental features and MRI findings in infantile Krabbe’s disease. AJR Am J Roentgenol 2009; 192:59–65. 36 Beslow LA, Schwartz ES, Bo¨nnemann CG. Thickening and enhancement of multiple cranial nerves in conjunction with cystic white matter lesions in early infantile Krabbe disease. Pediatr Radiol 2008; 38:694–696. Interesting new radiological finding with clinical relevance. 37 Duffner PK, Caviness VS Jr, Erbe RW, et al. The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York. Genet Med 2009; 11:450–454. Important report on the clinical transplantation outcome in Krabbe disease with important impact on clinical care of patients. 38 Duffner PK, Caggana M, Orsini JJ, et al. Newborn screening for Krabbe disease: the New York State model. Pediatr Neurol 2009; 40:245–252; discussion 253–255. 39 Strazza M, Luddi A, Carbone M, et al. Significant correction of pathology in brains of twitcher mice following injection of genetically modified mouse neural progenitor cells. Mol Genet Metab 2009; 97:27–34. Proof of concept that exogenously supplied neural progenitor cells can donate GALC enzyme to oligodendrocytes in the brains of affected twitcher mice resulting in normal myelination in the area of donor cells. 40 Luzi P, Abraham RM, Rafi MA, et al. Effects of treatments on inflammatory and apoptotic markers in the CNS of mice with globoid cell leukodystrophy. Brain Res 2009; 1300:146–158. Experimental new treatment option highlighting an anti-inflammatory approach in Krabbe disease that could be of practical value in patients with or without HSCT treatment. 41 Raymond GV, Seidman R, Monteith TS, et al. Head trauma can initiate the onset of adreno-leukodystrophy. J Neurol Sci 2009; 290:70–74. 42 Semmler A, Bao X, Cao G, et al. Genetic variants of methionine metabolism and X-ALD phenotype generation: results of a new study sample. J Neurol 2009; 256:1277–1280. Innovative aspect in X-ALD treatment. 43 Hein S, Scho¨nfeld P, Kahlert S, Reiser G. Toxic effects of X-linked adrenoleukodystrophy-associated, very long chain fatty acids on glial cells and neurons from rat hippocampus in culture. Hum Mol Genet 2008; 17:1750–1761. 44 Uto T, Contreras MA, Gilg AG, Singh I. Oxidative imbalance in nonstimulated X-adrenoleukodystrophy-derived lymphoblasts. Dev Neurosci 2008; 30: 410–418. 45 Yanagisawa N, Shimada K, Miyazaki T, et al. Enhanced production of nitric oxide, reactive oxygen species, and pro-inflammatory cytokines in very long chain saturated fatty acid-accumulated macrophages. Lipids Health Dis 2008; 7:48. 46 Singh J, Khan M, Singh I. Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy. J Lipid Res 2009; 50:135–147. New aspect providing information for a genetic link to brain inflammation in X-ALD. 47 Eichler FS, Ren JQ, Cossoy M, et al. Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy? Ann Neurol 2008; 63:729–742. The study provides further insights into inflammatory pathomechanisms leading to extensive demyelination in X-ALD that are prerequisite in the development of urgently needed new treatment in patients with cerebral X-ALD involvement. 48 Fourcade S, Lo´pez-Erauskin J, Galino J, et al. Early oxidative damage under lying neurodegeneration in X-adrenoleukodystrophy. Hum Mol Genet 2008; 17:1762–1773. This work widens the view on the pathogenetic background of X-ALD, opening new therapeutic options. 49 Deon M, Sitta A, Barschak AG, et al. Oxidative stress is induced in female carriers of X-linked adrenoleukodystrophy. J Neurol Sci 2008; 266:79–83. 50 Semmler A, Ko¨hler W, Jung HH, et al. Therapy of X-linked adrenoleukody strophy. Expert Rev Neurother 2008; 8:1367–1379. Comprehensive overview of X-ALD treatment options. 51 Thoms S, Grønborg S, Ga¨rtner J. Organelle interplay in peroxisomal disorders. Trends Mol Med 2009; 15:293–302. 52 Camo˜es F, Bonekamp NA, Delille HK, Schrader M. Organelle dynamics and dysfunction: a closer link between peroxisomes and mitochondria. J Inherit Metab Dis 2009; 32:163–180. 53 Singh I, Singh AK, Contreras MA. Peroxisomal dysfunction in inflammatory childhood white matter disorders: an unexpected contributor to neuropathology. J Child Neurol 2009; 24:1147–1157. 54 Brites P, Mooyer PA, El Mrabet L, et al. Plasmalogens participate in very-long chain fatty acid-induced pathology. Brain 2009; 132 (Pt 2):482–492. Important study in peroxisomal-deficient animals showing pathophysiological consequences on white matter inflammation and demyelination.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Leukodystrophies with late disease onset Ko¨hler 55 Ratai E, Kok T, Wiggins C, et al. Seven-Tesla proton magnetic resonance spectroscopic imaging in adult X-linked adrenoleukodystrophy. Arch Neurol 2008; 65:1488–1494. First magnetic resonance spectrosocopy study in X-ALD showing an elevated myo-inositol-to-creatine ratio correlating with the severity of X-ALD symptoms. 56 Smith SA, Golay X, Fatemi A, et al. Quantitative magnetization transfer characteristics of the human cervical spinal cord in vivo: application to adrenomyeloneuropathy. Magn Reson Med 2009; 61:22–27. Innovative MRI technique visualizing spinal cord pathology in AMN. 57 Maier EM, Mayerhofer PU, Asheuer M, et al. X-linked adrenoleukodystrophy phenotype is independent of ABCD2 genotype. Biochem Biophys Res Commun 2008; 377:176–180. Important work elucidating the function of ABCD2 as a potential disease modifier in X-ALD.
241
70 Meijer IA, Simoes-Lopes AA, Laurent S, et al. A novel duplication confirms the involvement of 5q23.2 in autosomal dominant leukodystrophy. Arch Neurol 2008; 65:1496–1501. 71 Brussino A, Vaula G, Cagnoli C, et al. A family with autosomal dominant leukodystrophy linked to 5q23.2-q23.3 without lamin B1 mutations. Eur J Neurol 2009 [Epub ahead of print]. 72 Freeman SH, Hyman BT, Sims KB, et al. Adult onset leukodystrophy with neuroaxonal spheroids: clinical, neuroimaging and neuropathologic observations. Brain Pathol 2009; 19:39–47. Comprehensive update on leukoencephalopathies with spheroids in adulthood. 73 Wider C, Van Gerpen JA, DeArmond S, et al. Leukoencephalopathy with spheroids (HDLS) and pigmentary leukodystrophy (POLD) A single entity? Neurology 2009; 72:1953–1959. Comprehensive update on leukoencephalopathies with spheroids in adulthood.
58 Fourcade S, Ruiz M, Camps C, et al. A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis. Am J Physiol Endocrinol Metab 2009; 296:E211–E221. Important work elucidating the function of ABCD2 as a potential disease modifier in X-ALD.
74 Schaefer RM, Tylki-Szyman´ska A, Hilz MJ. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs 2009; 69:2179–2205.
59 Weinhofer I, Kunze M, Rampler H, et al. Distinct modulatory roles for thyroid hormone receptors TRalpha and TRbeta in SREBP1-activated ABCD2 expression. Eur J Cell Biol 2008; 87:933–945.
76 Labauge P, Renard D, Castelnovo G, et al. Beta-mannosidosis: a new cause of spinocerebellar ataxia. Clin Neurol Neurosurg 2009; 111:109– 110.
60 Genin EC, Gondcaille C, Trompier D, Savary S. Induction of the adrenoleukodystrophy-related gene (ABCD2) by thyromimetics. J Steroid Biochem Mol Biol 2009; 116:37–43.
77 Brunetti-Pierri N, Scaglia F. GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol Genet Metab 2008; 94:391–396. Comprehensive overview of GM1 gangliosidosis.
61 Mastroeni R, Bensadoun JC, Charvin D, et al. Insulin-like growth factor-1 and neurotrophin-3 gene therapy prevents motor decline in an X-linked adrenoleukodystrophy mouse model. Ann Neurol 2009; 66:117–122. New treatment strategy using an intrathecal gene therapy approach in X-ALD mouse model showing that a viral-based, long-lasting delivery of insulin-like growth factor-1 and neurotrophin-3 significantly halts the progression of the disease and leads to potent protective effect against the demyelination process.
78 Shapiro BE, Pastores GM, Gianutsos J, et al. Miglustat in late-onset TaySachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment. Genet Med 2009; 11:425–433.
62 Peters C, Charnas LR, Tan Y, et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood 2004; 104:881–888. 63 Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326:818–823. Epoch-making results from hematopoietic stem cell gene therapy in X-ALD. 64 Maletkovic J, Schiffmann R, Gorospe JR, et al. Genetic and clinical hetero geneity in eIF2B-related disorder. J Child Neurol 2008; 23:205–215. Comprehensive overview in eIF2B-related disorders. 65 Horzinski L, Gonthier C, Rodriguez D, et al. Exon deletion in the noncatalytic domain of eIF2Bepsilon due to a splice site mutation leads to infantile forms of CACH/VWM with severe decrease of eIF2B GEF activity. Ann Hum Genet 2008; 72 (Pt 3):410–415.
75 Malm D, Nilssen Ø. Alpha-mannosidosis. Orphanet J Rare Dis 2008; 3:21.
79 Bach G. Mucolipidosis type IV. Mol Genet Metab 2001; 73:197–203. 80 Mochel F, Sedel F, Vanderver A, et al. Cerebellar ataxia with elevated cerebrospinal free sialic acid (CAFSA). Brain 2009; 132 (Pt 3):801–809. Important new findings in sialic acid-related disorders with clinical relevance. 81 Lossos A, Khoury M, Rizzo WB, et al. Phenotypic variability among adult siblings with Sjo¨gren–Larsson syndrome. Arch Neurol 2006; 63:278– 280. 82 Keren Z, Falik-Zaccai TC. Cerebrotendinous xanthomatosis (CTX): a treatable lipid storage disease. Pediatr Endocrinol Rev 2009; 7:6–11. 83 Ho¨rster F, Surtees R, Hoffmann GF. Disorders of intermediary metabolism: toxic leukoencephalopathies. J Inherit Metab Dis 2005; 28:345–356. 84 Padiath QS, Saigoh K, Schiffmann R, et al. Lamin B1 duplications cause autosomal dominant leukodystrophy. Nat Genet 2006; 38:1114–1123. 85 Scheper GC, van der Klok T, van Andel RJ, et al. Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nat Genet 2007; 39:534–539.
66 Mathis S, Scheper GC, Baumann N, et al. The ovarioleukodystrophy. Clin Neurol Neurosurg 2008; 110:1035–1037.
86 Blattner R, Von Moers A, Leegwater PA, et al. Clinical and genetic heterogeneity in megalencephalic leukoencephalopathy with subcortical cysts (MLC). Neuropediatrics 2003; 34:215–218.
67 Damon-Perriere N, Menegon P, Olivier A, et al. Intra-familial phenotypic heterogeneity in adult onset vanishing white matter disease. Clin Neurol Neurosurg 2008; 110:1068–1071.
87 Roe CR, Bottiglieri T, Wallace M, et al. Adult polyglucosan body disease (APBD): anaplerotic diet therapy (triheptanoin) and demonstration of defective methylation pathways. Mol Genet Metab 2009 [Epub ahead of print].
68 Vanderver A, Hathout Y, Maletkovic J, et al. Sensitivity and specificity of decreased CSF asialotransferrin for eIF2B-related disorder. Neurology 2008; 70:2226–2232. Study showing the clinical relevance of a new technique for diagnosing eIF2Brelated disorders.
88 Pantoni L, Pescini F, Nannucci S, et al. Comparison of clinical, familial, and MRI features of CADASIL and NOTCH3-negative patients. Neurology 2010; 74:57–63.
69 Sundblom J, Melberg A, Kalimo H, et al. MR imaging characteristics and neuropathology of the spinal cord in adult-onset autosomal dominant leukodystrophy with autonomic symptoms. AJNR Am J Neuroradiol 2009; 30:328– 335. Comprehensive study summarizing the current status of MRI changes in ADLD.
89 van der Knaap MS, Ramesh V, Schiffmann R, et al. Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord. Neurology 2006; 66:494–498. 90 Pareyson D, Fancellu R, Mariotti C, et al. Adult-onset Alexander disease: a series of eleven unrelated cases with review of the literature. Brain 2008; 131:2321–2331.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Investigations and treatment of chronic inflammatory demyelinating polyradiculoneuropathy and other inflammatory demyelinating polyneuropathies Jennifer A. Tracy and P. James B. Dyck Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA Correspondence to P. James B. Dyck, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA E-mail:
[email protected] Current Opinion in Neurology 2010, 23:242–248
Purpose of review The evaluation of demyelinating polyneuropathies and the data for treatment of inflammatory demyelinating peripheral neuropathies, particularly chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), will be discussed. Recent findings A large clinical trial showed short and long-term efficacy of intravenous immunoglobulin (IVIG) for the treatment of CIDP and the US Food and Drug Administration approved the use of IVIG (Gamunex) as a treatment for CIDP. Recent trials for other agents for CIDP treatment have not proved as promising, with a large study of methotrexate failing to show significant benefit. There are recent cases of monoclonal antibodies (e.g. rituximab, alemtuzumab) showing benefit in patients with CIDP, but the side effect profiles can be worrisome. Summary Clinical history, neurological exam, spinal fluid examination, and electrophysiological evaluation remain mainstays for the diagnosis of demyelinating inflammatory polyradiculoneuropathy. Genetic testing and nerve biopsy are important diagnostic tools in some patients. Potential treatments for immune-mediated demyelinating polyradiculoneuropathies are varied, with the authors generally favoring IVIG and/or corticosteroids as first-line agents. Plasma exchange can be helpful in selected patients. Data for efficacy of other oral immunomodulatory agents are based primarily on case reports and case series, and have not been uniformly positive. The use of monoclonal antibodies (particularly rituximab) may have promise, but further research needs to be done, and the risks need to be carefully considered. Keywords chronic inflammatory demyelinating polyradiculoneuropathy, CIDP, intravenous immunoglobulin, peripheral neuropathy Curr Opin Neurol 23:242–248 ß 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins 1350-7540
Introduction There is a wide range of causes for demyelinating polyneuropathies, and the underlying pathophysiology is very important for appropriate diagnosis, treatment, and prognostication. Inherited demyelinating polyneuropathies, such as hereditary motor and sensory neuropathy type 1 (HMSN1), and hereditary motor and sensory neuropathy type 3 (HMSN3, Dejerine-Sottas) do not respond to immune therapy and so need to be recognized. The diagnosis of acquired demyelinating polyneuropathies is of particular interest, because of the potential treatable nature of these diseases. The classic syndromes are acute inflammatory demyelinating polyradiculoneuropathy (AIDP, Guillain-Barre´ syndrome) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 1350-7540 ß 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
but many variants have been described, including MillerFisher syndrome, Lewis Sumner syndrome (focal or multifocal forms of CIDP), chronic inflammatory demyelinating mononeuropathy (CIDM), chronic inflammatory sensory polyradiculopathy (CISP), chronic ataxic neuropathy with ophthalmoplegia, monoclonal protein, and disialosyl antibodies (CANOMAD), other demyelinating neuropathies associated with the presence of monoclonal proteins [monoclonal gammopathy of undetermined significance (MGUS)-associated neuropathy, anti-myelin-associated glycoprotein (MAG) neuropathy, lymphoma-associated neuropathy], and possibly neuropathies associated with diabetes mellitus and multifocal motor neuropathy (MMN). Drug or infection-induced demyelinating neuropathies also need to be considered. We will review the investigations required for an accurate assessment of DOI:10.1097/WCO.0b013e3283394203
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Demyelinating polyneuropathies Tracy and Dyck 243
demyelinating neuropathy, and evidence for the efficacy of treatment. Given the scope of the topic, we will focus our review of treatment options primarily on CIDP.
Investigations The investigation of a demyelinating neuropathy begins with a careful history and physical examination. Important clues to an inherited cause include early onset and slow progression of symptoms/signs, a long history of ‘weak ankles’ with multiple sprains, symmetric findings, lack of or minimal positive sensory findings, a family history, either of known neuropathy or of ‘inverted champagne bottle legs’, high arches and hammertoes. The presence of late onset, rapid progression, focal onset and/or progression, preceding infection and/or immunization, and lack of family history suggests an acquired cause. A history of co-existing diseases and medications is necessary. The presence or absence of prior response to immunomodulatory therapy is important to ascertain. Findings on physical examination consistent with a protracted course (hammertoes, high arches, thin calves) are supportive of an inherited cause, but are not specific for this. Evaluations include nerve conduction studies/electromyography, cerebrospinal fluid (CSF) examination, complete blood count, electrolytes (including fasting glucose), monoclonal protein study, human immunodeficiency virus (HIV) testing, rheumatologic testing, and genetic testing. CSF analysis usually shows a cyto-albuminologic dissociation, with elevated protein with minimal or absent pleocytosis, in CIDP more than in inherited demyelinating polyradiculoneuropathies. Increased CSF white blood cell count is suggestive of an infectious cause, an alternative inflammatory cause (such as sarcoidosis), or of an underlying malignant process such as lymphoma. Cultures and cytology can be helpful in making these distinctions, and CT and/or PET scanning of the body may help reveal diagnostic abnormalities. The presence of a monoclonal protein in the blood (or urine) should initiate hematologic work-up for the presence of lymphoma, osteosclerotic myeloma and Castleman’s disease (in association with POEMS syndrome: polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes), MGUS, or other specific hematological abnormality. In some situations, testing for anti-MAG antibodies may be of utility. Rheumatologic testing may suggest the presence of an associated connective tissue disease. Genetic testing is commercially available for several known causes of inherited demyelinating polyneuropathy including abnormalities in PMP-22, myelin protein zero, EGR2, LITAF, and connexin-32 [1]. Classic electrodiagnostic features of demyelination include prolonged distal/peak motor and sensory latencies, prolonged F-wave latencies, temporal dispersion, and
conduction block. Uniform slowing of nerve conduction is suggestive of an inherited demyelinating polyneuropathy [2–4]. The presence of nonuniform slowing of nerve conduction, temporal dispersion and conduction block is felt to occur more frequently in acquired demyelinating polyneuropathies [2,3] but can also be seen in inherited disorders [5]. Mutations in connexin-32 have been reported to be associated with heterogeneous motor nerve conduction slowing between nerves in females [6]. Hereditary neuropathy with liability to pressure palsies, although usually easy to distinguish from these other disorders on electrophysiologic criteria, can also show conduction block as well as prolonged distal latencies. More recently, it has been suggested that the determination of terminal latency index (TLI) can help distinguish between anti-MAG neuropathy and HMSN1 [7]. There are several published recommended criteria for the diagnosis of CIDP [8–11] but no universally adopted consensus. It has been argued that the published criteria, although useful for research purposes, may be too rigid for clinical practice, and may exclude many patients with CIDP [12]. Nerve biopsy may be useful in selected patients for whom the diagnosis of an inherited or acquired demyelinating neuropathy is in question, and can often be helpful in the diagnoses of unexpected abnormalities such as sarcoidosis and vasculitis. There are limitations to nerve biopsies in these cases; as CIDP is often motor and proximal predominant, a sural nerve biopsy may fail to show diagnostic pathological changes. In addition, the major diagnostic changes are sometimes seen on teased fiber evaluations, which are not routinely performed at many institutions. Characteristic findings for CIDP, if present, include increased rates of segmental demyelination and remyelination on teased fiber evaluation, the presence of thinly myelinated fibers or ‘naked axons’ (lacking a surrounding myelin sheath), onion bulbs, and increased inflammation. A recent study by the authors showed that the pattern of onion bulb distribution can be predictive of acquired versus inherited cause, with a mixed pattern of onion bulbs (onion bulbs interspersed with normally myelinated axons) more predictive of an acquired cause, and a generalized pattern (all or nearly all axons in the specimen surrounded by onion bulbs) more predictive of an inherited demyelinating polyneuropathy [13]. In some cases, when the neuropathic process is focal and does not involve easily biopsied sensory nerves, and when there are focal findings on neuroimaging (including abnormal T2 signal, focal nerve enlargement, and/or contrast enhancement), fascicular biopsies of more proximal nerves, sometimes motor, have been performed. These biopsies require access to radiologists and surgeons with particular skill in interpreting magnetic resonance imaging (usually 3 Tesla) of peripheral nerve, and in
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
244 Demyelinating diseases
performing these biopsies with attention to removing a limited number of affected fascicles. A fascicular biopsy of motor nerve introduces the risk of causing a new motor deficit, and is only suitable for a limited subset of patients.
of IVIG-treated patients, and 88% of oral immunosuppressant-treated patients had improved strength. The typical intravenous methylprednisolone dosing used in this study was 1000 mg/day for 3–5 consecutive days, followed by 1000 mg weekly for the next month, with variable tapering after that point [16].
Treatment
Whereas corticosteroids can be beneficial in patients with CIDP, side effect management must be aggressive. We recommend calcium and vitamin D supplementation, weight-bearing exercise, and bisphosphonates for patients on long-term therapy [17]. In addition patients with long-term steroid use should receive Pneumocystis carinii prophylaxis. Fasting blood sugar and electrolytes should be monitored. Corticosteroids can have other untoward side effects (e.g. elevated blood pressure, cataracts), and close partnership between the neurologist and primary care doctor is necessary to make sure side effects are adequately controlled.
The judicious use of physical therapy and assistive devices such as ankle–foot orthoses, canes and safety measures in and outside the home are of the utmost importance for all patients with peripheral neuropathy, whatever the type. These will not be discussed further here, nor will we focus on the primary treatment of malignancy, infection or associated hematologic or rheumatologic diseases associated with demyelinating neuropathies. Our treatment discussion will focus upon the immunomodulatory agents used for the treatment of acquired demyelinating neuropathies, with our primary focus on CIDP.
Intravenous immunoglobulin Corticosteroids
Corticosteroids (typically oral prednisone) have been used extensively for the treatment of CIDP. These are clearly useful agents for many patients, though the literature for its efficacy is actually quite limited. A trial of 28 patients with CIDP treated with 3 months of oral prednisone showed small improvements in neurological disability and muscle strength [14]. In a prospective study of 10 CIDP patients treated with oral methylprednisolone, 500 mg weekly for 3 months, with subsequent dose adjustments based on clinical judgment, 6/9 patients who completed the study went into remission, after a mean of 27 months of treatment, with continued remission being achieved for a mean of 29 months (though none of the patients achieving remission had relapsed at the end of the study). The mean dose at 1 year was 316 mg/week of oral methylprednisolone. The median weight increased from 190 pounds before treatment to 215 pounds by 1 year after treatment, and over 3 years time, 5/9 patients had evidence of osteoporotic bone density loss on dualenergy X-ray absorptiometry scans [15]. These studies provide evidence of efficacy of oral corticosteroids in patients with CIDP, but there are concerns about the long-term tolerability of these medications. One potential strategy for dealing with this problem has been to use intravenous corticosteroids for disease management. A retrospective study of 39 patients who received primary treatment with oral prednisone or cyclosporine, versus treatment with intravenous methylprednisolone or intravenous immunoglobulin (IVIG) showed no statistically significant difference in the increase of strength attained in patients in each of those three categories. By the end of the analysis, 81% of intravenous methylprednisolone-treated patients, 86%
In a double-blind, placebo-controlled trial of IVIG (5 days) versus placebo in 28 patients, 4/15 patients in the IVIG group improved, as did 3/13 in the placebo group, with no statistically significant differences between the groups [18]. Subsequent trials with more patients and longer periods of treatment have, however, shown more promising results. A trial of 20 patients treated with IVIG or plasma exchange showed that they were both effective in CIDP [19]. Another study treated 30 patients with either IVIG (0.4 g/kg/day 5 days) or placebo and found statistically significant improvements in the IVIG-treated patients in neurological disability score, clinical grade, and grip strength [20]. A randomized double-blind trial of IVIG in 53 CIDP patients treated them with either 1 g/kg IVIG on days 1, 2, and 21, versus placebo, with evaluation of effect on muscle strength using a scale called the average muscle score (AMS). There were statistically significant improvements in AMS in the treated group at a day 42 follow-up; 11/30 patients treated with IVIG showed improvement on the Hughes’ functional disability scale by at least one functional grade. The most common side effect in this group was headache (67 versus 44% in the placebo group) [21]. That same year, a randomized double-blind cross-over trial of CIDP patients with 6 weeks of oral prednisolone (60 mg tapering down to 10 mg daily) versus IVIG (2 g/kg, over 1–2 days) showed improvements in disability score with both treatments, but no significant difference between groups [22]. Hughes et al. [23] published results of a large doubleblinded, placebo-controlled trial of the use of IVIG in CIDP patients. This trial included a short-term follow-up period, with a cross-over period for nonresponders, and an
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Demyelinating polyneuropathies Tracy and Dyck 245
extension phase for responders; 117 patients were included in the trial. The treatment group received a loading dose of 2 g/kg IVIG over 2–4 days, followed by maintenance infusions of 1 g/kg over 1–2 days every 3 weeks, for up to 24 weeks; the placebo group received albumin infusions. At the end of 24 weeks, 54% of the patients treated with IVIG and 21% of patients treated with placebo showed an improved INCAT disability score (the difference between groups was statistically significant). During the 24-week extension phase of the trial, patients treated with IVIG had a 13% probability of relapse compared to 45% of the patients treated with placebo. The most common side effects reported for the IVIG-treated patients were headache (32% patients), pyrexia (13% patients), and hypertension (9% patients). This large trial was very helpful in providing evidence for the efficacy of IVIG, and the US Food and Drug Administration (FDA) approved the use of IVIG (Gamunex) for the treatment of CIDP in late 2008. Plasma exchange
In 1986, Dyck et al. [24] performed a prospective trial of plasmapheresis treatment in patients with CIDP; 15 were treated with plasma exchanges and 14 received sham exchange over a 3-week period. Patients treated with plasma exchange had significant improvements in combined nerve conduction measurements compared with untreated patients. Hahn et al. [25] treated 18 CIDP patients with plasmapheresis in a cross-over double blind trial; 80% of the 15 patients who completed the trial showed significant improvement with plasma exchange. Of note, 8 of the 12 patients who showed a treatment response to plasma exchange had relapse within 2 weeks of the conclusion of treatment. Determining electrophysiologic parameters of response to plasma exchange has been difficult, with one study showing significant improvements in proximal ulnar M-wave amplitudes and areas with plasma exchange [26].
insufficient to detect significant responses [28]. Pentland et al. [29] described five patients with relapsing inflammatory polyneuropathy, four of whom had sustained improvement with the use of azathioprine (the maximum azathioprine dose used in this study was 300 mg/day), though some (if not all) patients were on concurrent corticosteroids or adrenocorticotropic hormone at the time of improvement. The authors also noted that the fifth patient was able to replace his corticosteroids with azathioprine. Dalakas and Engel [30] have also reported on a benefit of azathioprine in three of four steroidunresponsive patients. Mycophenolate mofetil
Mowzoon et al. [31] reported on two patients with CIDP, one with an associated monoclonal protein, and the other with diabetes mellitus, with good initial clinical response to mycophenolate mofetil. Umapathi and Hughes [32] described five patients (four with CIDP, one with multifocal motor neuropathy), unresponsive to other immunomodulatory treatment modalities, who were treated with mycophenolate mofetil, with a target dose of 1000 mg twice a day; the median treatment period was 5 months. Two of the CIDP patients were felt to have a minimal response to mycophenolate (one was treated for 11 months and the other for 5 months), though both patients discontinued the medication, one because of diarrhea, and one because ‘he did not feel better’ despite an increase in his Medical Research Council (MRC) score. Chaudhry et al. [33] reported improvements in strength in one of three CIDP patients treated with mycophenolate. Another trial of mycophenolate in immune-mediated neuropathies included 13 CIDP patients, and there were no significant improvements in MRC strength scores, sensory scores, or Rankin disability score, though three of the CIDP patients were individually felt to have some clinical improvements [34]. Methotrexate
Dyck et al. [19] treated 20 patients with either IVIG (0.4 g/kg weekly 3 weeks, then 0.2 g/kg weekly 3 weeks) or plasma exchange (twice a week for 3 weeks, then weekly for 3 weeks); there was then a washout period and a cross-over to the alternate treatment. Whereas patients in both groups showed significant improvements, there was no significant difference in outcomes between the IVIG and plasma exchange treatments. Azathioprine
A single randomized controlled trial of 27 patients comparing treatment with prednisone versus treatment with prednisone and azathioprine failed to show a significant outcome difference between the two groups [27], though the treatment period was only 9 months and there has been criticism that the dose (2 mg/kg/day) may have been
A retrospective study of 10 patients with CIDP treated with methotrexate (10–15 mg weekly doses), all of whom had previously been treated with at least two other immunomodulatory agents, showed improvement of MRC score by at least 2 points in 7 patients, leading the authors to suggest that a randomized controlled trial should be initiated [35]. A multicenter trial of 60 patients, all of whom were concurrently using corticosteroids or IVIG, treated patients with either placebo or methotrexate (7.5 mg weekly 4 weeks, then 10 mg weekly 4 weeks, and then 15 mg weekly for 32 weeks) used a primary endpoint of 20% reduction in mean weekly dose of either concurrent corticosteroid use or IVIG use by the end of the trial. Overall tolerance of methotrexate was good; lymphopenia occurred in 37% of the methotrexate group versus 18% in the placebo group. There was a significantly higher infection rate in the placebo group
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
246 Demyelinating diseases
(34%) than in the methotrexate group (14%) and a higher rate of mouth ulcers in the placebo group (16%) than in the methotrexate group (0%). No serious adverse events in either group was felt to be drug-related. Unfortunately, there was no significant difference in primary outcome between the methotrexate and the placebo group. The authors speculate that the lack of response could potentially have been due to either inadequate drug dosage or treatment duration, though they point out that the dose used in their trial was equal to that used in trials showing efficacy in autoimmune rheumatologic diseases [36]. A recent case report [37] described a 63-year-old patient with treatment-refractory CIDP, with a dramatic response with the use of weekly methotrexate. Cyclosporine
Barnett et al. [38] retrospectively reviewed 19 patients with treatment-refractory CIDP who were treated with cyclosporine A, and found that in the group with progressive CIDP, mean disability scores decreased, and in the relapsing group, the mean annual incidence of relapse decreased. Mahattanakul et al. [39] reported on eight patients with CIDP treated with cyclosporine A, for whom treatment was felt to be successful in three. Matsuda et al. [40] treated seven patients with refractory CIDP with cyclosporine A (titrated to plasma trough concentration 100–150 ng/ml) and found that grip strength was significantly increased, and modified Rankin and INCAT disability scores were significantly decreased; all had subjective symptom improvement. Cyclophosphamide
Good et al. [41] retrospectively reviewed the cases of 15 patients with CIDP treated with intravenous cyclophosphamide monthly for up to 6 months, and found that 11 of these patients had a complete remission, and 12 ‘returned to routine work’. All of the patients had drug-induced leukopenia, which normalized after 2–3 weeks; other complications reported included nausea, lightheadedness, headache, rash, alopecia, and reduction in hematocrit. The authors note that the best patient outcomes occurred when the disease had been present less than 10 months by the time of treatment. Brannagan et al. [42] treated four patients with CIDP and partial resistance to other therapies, with high-dose cyclophosphamide (200 mg/kg divided over 4 days), and all had improvement in strength and functional status. All patients received forced diuresis as well as mesna. Complications included neutropenic fever, reversible renal insufficiency, congestive heart failure, and Escherichia coli bacteremia, among others. Stem cell transplantation
Remenyi et al. [43] reported on a patient with CIDP with good response to allogeneic hematopoietic stem cell transplantation. Vermeulen and Van Oers [44] reported on a CIDP patient with good response to autologous stem
cell transplantation. However, they later reported that the same patient had a relapse 5 years after receiving his transplant, and he started treatment with IVIG [45]. Axelson et al. [46] described a severely affected CIDP patient who responded well to high-dose cyclophosphamide and autologous stem cell transplantation, and after relapse, responded to repeat treatment. Oyama et al. [47] described a treatment-refractory CIDP patient who responded well to nonmyeloablative autologous hematopoietic stem cell transplantation, with no exacerbations over a 22-month follow-up period. Rituximab and other monoclonal antibodies
Rituximab is a monoclonal antibody which targets the B-cell antigen, CD20, and has been used for the treatment of various types of autoimmune disease; recent attention has been given to its possible role in CIDP, particularly in patients in whom there is evidence of a significant antibody-mediated cause. Briani et al. [48] reported significant clinical improvement in a patient with an IgM kappa monoclonal protein and CIDP. Individual studies have also shown efficacy of rituximab in patients with CIDP and associated idiopathic thrombocytopenic purpura [49], Evans syndrome [50], sulfoglucuronyl paragloboside (SGPG) IgM antibodies [51], and diabetes mellitus [52]. A small trial was performed, with two patients with CIDP, two with MMN, one with anti-MAG neuropathy, and one with Sjo¨gren’s associated neuropathy, all of whom required the chronic use of IVIG. All patients received at least 4 weekly doses of rituximab at 375 mg/ m2, and the primary endpoint was reduction in IVIG dosage by 25% at 1 year after therapy. Only two patients were considered to be responders by this criterion (one with Sjo¨gren’s and the other with MMN); one of the CIDP patients had no change in overall IVIG dose and the other had increasing need for IVIG during the trial [53]. Renaud et al. [54] reported on nine patients with antiMAG antibody associated peripheral neuropathy treated with rituximab, and noted clinical improvement in six, though in all patients peripheral blood B-cell count was below the level of detection. Pestronk et al. [55] reported on 21 patients with neuropathy with associated serum IgM antibodies, treated with rituximab, and found that 18 had an improvement in strength of at least 12% of normal. Niermeijer et al. [56] prospectively treated 17 patients with severe MGUS-associated neuropathies (16 with demyelinating neuropathies) with rituximab and only 2/17 met the primary outcome of a one point or greater improvement on the Overall Disability Sum Score (ODSS), though there was an improvement of 5% or greater improvement of the distal summated MRC score in 4 and in the sensory summated score in 9. Of note, the patient with the greatest improvement on the ODSS was the single patient defined as having an axonal neuropathy.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Demyelinating polyneuropathies Tracy and Dyck 247
Etanercept (25 mg twice per week) was given to 10 refractory CIDP patients and 3 were felt to have ‘significant improvement’, whereas 3 others showed ‘possible improvement’ [57]. However, cases of CIDP have been reported associated with the use of antitumor necrosis factor antibody use (etanercept, infliximab) [58]. There is a single case report of a 19-year-old woman with CIDP, with frequent relapses, who, whereas responsive to IVIG, did not respond to corticosteroids, and had only a partial response to azathioprine, who was treated with alemtuzumab – a monoclonal antibody to the CD52 antigen (which leads to decreases in T and B lymphocytes and monocytes). She appeared to have some clinical benefit, but did have subsequent relapses which required further IVIG treatments [59]. Alemtuzumab is currently approved by the FDA for treatment for B-cell chronic lymphocytic leukemia, and most of the neurologic experience and interest in this treatment has been for its potential benefit in multiple sclerosis [60]. Though there is evidence for its efficacy, there is potential risk, with one large trial showing 23% developing autoimmune thyroid disease and 3% developing immune thrombocytopenic purpura [61].
limited, and the side effect profile is worrisome, and the authors are not currently using this agent for their CIDP patients.
References and recommended reading Papers of particular interest, published within the annual period of review, have been highlighted as: of special interest of outstanding interest Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 332–333). 1
Klein CJ. The inherited neuropathies. Neurologic Clinics 2007; 25:173–207.
2
Wilbourn AJ. Differentiating acquired from familial segmental demyelinating neuropathies by EMG. Electroencephalogr Clin Neurophysiol 1977; 43:616.
3
Lewis RA, Sumner AJ. The electrodiagnostic distinctions between chronic familial and acquired demyelinative neuropathies. Neurology 1982; 32:592– 596.
4
Kaku DA, Parry GJ, Malamut R, et al. Uniform slowing of conduction velocities in Charcot-Marie-Tooth polyneuropathy type 1. Neurology 1993; 43:2664– 2667.
5
Lewis RA, Sumner AJ, Shy ME. Electrophysiological features of inherited demyelinating neuropathies: a reappraisal in the era of molecular diagnosis. Muscle Nerve 2000; 23:1472–1487.
6
Dubourg O, Tardieu S, Birouk N, et al. Clinical, electrophysiological and molecular genetic characteristics of 93 patients with X-linked Charcot-MarieTooth disease. Brain 2001; 124:1958–1967.
7
Lupu VD, Mora CA, Dambrosia J, et al. Terminal latency index in neuropathy with antibodies against myelin-associated glycoproteins. Muscle Nerve 2007; 35:196–202.
8
Barohn RJ, Kissel JT, Warmolts JR, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989; 46:878.
9
Saperstein DS, Katz JS, Amato AA, et al. The clinical spectrum of chronic acquired demyelinating polyneuropathy. Muscle Nerve 2001; 24:311.
Conclusion The diagnosis of demyelinating neuropathy is usually straightforward based on history, physical and electrophysiological findings, but the next step, identifying whether a treatable neuropathy exists, has more pitfalls. The lack of clear consensus criteria for the diagnosis of CIDP makes the situation more complex, as well as limitations in commercial genetic testing for suspected inherited neuropathies. A search for underlying disease, such as diabetes mellitus, hematological malignancy, and HIV, is necessary to assess whether treatment should be focused solely on the underlying neuropathic process or on a more diffuse disorder. Once a diagnosis of CIDP is established, careful evaluation of the risks and benefits of each potential treatment should be considered for an individual patient. The authors generally use IVIG and/or corticosteroid treatments (often intravenous) as first-line agents, unless there are contraindications to their use, and the FDA has recently approved IVIG (Gamunex) for the treatment of CIDP. If corticosteroids are not able to be weaned over time (as in most cases), a steroid-sparing agent is generally added. There is not good head-to-head data of the oral steroid-sparing agents, and the choice is usually based on side effect profile and the patient’s coexisting medical conditions. Monoclonal antibodies such as rituximab have shown benefit in individual patients, but the authors are not presently using these as first-line agents in patients with CIDP (and no monoclonal protein), and encourage controlled clinical trials. The data for alemtuzumab is extremely
10 Joint task force of the EFNS and PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripheral Nerv Syst 2005; 10:220–228. 11 Ad hoc subcommittee of the American Academy of Neurology AIDS task force. Research criteria for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1991; 41:617–618. 12 Latov N. Comment on European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripheral Nerv Syst 2006; 11:88–89. 13 Tracy JA, Dyck PJ, Engelstad JK, et al. Pattern of onion-bulb formation predictive of inflammatory or inherited hypertrophic neuropathy. Neurology 2008; 70 (11 Suppl 1):A313. 14 Dyck PJ, O’Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11:136–141. 15 Muley SA, Kelkar P, Parry GJ. Treatment of chronic inflammatory demyelinat ing polyneuropathy with pulsed oral steroids. Arch Neurol 2008; 65:1460– 1464. Shows efficacy of weekly high-dose steroids, which could serve as an alternative option to typical daily oral dosing. 16 Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 2005; 62:249–254. 17 American College of Rheumatology Ad Hoc Committee on GlucocorticoidInduced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44:1496–1503. 18 Vermeulen M, van Doorn PA, Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993; 56a91:36–39. 19 Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36:838–845.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
248 Demyelinating diseases 20 Hahn AF, Bolton CF, Zochodne D, et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996; 119:1067–1077.
41 Good JL, Chehrenama M, Mayer RF, et al. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 1998; 51:1735–1738.
21 Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56:445–449.
42 Brannagan TH, Pradhan A, Heiman-Patterson T, et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002; 58:1856–1858.
22 Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50:195–201.
43 Remenyi P, Masszi T, Borbenyi Z, et al. CIDP cured by allogeneic hematopoietic stem cell transplantation. Eur J Neurol 2007; 14:e1–e2.
23 Hughes RAC, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomized placebocontrolled trial. Lancet Neurol 2008; 7:136–144. Large well organized trial which shows short and longer-term efficacy of IVIG in CIDP.
44 Vermeulen M, Van Oers MH. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2002; 72:127–128. 45 Vermeulen M, van Oers MH. Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation. J Neurol Neurosurg Psychiatry 2007; 78:1154.
24 Dyck PJ, Daube J, O’Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986; 314:461– 465.
46 Axelson HW, Oberg G, Askmark H. Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP. J Neurol Neurosurg Psychiatry 2008; 79:612–614. Case report which shows efficacy of aggressive therapies in severe CIDP.
25 Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996; 119:1055–1066.
47 Oyama Y, Sufit R, Loh Y, et al. Nonmyeloablative autologous hematopoietic stem cell transplantation for refractory CIDP. Neurology 2007; 69:1802–1803.
26 Ashworth NL, Zochodne DW, Hahn AF, et al. Impact of plasma exchange on indices of demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2000; 23:206–210. 27 Dyck PJ, O’Brien P, Swanson C, et al. Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology 1985; 35:1173–1176. 28 Hughes RAC, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004; 4:CD003280. 29 Pentland B, Adams GG, Mawdsley C. Chronic idiopathic polyneuropathy treated with azathioprine. J Neurol Neurosurg Psychiatry 1982; 45:866–869. 30 Dalakas MC, Engel WK. Chronic relapsing (disimmune) polyneuropathy— pathogenesis and treatment. Ann Neurol 1981; 9:134–145. 31 Mowzoon N, Sussman A, Bradley WG. Mycophenolate (Cellcept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurolog Sci 2001; 185:119–122. 32 Umapathi T, Hughes R. Mycophenolate in treatment-resistant inflammatory neuropathies. Eur J Neurol 2002; 9:683–685. 33 Chaudhry V, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001; 56:94–96. 34 Gorson KC, Amato AA, Ropper AH. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004; 63:715–717. 35 Fialho D, Chan YC, Allen DC, et al. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. J Neurol Neurosurg Psychiatry 2006; 77:544–547. 36 RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009; 8:158–164. Large trial which fails to show efficacy of methotrexate in enabling CIDP patients to reduce their corticosteroid or IVIG needs. 37 Diaz-Manera J, Rojas-Garcia R, Callardo E, et al. Response to methotrexate in a chronic inflammatory demyelinating polyradiculoneuropathy patient. Muscle Nerve 2009; 39:386–388. Shows significant improvement in a single CIDP patient treated with methotrexate. 38 Barnett MH, Pollard JD, Davies L, et al. Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1998; 21:454–460. 39 Mahattanakul W, Crawford TO, Griffin JW, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. J Neurol Neurosurg Psychiatry 1996; 60:185–187. 40 Matsuda M, Hoshi K, Gono T, et al. Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurolog Sci 2004; 224:29–35.
48 Briani C, Zara G, Zambello R, et al. Rituximab-responsive CIDP. Eur J Neurol 2004; 11:788. 49 Benedetti L, Franciotta D, Beronio A, et al. Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura. Muscle Nerve 2008; 38:1076–1077. Shows improvement in CIDP patient with use of rituximab. 50 Knecht H, Baumberger M, Tobon A, et al. Sustained remission of CIDP associated with Evans syndrome. Neurology 2004; 63:730–732. 51 Gono T, Matsuda M, Shimojima Y, et al. Rituximab therapy in chronic inflammatory demyelinating polyradiculoneuropathy with anti-SGPG IgM antibody. J Clin Neurosci 2006; 13:683–687. 52 Munch C, Anagnostou P, Meyer R, et al. Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. J Neurolog Sci 2007; 256:100–102. 53 Gorson KC, Natarajan N, Ropper AH, et al. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007; 35:66–69. 54 Renaud S, Gregor M, Fuhr P, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003; 27:611–615. 55 Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003; 74:485–489. 56 Niermeijer JMF, Eurelings M, Lokhorst HL, et al. Rituximab for polyneuropathy with IgM monoclonal gammopathy. J Neurol Neurosurg Psychiatry 2009; 80:1036–1039. Shows response to rituximab in a minority of treated patients. 57 Chin RL, Sherman WH, Sander HW, et al. Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurolog Sci 2003; 210:19–21. 58 Richez C, Blanco P, Lagueny A, et al. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology 2005; 64:468–470. 59 Hirst C, Raasch S, Llewelyn G, et al. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). J Neurol Neurosurg Psychiatry 2006; 77:800–802. 60 Rieckmann P. Concepts of induction and escalation therapy in multiple sclerosis. J Neurolog Sci 2009; 227 (Suppl 1):S4